Measuring the quality of care for patients with acute coronary syndrome: a process approach by Tra, J.
Joppe Tra
Measuring The Quality of Care for 
Patients with Acute Coronary Syndromes
M
easuring The Q
uality of C
are for Patients with Acute C
oronary Syndrom
es
Joppe Tra
A Process Approach
A Process A
pproach
Uitnodiging voor het bijwonen 
van de openbare verdediging van 
mijn proefschrift
Measuring the Quality 
of Care for Patients with 
Acute Coronary Syndrome: 
A Process Approach
Op dinsdag 20 maart om 9:45u in de 
aula van de Vrije Universiteit aan de 
Boelelaan 1105 te Amsterdam
Na afloop bent u van harte welkom 
op de receptie
Joppe Tra
06-17598142
joppetr@hotmail.com
Paranimfen
Staf Tra
staf.anne@chello.nl 
Joost Wammes
joostwammes@hotmail.com 
Measuring the Quality of Care for 
Patients with Acute Coronary Syndrome: 
A Process Approach
M
easuring the Q
uality of C
are for Patients w
ith A
cute C
oronary Syndrom
e: A
 Process A
pproach 
Joppe Tra
Joppe Tra
Measuring the quality of care for patients with 
acute coronary syndrome: a process approach
Joppe Tra
 Measuring the quality of care for patients with acute coronary syndrome: a process 
approach
Cover design:  Peter Gikandi, http://www.petergikandi.com 
 Corine Bond, http://www.corinebond.com
Printed by:  Gildeprint, Enschede
© Copyright, Joppe Tra, 2018, The Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval 
system, or transmitted in any form or by any means, without the written permission of 
the author or, when appropriate, from the publishers for the publications.
Financial support for the printing of this thesis was kindly provided by the VU University 
medical center and the Knowledge Institute of Medical Specialists.
VRIJE UNIVERSITEIT
Measuring the quality of care for patients with acute coronary syndrome: 
a process approach
ACADEMISCH PROEFSCHRIFT
ter verkrijging van de graad Doctor aan
de Vrije Universiteit Amsterdam,
op gezag van de rector magnificus
prof.dr. V. Subramaniam,
in het openbaar te verdedigen
ten overstaan van de promotiecommissie
van de Faculteit der Geneeskunde
op dinsdag 20 maart 2018 om 9:45 uur
in de aula van de universiteit,
De Boelelaan 1105
door
Joppe Tra
geboren te Eindhoven
promotor:  prof.dr. C. Wagner
copromotoren:  prof.dr. M.C. de Bruijne
 dr. I. van der Wulp
If you can’t describe what you are doing as a process, 
you don’t know what you’re doing.
 
W. Edwards Deming

TABLE OF CONTENTS
Chapter 1 Introduction p. 9
Chapter 2 Monitoring guideline adherence in the management of acute 
 coronary syndrome in hospitals: design of a multicentre study p. 31
 Published in the Netherlands Heart Journal 2014;22:346–353 
Chapter 3 Exploring the treatment delay in the care of patients with 
 ST-elevation myocardial infarction undergoing acute 
 percutaneous coronary intervention: a cross-sectional study p. 49
 Published in BMC Health Services Research 2015;15:340 
Chapter 4 Data quality issues impede comparability of hospital 
 treatment delay performance indicators p. 65
 Published in Netherlands Heart Journal. 2015;23(9):420-7 
Chapter 5 Multi-centre analysis of current ST-elevation myocardial 
 infarction acute care pathways p. 83
 Published in BMJ Open Heart 2017:4;e000458 
Chapter 6 Adherence to guidelines for the prescription of secondary 
 prevention medication at hospital discharge after acute 
 coronary syndrome: a multicentre study p. 103
 Published in the Netherlands Heart Journal 2015:23(4);214-221 
Chapter 7 Interventions to improve guideline adherence of care providers 
 in hospitals in the management of patients with acute coronary 
 syndrome and their effects: a systematic review p. 119
 Submitted for publication 
Chapter 8 Discussion and reflection p. 141
 Summary p. 169
 Samenvatting p. 175
 Dankwoord p. 181

Chapter 1
Introduction
Chapter 1
10
Introduction
11
1
This introductory chapter provides background information on the main topics and 
research questions of this thesis: acute coronary syndrome (ACS), its prevention and 
management, and measuring the quality of care. 
ACUTE CORONARY SYNDROME
ISCHAEMIC HEART DISEASE
In the year 1772, the English physician William Heberden described 20 patients with 
a ‘painful and most disagreeable sensation in the breast’ in Transactions in the Royal 
College of Physicians of London.1 He named the condition ‘Angina Pectoris’.2 Although 
he might have discounted the heart as a cause for angina pectoris, Heberden’s 
observations eventually led to the discovery of ischaemic heart disease.
Nowadays, ischaemic heart disease is the leading cause of death in the world.3 In 
Europe, almost 24% of all deaths is caused by ischaemic heart disease, totalling 2.1 
million deaths each year. Although this percentage will decrease slightly to 20.5% in 
the next 15 years,4 the burden of disease will remain immense. The most common 
ischaemic heart disease is ACS.
WHAT CAUSES ACUTE CORONARY SYNDROME?
Three coronary arteries located on the outside of the heart provide the heart muscle 
tissue, or myocardial tissue, with vital glucose- and oxygen-rich blood. In case of an 
ACS, this blood provision is reduced or cut off for a prolonged time, usually due to the 
rupture of an atherosclerotic plaque in the wall of one or more of the coronary arteries.5 
The reduction or deprivation of glucose and oxygen rich blood causes ischaemia, which 
in turn can result in tissue necrosis. The reduction in blood flow can lead to several 
signs and symptoms in patients, such as chest pain (angina pectoris), radiation of this 
pain to the upper extremities, nausea and excessive sweating.6 However, signs and 
symptoms may vary. For example, women, elderly, patients with diabetes mellitus, and 
patients with a history of heart failure tend to present more often without typical chest 
pain or discomfort, and more often with abdominal pain or muscle cramps in the jaw.7 
Also, several other conditions should be considered in the differential diagnoses, e.g. 
pericarditis. Consequently, additional diagnostics are required.
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CLINICAL MANIFESTATIONS AND DIAGNOSIS
In diagnosing acute coronary syndrome, three clinical manifestations can be 
distinguished based on electrocardiogram changes and biomarker values.8 As a result of 
ischaemia, the electrophysiological field of the myocardial tissue changes, which shows 
on the electrocardiogram as deviations in a particular part of the signal (ST-segment). 
Biomarkers (i.e. troponin, creatine-kinase (CK) and creatine-kinase muscle-brain (CK-
MB)) are enzymes which are released in the blood stream as a result of myocardial 
tissue necrosis.8 When the electrocardiogram shows an elevation of the ST-segment 
and the biomarker values are increased, the clinical manifestation of ACS is named 
ST-segment elevation myocardial infarction (STEMI). This is generally the result of a 
complete coronary artery occlusion.
When there is no complete occlusion of the coronary artery, the blood flow can still be 
heavily reduced, resulting in the release of biomarkers though the electrocardiogram 
may show no characteristic changes. This manifestation of ACS is named Non-ST-
segment Elevation Myocardial Infarction (NSTEMI).
When the blood flow is reduced but still sufficient for the myocardial tissue to survive, 
no biomarkers are released and no characteristic changes on the electrocardiogram 
are present. However, these patients may experience typical symptoms such as chest 
pain during rest. In these cases, the manifestation of ACS is named Unstable Angina 
pectoris (UA). 
Of all patients with ACS, 47% is diagnosed with STEMI and 48% with NSTEMI or UA, 
while 5% has an undetermined electrocardiogram pattern.9 An overview of the three 
manifestations is provided in Figure 1.
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Figure 1 The three clinical manifestations of acute coronary syndrome
FREQUENCY AND SEVERITY OF ACS
Internationally
The number of patients with an ACS decreased in the last decade. The incidence of 
STEMI and NSTEMI was 28% lower in 2008 than in 2000 (208 and 287 cases per 100,000 
person-years respectively).10 
Patients with an ACS have a higher risk of developing other life-threatening cardiac 
complications such as cardiogenic shock, heart failure11 or cardiac arrhythmias12. 
Consequently, acute coronary syndrome increases the risk of dying both on the short 
as well as the longer term. Of the patients with STEMI who are treated at the hospital, 
4.6% die during admission, while an additional 4.5% die within the six months after 
hospital discharge.13 Patients diagnosed with NSTEMI and UA are more likely to survive 
as in-hospital mortality and mortality after 6 months are 2.2% and 3.3% respectively. For 
STEMI, the in-hospital mortality decreased, while for NSTEMI and UA, the 6-month 
mortality decreased over the years.13 
Despite improvements in survival, ACS remains a major cause of mortality and 
morbidity in the world and further improvements in its management are imperative. 
Although recent numbers are lacking, the annual health care costs have been estimated 
at billions per country.14
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The Netherlands
In the Netherlands, 78 people are hospitalized with STEMI or NSTEMI every day.15 The 
mortality rates due to ACS have been decreasing slightly over the years.16 In 2014, over 
5,000 people died from STEMI or NSTEMI (Table 1).
Table 1 Deaths due to acute myocardial infarction in the Netherlands over the years 
1996-2015
Year 1996 2000 2005 2013 2014 2015
Death due to AMI 15,145 12,898 9,445 5,688 5,301 5,403
AMI = acute myocardial infarction. Source: Statline, Statistics Netherlands, Den Haag/Heerlen. Updated 
18-06-2017.
However, the costs of the management of patients with cardiovascular diseases have 
increased by 7.6% between 1999 and 2010. The total costs for patients with ischaemic 
heart disease were 2.1 billion euro in 2011, or 2.3% of the total health care costs.17 ACS 
therefore represents an enormous societal and financial burden, and aggressive and 
elaborate management is warranted.
PREVENTION AND MANAGEMENT OF ACS
Much research has been done on the prevention and management of cardiovascular 
disease, including ACS. The prevention starts with the promotion of a general healthy 
lifestyle and environment, e.g. not smoking and eating healthy.18 In addition, primary 
care focusses on monitoring people at increased risk of developing ACS, such as people 
with hypercholesterolaemia, high blood pressure or people who smoke. These risk 
factors can be controlled by interventions such as prescribing blood pressure lowering 
medication or advising on smoking cessation. When increased primary prevention 
efforts result in improved risk factor control (e.g. lower blood pressure), it is expected 
that the incidence of ACS will also decrease.19, 20 
When patients experience symptoms of ACS, it is essential that they recognize these, 
acknowledge their severity, and contact a health care provider as soon as possible. 
The care professionals who come into contact with the patient first have to assess the 
likelihood that the patient has an ACS.21 This is performed by means of history taking, 
electrocardiogram recording and biomarker measurement (at the hospital). After the 
diagnosis of ACS has been established, it is vital to assess the patient’s risk of heart 
failure, recurrent ACS or mortality. The management strategy depends on that risk, and 
differs between the three manifestations of ACS.22, 23 
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ACUTE MANAGEMENT OF STEMI
In the era of Heberden, there was little understanding of the pathophysiological 
mechanism of ACS. Patients were therefore ‘treated’ with bed rest until their chest 
pain was over.24 Nowadays in patients diagnosed with STEMI, it is commonly known 
that restoring the blood flow to the myocardial tissue (reperfusion) as soon as possible 
is of vital importance.25 Medication is administered immediately to reduce the blood 
clot formation e.g. acetylsalicylic acid and a P2Y12 receptor inhibitor. Subsequently, 
a coronary angiography is performed to identify the location of the stenosis and the 
severity of blood flow reduction in the coronary arteries. Angiography is an X-ray based 
technique with which the coronary arteries are visualized by means of a radioactive, 
fluorescent liquid that is injected into the arteries. When severe coronary stenosis is 
detected, the preferred reperfusion treatment is percutaneous coronary intervention 
(PCI).26 PCI is a minimally invasive (catheter based) technique first introduced by Swiss 
radiologist Andreas Grüntzig. With this technique, a balloon is placed and inflated on 
the location of the coronary stenosis, which forces the artery open.27 Grüntzig used a 
technique that was previously applied to open an occlusion in the arteries of the leg by 
Charles Dotter,28 hence the Dutch word for PCI ‘dotteren’. 
It is essential to treat STEMI patients with PCI as soon as possible, as the likelihood of 
dying after STEMI increases with 7% for every 30 minute increase in the time between 
symptom onset and reperfusion.29 The general consensus is that patients should receive 
PCI within 90 minutes from first (para)medical contact. While the time dependency of 
pharmacological reperfusion therapy (thrombolysis) was already confirmed by a meta-
analysis in 1994,30 it was not until the year 2000 that a similar time dependency was 
demonstrated for PCI by Cannon and colleagues31. 
When revascularization by means of PCI is not possible, e.g. due to multiple occluded 
arteries, patients are reviewed in a multidisciplinary heart team32 and referred for 
optimal pharmacological management or coronary artery bypass grafting (CABG). In 
this surgical procedure, the occlusion in the coronary artery is bypassed by grafting a 
blood vessel which is commonly excised from the patient’s arm or leg.
ACUTE MANAGEMENT OF NSTEMI AND UA
While coronary angiography and PCI are indicated for most patients with STEMI, not 
all patients with NSTEMI or UA benefit from it as the population is more heterogeneous 
in terms of risk and prognosis.22 Therefore it is important for these patients to weigh 
the risk and benefit of invasive treatment against the risk of reinfarction or death by 
means of validated risk scoring instruments.33 When the estimated risk of reinfarction 
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or death is low or the estimated risk of adverse outcomes after a PCI procedure is high, 
pharmacological therapy is provided to prevent disease progression.22 In case the patient 
is assigned to PCI treatment, the procedure should be initiated within two hours for 
very high risk, within 24 hours for high risk and within 72 hours for other patients.22 
SECONDARY PREVENTION
After the immediate treatment of ACS, the risk of a recurrent ACS is increased due to 
inflammation in the plaque.34 It is essential to prevent recurrence of ACS by means of 
additional pharmacological therapy, risk factor control and lifestyle changes.35 In order 
to reduce the risk of blood clot formation, medication is provided to inhibit platelet 
aggregation, e.g. a combination of acetylsalicylic acid and a P2Y12 receptor inhibitor. 
Moreover, statins are prescribed to lower cholesterol (one of the ACS risk factors) and 
to reduce the inflammation in the atherosclerotic plaque, consequently limiting the 
chances of a plaque to rupture.34 Finally, beta blockers and Angiotensin converting 
enzyme (ACE)-inhibitors are prescribed to lower the blood pressure. 
In addition to medication for secondary prevention, specialized cardiac rehabilitation 
programs which focus on physical exercise, lifestyle and psychosocial health after an 
ACS are provided.35
THE ORGANISATION OF ACS CARE IN THE NETHERLANDS
Many care providers are involved in the prevention and management of ACS in the 
Netherlands. General practitioners monitor people at an increased risk of ACS. When 
an acute coronary syndrome occurs during business hours, patients call or visit their 
general practitioner. Outside of business hours, general practitioners cooperate in 
after-hours clinics. The policy for general practitioners when they suspect an ACS is 
to call an ambulance immediately.36 Alternatively, the patient can call an ambulance 
directly through the national emergency phone number (112) or go to the emergency 
department of a hospital. The emergency medical services in the Netherlands (the 
combination of dispatch centres and ambulances) are organised in 25 self-dispatching 
ambulance regions (Figure 2).
For ambulances, the policy for patients suspected of STEMI is to make a tentative 
diagnosis based on careful evaluation of the patient’s signs and symptoms and 
an electrocardiogram performed on-site. In case a STEMI is confirmed by the 
electrocardiogram, acute care medication is provided (e.g. acetylsalicylic acid and 
P2Y12 inhibitor) and the patients is immediately transported to a PCI capable hospital 
to undergo primary PCI.37 PCI is the reperfusion therapy of choice in the Netherlands 
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as it has been shown to be superior compared to pharmacological reperfusion therapy 
(thrombolysis or fibrinolysis).38 At the start of our research (2013), 30 PCI capable 
hospitals served a population of 16.8 million people in the Netherlands. When compared 
to other European countries, this can be considered good geographical accessibility.39 
Patients with NSTEMI or UA are transported to the nearest hospital with appropriate 
care facilities (e.g. a coronary care unit). 
 
Figure 2 Ambulance regions and PCI centres (dots) in the Netherlands in 2013 (Sources: 
www.zorgatlas.nl, AZN, NVVC white lists for PCI centres)
Secondary prevention after ACS is initially provided in cardiac rehabilitation programs 
of hospitals in the Netherlands.40 These multidisciplinary programs consist of modules 
for physical exercise, psychological health, social health and lifestyle provided by 
cardiologists, nurses, physical therapists, psychologists, social workers and dieticians.35 
After participation in the program, secondary prevention therapy is continued during 
regular checks with a cardiologist and/or cardiac care nurse, and eventually taken over 
by the general practitioner. 
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VARIATION
The above description of the management of ACS in a care chain is based on perfect 
application of the cardiology guidelines. However, not all of these steps are taken 
for all patients with ACS, resulting in variation in its management. This variation 
can be caused by medical reasons and/or patient preference, but some variation is 
unwarranted. This unwarranted variation potentially affects the quality of care (and 
thereby patient outcomes)41 and is therefore of interest for the field of health services 
research.
THE QUALITY OF CARE FOR PATIENTS WITH ACS
According to the Institute Of Medicine and the World Health Organization, health 
care should be effective, efficient, accessible, acceptable, patient-centred, equitable 
and safe.42 In this thesis, the focus will be on the effectiveness of the care for patients 
diagnosed with ACS. Effectiveness is defined as the extent to which the delivered health 
care is adherent to an evidence base and results in improved outcomes for patients, e.g. 
reduced morbidity and mortality, and an improved quality of life.41 Adherence to the 
evidence base is important to reduce under- and overuse of interventions in health care 
as new evidence comes to light. However, the evidence base is ever growing. In order 
to keep up with all the developments within the medical specialism of cardiology, one 
would need to read 75 papers on trials and 11 papers on systematic reviews every day.43 
The evidence is therefore periodically summarized in evidence-based guidelines.42
GUIDELINES
Use of these guidelines standardizes care and assists physicians in making treatment 
decisions for patients with ACS. One of the key developers of cardiology guidelines 
in Europe is the European Society of Cardiology (ESC). The first ESC guideline for 
the management of ACS was presented in 1996.44 Since then, multiple guidelines 
on the management of STEMI and NSTEMI/UA, and specifically on prevention and 
revascularization have been published. These guidelines are created by means of 
a review of the literature, of which the findings are synthesized by a task force.45 In 
general, adhering to the guidelines can be considered good quality of care, although 
physicians can always deviate from guidelines with sound medical rationale. However, 
creating evidence-based guidelines does not guarantee that care providers also know 
of, use and apply them in clinical practice. Suboptimal implementation can result in 
unwarranted practice variation, e.g. patients in one hospital are treated differently 
than in another hospital without medical rationale for this difference. Therefore, it 
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is important to monitor and improve guideline adherence, e.g. by means of quality 
indicators. 
QUALITY INDICATORS
The purpose of quality indicators is to measure, evaluate and ultimately improve the 
quality of care, and/or to provide transparency in the quality of care for accountability 
purposes. The quality of health care can be evaluated on its structures, processes 
and outcomes.46 In order to improve the outcomes of care, it is essential to have an 
organisational structure in which appropriately trained health care professionals are in 
the right place at the right time. In addition, the care processes should be in accordance 
with the latest scientific evidence. Adhering to these two criteria should eventually lead 
to optimal patient outcomes. 
Development of quality indicators is preferably performed by combining a systematic 
review of the literature with consensus meetings.47 The literature review is used to 
identify all possible evidence-based aspects of the care, resulting in a large pool of 
potential quality indicators. This pool needs to be reduced as the administrative burden 
in hospitals is already high and can take resources away from patient care. In one or 
more consensus meetings, an expert panel therefore selects a number of indicators 
which they consider as most useful, reliable and valid in evaluating the quality of 
care. Only the quality indicators with satisfactory ratings on all criteria are included 
in the final indicator set. Because the guideline development should already include a 
systematic literature review and an expert panel, the development of quality indicators 
can be integrated in this process. Since guidelines are generally lengthy manuscripts 
with numerous recommendations, only the recommendations with the strongest link 
to patient outcomes and measurable in practice should be selected to serve as quality 
indicator.47 The synthesis from scientific evidence to quality indicators is summarized 
in Figure 3. 
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Figure 3  The synthesis of scientific evidence into quality indicators 
 
Quality indicators can be informative for many stakeholders in health care i.e. 
clinicians, hospital executive boards, health insurance companies, the health care 
inspectorate and patients.48  
Clinicians can use their performance on indicators to monitor and improve their 
practice and identify unwarranted practice variation within their organisation, 
assisted by quality officers at the hospital (performance feedback). By comparing their 
practice to other, comparable care providers (benchmarking), they can identify 
suboptimal performance. Benchmarking has been identified as an excellent tool to 
improve practice.49 Ideally, measuring quality indicators leads to health care 
organisations that are aiming to continuously improve their practice, i.e. learning 
organisations.50 
The hospital executive board is ultimately responsible for the quality of the care 
provided in the hospital. Quality indicators offer the executive board of a hospital a 
way to monitor the quality performance of various hospital departments, usually 
through quality officers. In organisational management, these indicators can be a 
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Quality indicators can be informative for many stakeholders in health care i.e. clinicians, 
hospital executive boards, health insurance companies, the health care inspectorate 
and patients.48 
Clinicians can use their performance on indicators to monitor and improve their 
practice and identify unwarranted practice variation within their organisation, assisted 
by quality officers at the hospital (performance feedback). By comparing their practice 
to other, comparable care providers (benchmarking), they can identify suboptimal 
performance. Benchmarking has been identified as an excellent tool to improve 
practice.49 Ideally, measuring quality indicators leads to health care organisations that 
are aiming to continuously improve their practice, i.e. learning organisations.50
The hospital executive board is ultimately responsible for the quality of the care 
provided in the hospital. Quality indicators offer the executive board of a hospital a way 
to monitor the quality performance of various hospital departments, usually through 
quality officers. In organisational management, these indicators can be a valuable 
addition to other performance indicators, e.g. financial or human resource indicators. 
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Besides clinicians and the hospital itself, the information derived from quality indicators 
can also be of use to health insurance companies. The Dutch health care system is 
designed with a quality role for the health care insurance companies in mind. These 
companies should selectively purchase care that conforms to their predefined quality 
standards. So far, there is little reliable and valid information pertaining to health care 
quality available. 
Furthermore, the health care inspectorate (IGZ) can use the indicators to monitor 
performance and safety of the provided care and intervene when it falls below a certain 
threshold and patients might be at risk. 
Finally, when the right content is presented in the right form, patients should be able to 
use information from indicators to make an informed choice for a care provider when 
they require care.51 In the Netherlands, this role is facilitated by the Netherlands Health 
Care Institutes (Zorginstituut). 
QUALITY IMPROVEMENT
The overarching goal of monitoring the quality of care is to facilitate continuous quality 
improvement. Monitoring is therefore a vital part of many quality improvement models, 
e.g. Six Sigma (define, measure, analyse, improve, control), Lean (reducing the number 
of process steps) and Plan-Do-Check-Act.52 The latter is one of the most commonly 
used methods for quality improvement in health care. By monitoring the current 
performance, targets for improvement can be identified and the most appropriate 
improvement strategy can be identified by in-depth analyses of the results on the 
quality indicators (Plan). When carrying out the plans (Do), it is vital to monitor the 
effectiveness of the quality improvement efforts (Check). The information from quality 
indicators enables measurement of the effectiveness of the quality improvement efforts 
and adjustment where required (Act). Afterwards, new targets for quality improvement 
are defined and the cycle continues.
In health care, the ultimate goal of quality improvement is to improve patient outcomes. 
However, a sole focus on outcomes offers no direction for improvement, as it is unclear 
what might have contributed to the improved patient outcomes. Thus, measuring 
structures and processes provides insight in where improvements can be made. In 
the management of ACS, process improvements have been linked to improvements 
in outcomes53,54 and therefore provide a useful approach in improving the care. 
Improving the structure and process of care will ideally lead to improved outcomes. 
Before improvement is possible, the current quality of the process of care should first 
be monitored.55
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VMS SAFETY MANAGEMENT PROGRAM
In 2004, a report of Shell Netherlands CEO Rein Willems (expert in safety management) 
recommended several ways to improve hospital care in the Netherlands.56 Furthermore, 
a report on adverse events in 2007 indicated that 5.7% of the patients treated in 
hospitals experienced an adverse event57 i.e. an unintended injury related to medical 
management instead of the disease.58 As a result, the Netherlands Federation of 
hospitals (NVZ), the Netherlands Federation of University Medical Centres (NFU), 
the Dutch nursing society (V&VN) and Netherlands Order of Medical Specialists 
(OMS, currently known as FMS) initiated a safety program. The program focussed on 
ten clinical themes (and eventually an eleventh was added) and on implementing a 
safety management system to reduce adverse events. A safety management system is a 
hospital system to continuously identify risks, report incidents, improve performance, 
create a safety culture, and document, evaluate and adapt safety policy. 
One of the clinical themes was ‘Optimal care for acute coronary syndromes’. For each 
theme, a practice guide was developed by an expert panel from the respective field. The 
practice guide for ACS management highlighted important recommendations from the 
ESC guidelines and contained a set of five quality indicators to evaluate the structure, 
process and outcome of care. To evaluate the structure of ACS care, all hospitals 
were required to have a policy to refer all ACS patients for cardiac rehabilitation. The 
process was evaluated by three quality indicators: the number of STEMI patients who 
were treated with PCI within 90 minutes from first medical contact; the number of 
NSTEMI/UA patients in which validated cardiac risk scores were used to decide on the 
type of treatment to initiate; and the number of ACS patients in which the guideline 
recommended secondary prevention medication was prescribed at discharge. Finally, 
the outcome of care was evaluated by determining the number of patients who died 
within 30 days after being diagnosed with ACS (for internal use only). The quality 
indicators are shown within the care pathway of ACS in Figure 4. 
The intention of this safety program was that hospitals would upload the results on 
these quality indicators to a national online tool, in order to enable benchmarking of 
performance. However, this challenge proved too big, resulting in a lack of national 
data and a premature termination of the online tool. Consequently, there was no 
information about the performance of hospitals on the VMS quality indicators. To 
obtain this information, independent research institutes (EMGO+ and NIVEL) were 
asked by the Dutch Ministry of Health, Welfare and Sports to evaluate the effects of 
the VMS program.
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Figure 4  The usual management of patients with acute coronary syndrome and the 
VMS quality indicators. For overview purposes, coronary artery bypass grafting was 
not included as a treatment option. ACS = acute coronary syndrome; ECG = 
electrocardiogram; STEMI = ST-segment elevation myocardial infarction; NSTE-ACS = 
non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment 
elevation myocardial infarction; UA = unstable angina; intermed = intermediate; 
golden five = acetylsalicylic acid, P2Y12 receptor inhibitor, statin, beta blocker and 
angiotensin converting enzyme inhibitor. VMS ACS quality are highlighted in blue. 
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FOCUS AND OBJECTIVES
Although the quality of care for patients with ACS has improved tremendously over 
the years, many patients still die as a result of ACS. Consequently, small improvements 
in the quality of care can result in large positive effects on patient outcomes on a 
national level. In the management of ACS, process improvements have been linked to 
improvements in outcomes53, 54 and therefore provide a useful approach in improving 
the care. Furthermore, several interventions to improve ACS care processes were 
previously described in scientific literature.59, 60
However, there is little information about the quality of the care process in the 
management of ACS patients in the Netherlands. Previous initiatives to obtain 
information about the quality of the care process have predominantly been local 61, 62 
or regional 63, 64 and indicate that there is ample room for improvement. In addition, 
there is no national data ACS registry,65 in contrast to other countries (e.g. Sweden, 
United Kingdom, and the United States66). Due to the premature termination of the 
online VMS tool to upload the results of the quality indicators, there is no information 
on the potential room for improvement and unwarranted practice variation in Dutch 
ACS care. 
Therefore, in this thesis the quality of ACS management is evaluated by measuring two 
process quality indicators with an established association with patient outcomes from 
the VMS quality improvement program: timely invasive treatment31, and prescription 
of secondary prevention medication at discharge53. These quality indicators were 
subsequently adapted to match the ESC guidelines more closely and were further 
specified to match Dutch Cardiology practice (e.g. the start and end of the treatment 
delay indicator). 
The research questions of the thesis are: 
1) to what degree are the guideline recommendations for minimizing treatment delay in 
STEMI and the prescription of secondary prevention medication adhered to in Dutch 
hospitals?
2) to what extent is there unwarranted process variation in the performance of hospitals 
on these quality indicators? 
3) what interventions are most effective for improving the ACS care process?
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These research questions are described in several chapters. In chapter 2 an overview of 
the literature and the design of a national study to evaluate the quality of the process 
of ACS management by means of patient record review are presented. In chapter 3 the 
treatment delay and associated factors for patients with STEMI are explored. Chapter 
4 describes the effects of data and definition issues on the treatment delay quality 
indicator scores. In chapter 5 a qualitative analysis (by means of a multiple case study) 
of the acute processes of care for STEMI patients in more detail, including accelerating 
factors as perceived by health care providers. In chapter 6 the guideline adherence and 
associated factors in prescribing secondary prevention medication at discharge from 
the hospital are explored. Chapter 7 contains a systematic review of interventions to 
improve guideline adherence in the process of ACS care and their effectiveness. Finally, 
in chapter 8 the main findings are discussed; the VMS ACS quality indicators are 
reflected upon; (methodological) considerations are presented; and lessons learned 
are summarized in recommendations for clinical practice and future research. 
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ABSTRACT 
Background: Increasing guideline adherence in the management of acute coronary 
syndrome (ACS) in hospitals potentially reduces heart failure and mortality. 
Therefore, an expert panel identified three guideline recommendations as the most 
important aims for improvement in ACS care, i.e. timely invasive treatment, use of 
risk scoring instruments and prescription of secondary prevention medication at 
discharge.
Aims: This study aims to evaluate in-hospital guideline adherence in the care of 
patients diagnosed with ACS and to identify associated factors.
Methods: The study has a cross-sectional design. Data are collected in 13 hospitals 
in the Netherlands by means of retrospective chart review of patients discharged 
in 2012 with a diagnosis of ACS. The primary outcomes will be the percentages of 
patients receiving timely invasive treatment, with a documented cardiac risk score, 
and with a prescription of the guideline-recommended discharge medication. 
In addition, factors associated with guideline adherence will be studied using 
generalised linear (mixed) models.
Discussion: This study explores guideline adherence in Dutch hospitals in the 
management of patients diagnosed with ACS, using a data source universally 
available in hospitals. The results of this study can be informative for professionals 
involved in ACS care as they facilitate targeted improvement efforts.
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BACKGROUND
Patients diagnosed with an acute coronary syndrome (ACS) have a high risk of dying 
from their condition. Mortality rates differ for the three clinical manifestations of 
ACS: ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation 
myocardial infarction (NSTEMI) and unstable angina (UA).1 The symptoms of ACS 
are usually caused by the same pathophysiological mechanism, i.e. coronary stenosis. 
However, the differences in severity of coronary stenosis and mortality have led to 
differences in the management of ACS.2, 3
Improved management strategies for patients diagnosed with ACS have led to a 
decrease in mortality rates in the past years.4-6 For patients with STEMI the strategy 
progressed from acute pharmacological intervention (thrombolysis) to immediate 
percutaneous coronary intervention (PCI).7 In the management of NSTEMI and UA 
patients, risk scoring instruments were developed and implemented to estimate 
patients’ future risk of major adverse cardiac events in order to weigh the risks and 
benefits of invasive treatment.8 Independent of the type of ACS, prescribing secondary 
prevention medication further reduces morbidity and prevents additional episodes of 
ACS.9 Using the aforementioned strategies increases patients’ chances of survival10, 11 
and these strategies are therefore incorporated in international cardiology guidelines12, 
13.
However, previous studies reported that not all patients are treated according to 
these guideline-recommended strategies.14, 15 For example, patients with higher age, 
female sex, prior heart failure, renal insufficiency or coronary artery bypass graft 
(CABG) surgery during admission were less likely to receive guideline-recommended 
discharge medication.16 Also, variation in guideline adherence between hospitals has 
been reported.10 To identify room for improvement in the management of ACS, it is 
imperative to monitor guideline adherence and to identify associated factors.
The objective of this study is therefore to determine the degree of ACS guideline adherence 
in Dutch hospitals. A Dutch expert panel identified timely invasive treatment, use of 
cardiac risk scoring instruments and prescribing guideline-recommended discharge 
medication as the most important aims for improvement in ACS care. A secondary 
objective of this study is to explore patient and hospital characteristics associated with 
guideline adherence. In the present paper, the design of the study will be outlined.
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RESEARCH QUESTIONS
To what degree are:
•	 patients diagnosed with STEMI treated with PCI within 90 min of first (para)
medical contact?
•	 cardiac risk scoring instruments used in the management of patients diagnosed 
with NSTEMI/UA?
•	 the recommended medicines for secondary prevention prescribed to patients 
diagnosed with ACS at discharge from the hospital?
Additionally, what patient and hospital characteristics are associated with guideline 
adherence?
METHODS/DESIGN
DESIGN
The study has a cross-sectional design.
SETTING
In the Netherlands 30 out of the 91 hospitals offer PCI, of which 16 also provide 
CABG surgery. The three guideline recommendations monitored in the present study 
were identified from the European Society of Cardiology guidelines by an expert 
panel consisting of cardiologists, an emergency department medical resident, an 
intensive care/cardiac care nurse and health care scientists. Adherence to these three 
recommendations is measured over 2012, the last year of a national quality improvement 
program. The program aims to decrease in-hospital mortality caused by ten high-risk 
patient safety threats, including ACS.17
SELECTION OF HOSPITALS
The study is being conducted in 13 hospitals, selected by means of a multi-stage random 
sampling procedure. Initially six PCI-capable and six non-PCI-capable hospitals 
with a cardiology department were randomly selected from a pool of 40 randomly 
selected hospitals. Three PCI-capable hospitals declined participation, for which three 
additional PCI-capable hospitals were selected. Because the number of STEMI patients 
was relatively small, an additional PCI-capable hospital was selected. The hospitals are 
located in 7 of the 12 Dutch provinces, with bed capacities ranging between 200 and 
1200 beds (Table 1).
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DATA COLLECTION
The data are collected by means of retrospective chart review of electronic and/or paper-
based medical, nursing and catheterisation laboratory charts of patients discharged 
between January 1st and December 31st, 2012. Monthly, potential study charts are selected 
from the hospital billing system using diagnosis-treatment combination codes. Charts 
of patients discharged with a confirmed diagnosis of ACS (indicated in the discharge 
letter) are considered for inclusion (Fig. 1). When the discharge diagnosis is unclear, the 
chart is discussed with a cardiologist or other attending physician working in the field 
of cardiology. Charts of patients without a discharge diagnosis of ACS, a secondary ACS 
(e.g. due to anaemia), elective procedures, missing or uninformative charts, and charts 
of patients under the age of 18 years are excluded from the study. Moreover, additional 
exclusion criteria were defined for each process indicator separately. For timely invasive 
treatment, charts of STEMI patients not going for acute PCI are excluded. For use of risk 
scoring instruments, charts of patients transferred from another hospital are excluded. 
For discharge medication, charts of patients who were transferred to another hospital, 
patients who died during their admission or received palliative treatment are excluded.
If the monthly number of charts exceeds the screening capacity, screening of the charts 
is performed in chronological order of discharge representing STEMI and NSTEMI/
UA equally, and terminated when the chart abstractors are practically unable to screen 
additional charts.
In two hospitals, the pre-selection procedure based on the hospital billing system 
is not possible. Therefore, in one hospital the pre-selection of charts is performed 
by requesting all charts of patients with a suspected or confirmed diagnosis of ACS 
through the cardiology department’s secretariat. In the other hospital, local hospital 
regulations require that patients with a suspected ACS are informed about the study 
and asked to give informed consent before their chart can be considered for inclusion. 
Due to the declined invitations and deviations in inclusion procedures, data collection 
in 5 hospitals will comprise 9 or 10 months instead of 12 months.
STUDY OUTCOMES
The study has three main outcome measures. First, the percentage of STEMI patients 
in which the PCI procedure started within 90 minutes from first (para)medical contact. 
Second, the percentage of NSTEMI or UA patients where use of a validated risk scoring 
instrument was documented. Finally, the percentage of ACS patients with a prescription 
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of the recommended discharge medication, documentation of a contraindication or 
other reason for not receiving the recommended medication. Additionally, patient and 
hospital characteristics associated with guideline adherence will be identified.
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Figure 1. Flow chart of the selection of patient charts. ACS acute coronary 
syndrome; STEMI ST-segment elevation myocardial infarction; NSTEMI non-ST-
segment elevation myocardial infarction; UA unstable angina 
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Table 2. Information recorded for all ACS patients
General information Discharge medication (yes/no)
Gender Acetylsalicylic acid
Date of birth Thienopyridine
Admission date and time Statin
Complaints Beta blocker
Discharge date Angiotensin Converting Enzyme-inhibitor
Discharge status (discharged, deceased, unknown)
Contraindications (yes/no)
History of cardiac disease (yes/no) Acetylsalicylic acid
Coronary vascular disease Coagulation defect
Peripheral vascular disease Active peptic ulcer (ulcus pepticum)
(Unstable) angina pectoris   Stroke (bleeding)
Acute myocardial infarction Liver failure
Coronary artery bypass graft surgery, year: ______ Kidney failure
Percutaneous coronary intervention, year: ______ Allergy/oversensitivity
Intervention/acute myocardial infarction < 6 months Treatment with anti-coagulant medication 
G6PD-deficiency 
Risk factors (yes/no) Other:
Diabetes mellitus Thienopyridine
Hypertension Transient ischemic attack/cerebrovascular 
accident
Kidney failure Active peptic ulcer (ulcus pepticum)
Chronic heart failure Liver failure
Positive family history  Pathological bleeding (from ulcus pepticum or 
intracranial bleeding)Smoker
Previous smoker Other:
Elevated cholesterol levels (statin use in history, 
hyperlipidaemia, hypercholesterolemia)      
Obesity (body mass index >30 kg/m2)  
Obesity (body mass index >30 kg/m2)  
Statin
Liver function impairment
Renal impairment
Other:
Coronary stenosis >50% (in history) Beta blocker
Age >70 year Sick-sinus syndrome
Male sex 2nd and 3rd degree AV-block (ECG)
Aspirin use (<7 days) Hypotension
Cardiogenic shock
Vital functions Sinus bradycardia
Cardiogenic shock (yes/no) Unstable or untreated heart failure
Heart failure (yes/no) Pheochromocytoma
Resuscitation (yes/no) Bronchial asthma (anamnesis)
Blood pressure on arrival Severe peripheral circulation defects
Heart rate (beats per minute) Metabolic acidosis
Electrocardiogram date and time Pulmonary hypertension 
Electrocardiogram interpretation 
Biomarker values (troponin, creatinin kinase (CK), 
creatinin kinase-muscle/brain (CK-MB), creatinin)
Kidney failure 
Liver failure
Myocardial infarction with heart frequency 
<45, P-Q >0.24, systolic blood pressure <100
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Cardiac rehabilitation (yes/no) Other:
Enlistment for cardiac rehabilitation Angiotensin Converting Enzyme-inhibitor
Kidney failure
Other
ACS = Acute Coronary Syndrome
RECORDED VARIABLES
From all charts, the following information is abstracted: demographic and clinical 
information including gender, age, cardiac history, risk factors, biomarker values, 
electrocardiogram findings, resuscitation, heart failure, cardiogenic shock on arrival 
and month of discharge (Table 2).
In addition, for the timely invasive treatment indicator, the following variables are 
recorded: routing of the patient, type of first (para)medical contact, place of first 
electrocardiogram, type of treatment, and the dates and times of first (para)medical 
contact, first (ambulance/general practitioner) electrocardiogram and sheath insertion 
(start of PCI) (Table 3).
Table 3. Additional recorded variables for STEMI patients
General information
Routing out-of-hospital
Type of treatment (pharmacological, acute percutaneous coronary intervention, non-
acute percutaneous coronary intervention, coronary artery bypass graft surgery)
Discipline of first (para)medical contact
Discipline of first electrocardiogram
Number of diseased vessels
Location of stenoses
Time variables
Symptom onset
First (para)medical contact
First electrocardiogram
Sheath insertion
First balloon inflation or thrombus aspiration
STEMI = ST-segment Elevation Myocardial Infarction
To evaluate cardiac risk score adherence, application of a validated risk scoring 
instrument (e.g. GRACE18, 19, TIMI20, FRISC21, HEART22 and PURSUIT8), type of 
instrument, risk score outcome, date of application, and type of treatment are recorded 
(Table 4).
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Table 4. Additional recorded variables for NSTEMI and UA patients
General information
Routing in-hospital
Catheterization (yes/no)
Type of treatment (pharmacological, percutaneous coronary intervention, coronary 
artery bypass graft, unknown, other)
Risk score
Use of validated risk score (yes/no)
Date of application
Type of instrument(s)
Risk score outcome
Risk score outcome classification
Additional diagnostics
NSTEMI = Non-ST-segment Elevation Myocardial Infarction; UA = Unstable Angina
Finally, for discharge medication, prescription of acetylsalicylic acid, thienopyridine, 
statin, beta blocker and angiotensin-converting enzyme (ACE) inhibitor and 
contraindications or other reasons for not prescribing all or some of the medication are 
recorded (Table 2). Contraindications were derived from an annually updated database 
containing information about all medication registered in the Netherlands.23
ABSTRACTION OF DATA
All data are collected on standard case report forms. Variables are defined in code-
books. Two researchers (JT & JE) developed the codebooks and case report forms based 
on the European Society of Cardiology guidelines. The case report forms were discussed 
within the research group, tested in two pilot measurements and adjusted accordingly. 
The data are collected by six chart abstractors who were introduced to the subject of 
ACS and instructed in the chart review procedures by JT and JE. Chart reviews were 
supervised until the quality of the chart reviews was satisfactory. The data are entered 
into a database using a data entry program with fixed entry fields (BLAISE version 4.7, 
Statistics Netherlands) and compared with the original case report form by a second 
researcher.
To ensure reliability of the data and to assess the quality of the codebook, a sample 
of charts (5–10 %) is independently screened again by one of the five other chart 
abstractors. The two case report forms are compared, and differences are discussed 
until consensus is reached. If necessary, changes are made in the original case report 
form. The reliability between the chart abstractors will be calculated by means of the 
percentage of agreement for each variable.
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STATISTICAL ANALYSES
MISSING DATA
Missing data patterns will be analysed by means of missing value analyses. Depending on 
the pattern24, missing values will be imputed by means of a single imputation (missing 
completely at random) or multiple imputation procedure (missing at random)25.
DESCRIPTIVE STATISTICS
The degree of adherence to the three process indicators will be presented by descriptive 
statistics. Associations of patient and hospital characteristics with guideline adherence 
are studied in separate analyses.
TIMELY INVASIVE TREATMENT
The time to PCI in minutes will be entered as a continuous dependent variable in 
a generalised linear model taking into account its distribution, as time variables 
are generally not normally distributed. In univariate analyses, associations of the 
independent variables, i.e. patient and admission characteristics, are studied. To 
account for clustering of patient data within hospitals, the variable ‘hospital’ and its 
significant interactions with any other of the predictor variables will be entered as a 
covariate in all univariate models.26 This is because the hospital sample size (7 PCI-
capable hospitals) is considered small for multilevel regression analysis.27 All variables 
and interactions significantly (p ≤ 0.05) associated with the time to PCI will be included 
in the multiple generalised linear model. Furthermore, to minimise the probability of 
making a type II error, all non-significant variables from the univariate models will 
be added to the multiple generalised linear model one by one. Significant variables 
(p ≤ 0.05) will be added to the final model.
USE OF RISK SCORING INSTRUMENTS
Associations of independent variables with the use of cardiac risk scoring instruments 
will be studied by means of a generalised linear mixed model (GLMM). In the analysis, 
the binary dependent variable will be the use of a validated risk score instrument. 
Independent variables will be patient characteristics, hospital characteristics and 
month of discharge. To account for clustering of the data, the model will comprise 
random effects for hospitals. First, independent variables will be tested separately 
correcting for the random hospital effects. Second, all independent variables with a 
significance level below p ≤ 0.15 will be selected. Next, pairs of selected independent 
variables will be tested jointly.
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Last, all significant (p ≤ 0.05) variables from the previous steps will be included in the 
final multivariable model. This final step also comprises a cautious consideration of 
significant (p ≤ 0.05) interaction terms.
DISCHARGE MEDICATION
Associations of independent variables with the prescription of the recommended 
discharge medication will be studied by means of GLMM. In these analyses, prescription 
of the five guideline-recommended medicines or documentation of contraindications 
(yes/no) will be the binary dependent variable. The effects of the independent variables 
including patient, hospital and discharge characteristics will be tested in univariate 
analyses. All variables with a significant association (p ≤ 0.05) with the dependent 
variable will be included in a multivariable model. To account for the effects of 
collinearity, all variables not significantly related to prescription of the recommended 
discharge medication in the univariate models will be added to the multivariable 
generalised linear mixed model one by one. Interactions will be tested and added to 
the multivariable model in case of a significant effect. In all models, hospital will be 
entered as a random effect variable to account for clustering of the data. As not all 
medicines are indicated for all patients with ACS according to the European Society 
of Cardiology guidelines (e.g. ACE-inhibitors are recommended for all patients with 
ACS, but only indicated for those patients with a reduced cardiac function), additional 
models will be created to analyse the effects of patient and hospital characteristics on 
the prescription of ≤3 and ≥4 medicines or documentation of a contraindication.
SOFTWARE
The data will be analysed in IBM SPSS Statistics (version 20 for Windows) and R 
(version 3.0.0 for Windows).
ETHICAL APPROVAL AND CONFIDENTIALITY
The study protocol was approved by the medical ethics review committee of the VU 
University Medical Centre. To protect patients’ and hospitals’ privacy, they are assigned 
a unique observation code. All data are stored on a password protected network server 
of the VU University Medical Centre, to which only the participating researchers have 
access. All chart abstractors signed a confidentiality agreement and the study was 
registered with the Dutch Data Protection Agency.
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DISCUSSION
This paper describes the design of a study of the quality of Dutch ACS care by evaluating 
the degree to which hospitals adhere to three key quality indicators from (inter)national 
guidelines and by exploring factors associated with guideline adherence.
Previous North American studies that monitored guideline adherence have successfully 
identified associated factors10, 16, 28, after which targeted quality improvement efforts 
could be applied. These efforts increased the likelihood that patients were treated 
on time with PCI29, risk scores were documented 30 and the recommended discharge 
medication was prescribed31. Therefore, the monitoring of guideline adherence as the 
foundation for targeted quality improvement efforts seems promising.
The three guideline recommendations evaluated in this study were selected from the 
European Society of Cardiology guidelines12, 13, but are also included in other (inter)
national guidelines32-34. The methods used in this study can be applied to evaluate the 
process of ACS care in other countries, especially in countries where large, national 
registries of guideline adherence are lacking.
POTENTIAL LIMITATIONS
In designing the study, several limitations have to be taken into account. First, the 
documented information in the charts and variability between the chart abstractors 
may affect the reliability of the data. This will be reduced by using standardised case 
report forms, a codebook and by interim reliability checks of the data. Second, using 
the diagnosis in the discharge letter as inclusion criterion may not be as reliable as 
applying our own diagnostic criteria. However, it was considered important to take into 
account the interpretation of the treating physician at the time of hospitalisation of 
the patient. Third, the presence of researchers on site, and quarterly feedback from the 
national quality improvement program might influence hospitals’ performance on the 
outcomes. However, in a report on the evaluation of the quality improvement program 
the effect of this national intervention was limited35. Finally, the selection of hospitals 
and patients could not be performed completely randomly due to practical limitations. 
However, the hospitals included in this study were geographically spread over the 
country, thereby limiting the influence of potential regional variation in guideline 
adherence. Additionally, the outcomes of this study are corrected for the influence of 
individual hospitals in the statistical models.
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CONCLUSION
Evidence-based guidelines are of vital importance in safely and effectively treating 
patients diagnosed with ACS. The results of this study will provide insight into the 
degree of guideline adherence in Dutch hospitals for the management of patients with 
ACS and identify room for further improvement. Furthermore, patient and hospital 
characteristics associated with guideline adherence will be identified, which may 
facilitate targeted improvement strategies.
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ABSTRACT 
Background: A short delay between diagnosis and treatment for patients diagnosed 
with ST-elevation myocardial infarction (STEMI) is vital to prevent cardiac damage 
and mortality. The objective of this study was to explore the treatment delay and 
associated factors in the management of patients diagnosed with STEMI going for 
percutaneous coronary intervention (PCI).
Methods: In a cross-sectional multicentre study, the treatment delay (time 
between first electrocardiogram and start of PCI procedure) of STEMI patients 
in seven PCI centres in the Netherlands was measured. Data were analyzed by 
means of multivariable generalized linear models, accounting for a non-normally 
distributed outcome and clustering of patients within centres.
Results: In total, 1017 patient charts were included. The majority of the patients 
(78.7 %) were treated within the guideline recommended time target of 90 min. 
Overall, the median treatment delay was 64 min (interquartile range 47–82). A 
significantly prolonged delay was found among patients of whom their first 
electrocardiogram was performed at a general practitioner’s practice (+23.9 min; 95 
% confidence interval 9.9–40.8) or in-hospital (+9.5 min; 95 % confidence interval 
2.5–17.3), patients requiring interhospital transfer (+14.6 min; 95 % confidence 
interval 7.6–22.4) or presenting with acute heart failure on admission (+17.6 min; 
95 % confidence interval 7.9–28.7).
Conclusions: Despite a short median delay between first electrocardiogram and 
PCI, the time targets are occasionally exceeded for patients diagnosed with STEMI. 
To further improve the process of care, PCI centres should focus on improving 
regional STEMI care networks, involving general practitioners, emergency 
departments and referring hospitals.
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BACKGROUND
There is a strong association between the time to reperfusion treatment and mortality 
for patients with ST-elevation myocardial infarction (STEMI).1 Every 30 min delay from 
symptom onset to percutaneous coronary intervention (PCI) increases patients’ risk 
of dying by 7.5 %.2 In contrast to other factors that influence the likelihood of dying 
from STEMI, e.g. heart failure, diabetes or an anterior infarction,3 the time to PCI can 
be influenced immediately by health care providers. Furthermore, time to PCI can 
be reduced in the long run by optimizing the process of care within PCI centres and 
regions.4
The importance of timely PCI treatment has been acknowledged by the European 
Society of Cardiology in their guidelines on the management of patients diagnosed with 
STEMI.5 These guidelines recommend primary PCI over fibrinolysis as the preferred 
reperfusion treatment, yet only when it can be performed within 120 min after first 
(para) medical contact. However, treatment within 90 min from first (para) medical 
contact is highly preferred, or even within 60 min in case the patients’ symptoms 
started less than two hours ago, or they present directly to a PCI centre.
Despite these recommendations, previous studies reported that a substantial number 
of patients are not treated within the recommended time targets, putting them at 
increased risk of dying from STEMI.6-8 Certain patient groups experienced a longer 
treatment delay e.g. patients who are transported from a referring hospital to a PCI 
centre (interhospital transfer).9, 10 Since these studies were performed, new management 
guidelines for STEMI were published by the European Society of Cardiology which 
recommend strategies on limiting delay, e.g. by building STEMI care networks 
consisting of PCI centres, referring hospitals and ambulance services.5
In the Netherlands, 30 out of 91 hospitals provide PCI, serving an average population 
of approximately 0.6 million citizens per PCI centre. Due to the good geographical 
accessibility of PCI centres in the Netherlands,11 PCI is the standard treatment for all 
patients diagnosed with STEMI without contra-indications for PCI. Once patients 
contact the ambulance services and they are suspected of STEMI, the goal is to directly 
transport them to the nearest PCI centre.12 However, patients can also contact the 
general practitioner or emergency department, resulting in deviating patient routes.
The process of care for patients with STEMI going for PCI is complex, and improving 
it is difficult.13 By identifying patients with a prolonged treatment delay, improvements 
in the current strategies can be facilitated or additional strategies can be developed. 
In the present study, the degree to which patients were treated within the European 
guideline recommended time targets was explored, as well as patient and admission 
characteristics associated with a prolonged treatment delay.
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METHODS
STUDY DESIGN
A cross-sectional multicentre study was conducted in the Netherlands. The study 
design, setting and methods have been previously described in detail elsewhere14 and 
are briefly outlined below.
SETTING AND POPULATION
In total, seven PCI centres in the Netherlands, selected by means of a multistage 
random selection procedure, participated in the present study. The number of acute 
PCI procedures for STEMI patients performed by the included PCI centres ranged from 
approximately 250 to more than 500 procedures per year, and five centres also provided 
thoracic surgery (Table 1).
Table 1. PCI centre characteristics (n=7)
Centre nr Type Thoracic surgery Nr of acute PCIs for 
STEMI per year*
Nr of patients 
included
1 Teaching No <300 127
2 Teaching Yes >500 112
3 Teaching No 300-400 171
4 Academic Yes >500 236
5 Academic Yes 400-500 139
6 Teaching Yes >500 112
7 Teaching Yes 400-500 120
* Based on data from the Dutch health care inspectorate, categorized to guarantee anonymity 
 of the participating centres
PCI = percutaneous coronary intervention; STEMI = ST-elevation myocardial infarction
Monthly, from each PCI centre patients diagnosed with STEMI who were discharged 
between January 1stand December 31st of 2012 were preselected by means of the hospital 
financial system codes. The charts were screened manually to confirm a documented 
discharge diagnosis of STEMI. In case the discharge diagnosis was unclear or ambiguous, 
the chart was discussed with a cardiologist or other on-site physician working in 
cardiology. Charts of patients without a discharge diagnosis of STEMI, a secondary 
infarction (e.g. due to anaemia) or with insufficient information were excluded from 
the study. Also, charts of patients with a documented sub-acute or old infarction (e.g. 
patients with an infarction of more than 12 h old, where PCI offers no clinical benefit 
over pharmacological treatment anymore), or ST-resolution on the electrocardiogram 
in combination with the absence of symptoms on admission were excluded from the 
study. Finally, charts of patients with a treatment delay of more than 6 h were excluded 
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from the study, as it was unlikely that the goal was to treat these patients with PCI 
immediately. As a result of the eight hour shifts of the data abstractors, patients were 
included in the study in chronological order of discharge until the researchers were 
practically unable to screen additional charts on the day of the measurement.
DATA COLLECTION
Data were abstracted from patient charts by six researchers. Because the time of first 
(para) medical contact was not registered consistently in all PCI centres, the time of 
the first (pre) hospital electrocardiogram was abstracted. In case patients developed 
a STEMI while being hospitalized for another illness or complaint, the time of the 
first electrocardiogram with ST-elevation in-hospital was registered. In addition, 
the time of sheath insertion at the catheterization room was registered as start of 
the PCI procedure. As a result, the treatment delay was defined as the time between 
first (diagnostic) electrocardiogram and sheath insertion. Additionally, demographic 
characteristics, cardiac risk factors, cardiac history and admission characteristics were 
abstracted from patient charts.
To ensure reliable data abstraction 80 charts (6.8 %) were screened by two researchers 
independently and the findings were compared. Differences were discussed until 
consensus was reached and adapted in the original case report form accordingly. 
Interrater reliability was calculated by means of percentages agreement for each 
extracted variable and ranged between acceptable (70 %) and perfect (100 %), with 
exception of the variable ‘type of first (para) medical contact’ (68 %). As a result of the 
latter variable’s lower reliability and its unlikely influence on the delay starting from 
first electrocardiogram, this variable was excluded from the analyses.
MISSING DATA
The treatment delay was calculated by determining the difference in minutes between 
the first electrocardiogram and sheath insertion. The resulting values were screened 
and negative values were set to missing.
In total, 6.8 % of the values of all variables in the dataset were missing. The percentage 
of missing values per variable ranged from 0.1 % (i.e. resuscitation, age, length of 
stay) to 31.6 % (time from chest pain to first electrocardiogram). The variables gender, 
month of discharge and weekend presentation had no missing values. To explore the 
underlying missing data mechanism, associations between missing and non-missing 
values were studied and Little’s test was conducted in IBM SPSS (version 20 for 
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Windows). The test was significant (p < 0.001), indicating that missing values in the 
dataset were not missing completely at random but either missing at random or missing 
not at random.15 As a result, the missing data were imputed with multiple imputation 
by assuming the data were missing at random, in which the probability for a variable 
being missing is dependent on the value of other variables in the dataset. The data were 
imputed following the approach of van Buuren.16 Prior to imputation, non-normally 
distributed continuous variables i.e. time from chest pain to electrocardiogram, 
treatment delay, and creatinine level on admission were transformed using the Box-
Cox power transformation.17 In total, 32 imputed datasets were created, following 
recommendations of White et al..18 The plausibility of the imputed data and the 
assumed missing data mechanism were checked by exploring the distributions of the 
imputed data in comparison to the original data. In these analyses, it appeared that 
the distributions of the imputed variables were comparable to those of the original 
data. It was therefore assumed that the imputation resulted in plausible values. After 
imputation, all transformed variables were transformed back to their original units. 
Model estimates were calculated for each dataset and pooled using Rubin’s rules 
embedded in the mice procedure.
Data were imputed using the mice package in R (version 3.0.0 for Microsoft Windows).19
STATISTICAL ANALYSES
Descriptive statistics were used to report patient and admission characteristics as well 
as to determine the frequency of patients who were treated within 90 and 120 min after 
first electrocardiogram. In addition, we investigated the frequency of being treated 
within 60 min for the subgroup of patients whose symptoms started less than 2 h ago or 
who presented directly to a PCI centre. For continuous variables with an approximately 
normal distribution, the means with 95 % confidence intervals (CI) are described, while 
for continuous variables with a skewed distribution the medians with interquartile 
ranges (IQR) are described. The associations of patient and admission characteristics 
with the treatment delay were tested using generalized linear models which take into 
account a skewed (Gamma distributed) outcome variable. Additionally, a log link was 
applied because negative time values are impossible.
The goal of the study was to explore factors associated with the treatment delay. 
Therefore, in univariate analyses, it was tested which variables were significantly 
(p < 0.05) associated with treatment delay. Explanatory variables with a significant 
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effect on treatment delay were entered into a multivariable generalized linear model. 
To correct for clustering of patients in PCI centres, the variable ‘PCI centre’ was added 
as a covariate in all analyses. Moreover, the process of care might differ between PCI 
centres, and therefore associations between explanatory variables and the outcome 
variable might differ. To correct for these differences, interaction terms between the 
explanatory variables and PCI centre were tested and added to the model in case they 
significantly improved the model fit.
Additionally, because collinearity can lead to unjustified exclusion of explanatory 
variables, all variables not significantly associated in the univariate analyses were 
added to the multivariable model one by one. Variables with a significant improvement 
of the model fit were added to the final multivariable model. The results of the final 
multivariable model were interpreted as the minimal delay in minutes per variable, 
holding all other variables constant. As a result of the underlying missing data pattern 
of missing at random, all reported results were based on analyses of the imputed data.
ETHICAL APPROVAL
The study protocol was approved by the medical ethical review committee of the 
VU University medical centre. Anonymity of patients and PCI centres was protected 
by coding patient and centre characteristics i.e. no names or addresses of patients 
or centres, or patient identification numbers were recorded. Data were stored on a 
password protected network of the EMGO+ / VU University medical centre. All chart 
abstractors signed confidentiality agreements, and the study was registered with the 
Dutch Data Protection Agency.
RESULTS
In total, a sample of 1170 charts of patients with a confirmed discharge diagnosis of 
STEMI was selected. Of these charts, 150 (12.8 %) patients received pharmacological 
treatment or non-acute PCI, and 3 (0.3 %) had a treatment delay of more than six 
hours. These patient charts were subsequently excluded from the study, leaving 1017 
charts for further analyses. The number of included charts per PCI centre ranged from 
112 to 236.
The mean age of patients presenting with STEMI and going for acute PCI was 62.5 years 
(95 % confidence interval: 61.3–63.7) (Table 3). The median time between symptom 
onset and first electrocardiogram was 81 min (interquartile range: 20–142) (Table 4).
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TREATMENT WITHIN GUIDELINE RECOMMENDED TIMES
The treatment times and ischemic times of the observed data are presented in Table 2. 
After imputation of the missing values, the median time from first electrocardiogram 
to PCI was 64 min (interquartile range: 47–82). PCI centres were able to treat 800 (78.7 
%) patients within 90 min from first electrocardiogram with PCI, and 918 (90.3 %) 
patients within 120 min. Of the patients who presented within two hours of symptom 
onset or who presented directly to a PCI centre (n = 700), 312 (44.6 %) were treated 
within 60 min as recommended by the guidelines.
FACTORS ASSOCIATED WITH TREATMENT DELAY
In univariate analyses, of the patient characteristics, a prior myocardial infarction 
(p = 0.046) and prior use of anticoagulants (within the last seven days) (p = 0.007) were 
significantly associated with treatment delay (Table 3).
Moreover, of the admission characteristics, the location where the first electrocardiogram 
was made (p < 0.001), interhospital transfer for PCI (p < 0.001), acute heart failure on 
admission (p < 0.001), creatinine level on admission (p = 0.03) and a stenosis in the 
left anterior descending coronary artery (p = 0.03) were significantly associated with 
treatment delay (Table 4).
When looking at differences in delaying factors per PCI centre, no interactions of PCI 
centre with patient or admission characteristics were significantly associated with 
treatment delay.
Variables with a significant association with treatment delay in univariate models were 
added to a multivariable generalized linear model. One variable with a non-significant 
association in univariate analyses improved the multivariable model fit (stenosis in the 
circumflex artery, p = 0.03) and was added to the multivariable model. No interactions 
significantly improved the multivariable model fit. In the final multivariable model, 
patients of whom their first electrocardiogram was performed at a general practitioner 
(+23.9 min; 95 % CI 9.9–40.8) or hospital (+9.5 min; 95 % CI 2.5–17.3) had an additional 
treatment delay compared to patients of whom their first electrocardiogram was made 
in the ambulance (Table 5). Moreover, patients who required interhospital transfer 
(+14.6 min; 95 % CI 7.6–22.4), with acute heart failure on admission (+17.6 min; 95 % 
CI 7.9–28.7) or with a stenosis in the circumflex artery (+4.3 min; 95 % CI 0.4–8.6) had 
a significantly longer treatment delay.
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Table 2. Treatment delay and ischemic time in various patient groups based on observed 
data
Characteristic n missing (%) treatment 
delay* 
missing (%) ischemic time** 
All patients 1017 139 (13.7%) 64 (51-84) 330 (32.4%) 148 (105-266)
Interhospital transfer for PCI
- yes
- no
1009
199
810
25 (21.6%)
110 (13.6%)
77 (58-110)
62.0 (49-79)
76 (38.2%)
248 (30.6%)
173 (118-274)
145 (101-219)
First ECG
- General practitioner
- Ambulance
- Hospital
874
25
707
142
2 (8.0%)
55 (7.8%)
10 (7.0%)
86 (68-113)
62 (49-78)
77 (60-111)
4 (16.0%)
184 (26.0%)
49 (34.5%)
199 (161-341)
141 (100-215)
189 (119-324)
* Treatment delay was defined in minutes as ranging from first electrocardiogram with ST-
elevation to start of the percutaneous coronary intervention and is not corrected for the effects of 
other independent variables
** Ischemic time was defined in minutes as ranging from symptom onset to start of the 
percutaneous coronary intervention
PCI = percutaneous coronary intervention; ECG = electrocardiogram
Table 3. Original and imputed admission characteristics and associations with on 
treatment delay in univariate analysis (n=1017)
Variable missing (%) value imputed value p-value*
Time from chest pain to ECG (median 
(IQR) minutes)
321 (31.6%) 78 (41-148) 81 (20-142) 0.12
Treatment delay (median (IQR) minutes 
from ECG to PCI)
139 (13.7%) 64 (51-84) 64 (47-82) N/A
First ECG
- General practitioner
- Ambulance
- Hospital
143 (14.1%)
25 (2.9%)
707 (80.9%)
142 (16.2%)
34 (3.3%)
809 (79.6%)
174 (17.1%)
<0.001
Weekend presentation 0 (0%) 291 (28.6%) 291 (28.6%) 0.92
Weekday evening presentation 152 (14.9%) 385 (44.5%) 450 (44.2%) 0.15
Month of discharge 0 (0%) N/A N/A 0.72
Interhospital transfer for PCI 8 (0.8%) 199 (19.7%) 200 (19.7%) <0.001
Systolic blood pressure on admission 
(mean (SD) mmHg)
45 (4.4%) 130 (26) 130 (27) 0.82
Heart rate on admission (mean (SD) 
beats/minute)
161 (15.8%) 75 (18) 75 (18) 0.48
Resuscitation 1 (0.1%) 99 (9.7%) 99 (9.7%) 0.31
Acute heart failure on admission 54 (5.3%) 47 (4.9%) 58 (5.7%) <0.001
Cardiogenic shock on admission 71 (7.0%) 37 (3.9%) 46 (4.5%) 0.06
Creatinine level on admission (median 
(IQR) mmol/L)
112 (11.0%) 78 (66-91) 77.8 (65.0-90.6) 0.03
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Table 3 continued. Original and imputed admission characteristics and associations with 
on treatment delay in univariate analysis (n=1017)
Variable missing (%) value imputed value p-value*
Nr of diseased vessels
- One
- Two
- Three
22 (2.2%)
555 (55.8%)
264 (26.5%)
176 (17.7%)
566 (55.7%)
269 (26.4%)
182 (17.9%)
0.56
Location stenoses †
- Left main 
- Right coronary
- Left anterior descending
- Circumflex
7 (0.7%)
6 (0.6%)
5 (0.5%)
7 (0.7%)
27 (2.7%)
565 (55.9%)
648 (64.0%)
400 (39.6%)
27 (2.7%)
569 (55.9%)
652 (64.1%)
405 (39.8%)
0.20
0.10
0.03
0.06
* P-values are calculated using the Wald statistics, comparing a generalized linear model with 
and without the imputed variable, corrected for clustering of patients in PCI centres
† Only stenoses ≥50%. A single patient can have more than 1 stenosis
ECG = electrocardiogram; IQR = interquartile range; PCI = percutaneous coronary intervention;  
N/A = not applicable; SD = standard deviation; mmHg = millimeter of mercury; mmol/L = 
millimoles per litre
Significant results are highlighted in bold
Table 4. Associations of patient characteristics with time from first electrocardiogram to 
PCI in the multivariable analysis
Variable % increase in 
treatment delay 
(95% CI)
Minimal increase in 
treatment delay in 
minutes (95% CI)*
p-value
Intercept N/A 59.8 (51.5;69.4) N/A
Prior myocardial infarction 3.0% (-7.6;14.9) 1.8 (-4.5;8.9) 0.59
Prior use of anticoagulants (≤7 days) 6.7% (-2.3;16.5) 4.0  (-1.4;9.9 ) 0.15
First ECG at the general practitioner 40.0% (16.5;68.2) 23.9  (9.9;40.8) <0.001
First ECG in the hospital 15.9% (4.1;28.9) 9.5 (2.5;17.3) 0.007
Interhospital transfer for PCI 24.4% (12.7;37.4) 14.6 (7.6;22.4) <0.001
Acute heart failure on admission 29.5% (13.2;48.0) 17.6 (7.9;28.7) <0.001
Creatinine level on admission (per mmol/L) 0.1% (-0.04;0.2) 0.06 (-0.02 ;0.14) 0.16
Stenosis in left anterior descending 4.1% (-2.2;10.9) 2.5 (-1.3;6.5) 0.21
Stenosis in circumflex artery 7.3% (0.6;14.4) 4.3 (0.4;8.6) 0.03
N/A = not applicable; CI = confidence interval; PCI = percutaneous coronary intervention; 
ECG = electrocardiogram
Significant results are highlighted in bold
* As a result of the generalized linear model with a gamma distributed outcome and a log 
link, combining the effects of independent variables should be performed with caution due to 
multiplicative (and not additive) effects
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DISCUSSION
Treating STEMI patients with primary PCI within the guideline recommended time 
frames is complex, and strategies to achieve them have been published in international 
guidelines in recent years. In this study, the treatment delay of patients with STEMI 
and associated factors were explored. Despite a median treatment delay of 64 min, the 
time target of 90 min was exceeded in 21.3 % of the patients. In an attempt to explain 
these findings, factors associated with a prolonged treatment delay were identified. 
Patients of whom an electrocardiogram was made at a general practitioner or hospital, 
patients requiring interhospital transfer for PCI, patients with acute heart failure or 
with a stenosis in the circumflex artery were more likely to experience a prolonged 
treatment delay. These patients have an increased but potentially preventable risk of 
cardiac damage and dying.
Several studies have investigated treatment delay previously, and found a longer median 
treatment delay than in this study.9, 10, 20 This finding may be explained by the use of a 
different definition of delay, e.g. from first (para) medical contact to PCI instead of first 
electrocardiogram to PCI. It may also be explained by the relatively high number of PCI 
centres in the Netherlands distributed over the country, resulting in good geographical 
accessibility.
The delaying factors identified in this study are comparable to other studies, in which 
patients who were transferred between hospitals had a prolonged treatment delay.9, 10, 
21 Also, a prolonged treatment delay and higher mortality were found for patients who 
first contacted a general practitioner instead of direct contact with emergency medical 
services or the hospital.22 However, in the present study, patients of whom their first 
electrocardiogram was made at a hospital also had a prolonged delay than patients 
who contacted the emergency medical services directly. These findings confirm that 
contacting the ambulance services when experiencing cardiac complaints is of vital 
importance for patients with a potential STEMI in limiting treatment delay. While 
transporting a patient directly to a PCI centre, ambulance services can contact the PCI 
centre and initiate catheterization room activation.23  This supports the European Society 
of Cardiology recommendation that the general population should be encouraged to 
contact the ambulance services instead of the general practitioner or hospital when 
experiencing symptoms of STEMI.5 However, influencing the behaviour of potential 
STEMI patients is difficult.24, 25 Therefore, new interventions to reduce patient delay are 
required, but until then improvement efforts should focus on reducing system delay 
(time from first (para) medical contact to wire passage).
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Additionally, there has been a call to form STEMI care networks with which providers 
of STEMI care can initiate interventions to speed up the process of care. In the 
Netherlands, this initiative has resulted in a national program to improve organization 
of STEMI care per region.26 For these initiatives, it is recommended to involve all 
relevant stakeholders i.e. PCI centres, referring hospitals, emergency departments 
and general practitioners within the network region. Previous improvement studies 
which excluded patients who were transferred between hospitals found no significant 
survival benefit of reducing the door-to-balloon time by 16 min.27 In this study, we have 
shown that interhospital transfer was one of the strongest predictor for a prolonged 
treatment delay. These patients therefore potentially benefit the most from reducing 
the treatment delay, which might result in improvements in survival. Consequently, in 
future studies it is important to include all patients undergoing primary PCI.
The finding that patients with acute heart failure were more likely to experience a 
prolonged treatment delay than patients without acute heart failure may be explained 
by the fact that they require more elaborate stabilization in the acute care phase. It is 
uncertain whether this delay can be reduced without compromising the safety of the 
patient, and therefore a longer delay might have to be accepted.
Also, patients presenting with a stenosis in the circumflex artery experienced a 
significantly prolonged treatment delay. A stenosis in the circumflex artery might 
indicate a lateral or posterior infarction. These patients tend to present with limited 
electrocardiogram abnormalities,28 which hampers rapid diagnosis. Use of a posterior 
electrocardiogram in the ambulance may speed up diagnosis and reduce the 
treatment delay for these patients. However, the difficulty of interpreting a posterior 
electrocardiogram might result in unnecessary activations of the catheterization room, 
and continuous education for paramedics in the regional STEMI care networks might 
be required.
LIMITATIONS
Some limitations of this study need to be taken into account when interpreting the 
results. First, the time from first (para) medical contact to wire passage, as specified in 
the European Society of Cardiology guidelines, was not registered in all participating 
PCI centres. Therefore, the time from first electrocardiogram (diagnosis) to sheath 
insertion was used to determine the treatment delay. This definition is only part of 
the time to reperfusion as described in cardiac guidelines,5, 6 who differentiate between 
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patient delay (symptom onset to first (para) medical contact) and system delay (first 
(para) medical contact to wire passage). As a consequence, the results of this study 
underestimate the treatment delay of STEMI patients in the Netherlands compared to 
other studies.29
Second, the treatment times registered in the participating PCI centres were not 
primarily registered for scientific research. This could potentially compromise the 
validity of the registered times, which would have affected the reliability of the study 
findings. However, we used automatically registered times as much as possible, i.e. times 
registered on an electrocardiogram or in the catheterization room system, and checked 
the plausibility of the calculated treatment delay. Also, the equivalent time variables 
were used by PCI centres to report quality indicators to the national government and 
were therefore also used to make policy decisions.
Third, the PCI centre in which a patient was treated was only used as a statistical 
correction in this study because of size differences between the regions in which centres 
were located. Consequently, in case of significant differences in the treatment delay 
between centres, it would be impossible to differentiate between differences caused by 
regional size or by differences in health care organization.
Fourth, in this study it was not possible to identify the correlation between treatment 
delay and hospital mortality. In the Netherlands, it is common practice to transport 
the patient from the PCI centre to their local hospital shortly after the PCI procedure 
for follow-up care. Due to Dutch privacy regulations, no information of patients could 
be linked for research purposes between hospitals. As a result, no information about 
hospital mortality could be obtained.
Finally, chart review is a data collection method with a high risk of missing values. 
However, it would be inappropriate to delete all cases with missing values as this can 
introduce bias in the study population. Therefore, extensive methods were used in this 
study to account for these missing values.
CONCLUSIONS
Despite a median treatment delay within guideline recommendations, patients 
diagnosed with STEMI who required PCI treatment were occasionally not treated on 
time as recommended in the European guidelines. A first electrocardiogram made at 
the general practitioner or hospital, and interhospital transfer resulted in a prolonged 
treatment delay for these patients. To further improve the process of care, efforts should 
focus on strengthening STEMI care networks, incorporating all relevant stakeholders 
in a region including general practitioners, referring hospitals and emergency 
departments.
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ABSTRACT 
Aim: To assess the comparability of five performance indicator scores for treatment 
delay among patients diagnosed with ST-segment elevation myocardial infarction 
(STEMI) undergoing primary percutaneous coronary intervention in relation to 
the quality of the underlying data.
Methods: Secondary analyses were performed on data from 1017 patients in 
seven Dutch hospitals. Data were collected using standardised forms for patients 
discharged in 2012. Comparability was assessed as the number of occasions the 
indicator threshold was reached for each hospital.
Results: Hospitals recorded different time points based on different interpretations 
of the definitions. This led to substantial differences in indicator scores, ranging 
from 57 to 100 % of the indictor threshold being reached. Some hospitals recorded 
all the required data elements for calculating the performance indicators but 
none of the data elements could be retrieved in a fully automated way. Moreover, 
recording accessibility and completeness of time points varied widely within and 
between hospitals.
Conclusion: Hospitals use different definitions for treatment delay and vary 
greatly in the extent to which the necessary data are available, accessible and 
complete, impeding comparability between hospitals. Indicator developers, users 
and hospitals providing data should be aware of these issues and aim to improve 
data quality in order to facilitate comparability of performance indicators.
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INTRODUCTION
Assessment of the quality of care by means of performance indicators is an integral part 
of modern day health care. Performance indicators are a tool in quality improvement 
and provide the government, physicians, patients, scientific society and insurance 
companies an indication of hospital performance, which is increasingly demanded.3 
As comparing performance indicator scores between hospitals can have major 
consequences, including lay press ranking lists and government and insurance company 
sanctions, performance indicator scores need to be comparable.
There are several steps in the process that leads from an event happening in clinical 
practice to a performance indicator intended to measure the performance of a clinical 
practice regarding that event.4 This process is illustrated in Fig. 1. Variations in any of 
these steps will lead to different performance indicator scores. Ideally, data recorded for 
performance indicators are based on sound clinical practice guidelines, in which the 
definitions and inclusion and exclusion criteria of the performance indicator are clear 
and unambiguous and then processed in a uniform way to calculate the performance 
indicator in a uniform way. In reality, however, definitions are far from unambiguous 
and data are recorded in a variety of ways, impeding comparability of indicators for 
external quality control.5, 6 This means that users of performance indicators need to be 
aware of the possible impact of variations in definitions and quality of the data in terms 
of availability, accessibility and completeness.7, 8 The more unambiguous the definitions 
and the higher the quality of the underlying data, the more likely the performance 
indicator scores will be accurate and consistent between hospitals.11
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quality f t  data in terms of availability, accessibility and completeness.7, 8 The more 
unambiguous the definitions and the higher the quality of the underlying data, the 
more likely t e perform nce indicator scores will be accurate and consistent between 
hospit ls.11 
 
Figure 1 - Comparability of data: flow from collection to interpretation. 
Figure 1. Comparability of data: flow from collection to interpretation.
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For patients diagnosed with ST-segment elevation myocardial infarction (STEMI), 
international guidelines recommend timely invasive treatment by primary 
percutaneous coronary intervention (PCI), generally within 90 min of first medical 
contact.1, 12 Delays in timely invasive treatment by PCI caused by, for example, residential 
distance rapidly decrease the benefits over alternative treatments,13, 14 while shortening 
delays has the potential to contribute to decreased heart failure and mortality.15, 16 It is, 
however, unclear to what extent the treatment delay indicator scores are comparable 
between hospitals. This study therefore aims to investigate to what extent variations 
in definitions influence performance indicator scores. Moreover, we investigate to 
what extent the quality of data in terms of availability, accessibility and completeness 
influences performance indicator scores. We conclude by providing recommendations 
for improving comparability of performance indicator scores.
METHODS
PATIENT DATA
Secondary data were used from two university hospitals and five tertiary teaching 
hospitals performing PCI participating in the acute coronary syndromes (ACS) 
program evaluation, within the larger national safety management program: ‘VMS 
safety management program’.2
Data from these seven hospitals were collected manually by six chart abstractors using 
standardised case report forms. All abstractors had a background in research and 
received instructions for the chart review procedures by JT and JE. The chart abstractors 
collected data by means of retrospective review of the medical records in electronic 
or paper-based medical, nursing or catheterisation laboratory records of patients 
discharged between 1 January and 31 December 2012. Each month, eligible records of 
patients discharged in the preceding month were selected from the hospital billing 
system using the diagnosis treatment combination code. To determine the STEMI 
population, chart abstractors first considered all the records of patients diagnosed with 
ACS for inclusion. Next, the chart abstractors checked whether the discharge letter 
confirmed the ACS diagnosis. When the discharge diagnosis was unclear, the record 
was discussed with a cardiologist or other attending physician working in the field of 
cardiology. Charts of patients with a treatment delay not exceeding 6 h were included 
in the study.9 Charts of patients without a discharge diagnosis of STEMI, those not 
undergoing an acute PCI, patients with secondary ACS (e.g. due to anaemia), those 
undergoing elective procedures, patients with missing or uninformative charts and 
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the charts of patients under the age of 18 years were excluded from the study. Chart 
abstractors signed a confidentiality agreement and all data were stored on a password 
protected network server of the VU University Medical Centre.
QUALITY INDICATOR DEFINITIONS
Five definitions for the treatment delay indicator were derived from literature 
(Table 1 and Fig. 2): (A) The Dutch ‘VMS safety management program’ guidelines2; (B) 
The adjusted Dutch ‘VMS safety management program’ evaluation2; (C) The mean door-
to-needle time9; (D) The door-to-balloon time (American ACC/AHA guidelines for the 
management of STEMI10, 12); and (E) The European Society of Cardiology guidelines for 
the management of STEMI1. In these five definitions, treatment delay was defined as: (A) 
PCI within 90 min of first medical/paramedical contact; (B) PCI within 90 min of first 
electrocardiogram (ECG); (C) the mean door-to-needle time (no threshold provided); 
(D) PCI within 90 min of hospital arrival, and (E) PCI within 90 min after first medical 
contact. The B definition is an adaption of the A definition, because the time of first 
medical/paramedical contact was not registered consistently in all PCI centres but the 
time of the first ECG was. Thus, for this study, treatment delay was defined as the time 
from first ECG to PCI. Noteworthy is further that indicator C asks for the mean door-to-
needle time, illustrating that different organisations ask hospitals to register different 
information. Moreover, although none of the PCI centres registered the time of wire 
passage in the culprit artery, which is used by the ESC in the last definition, we provide 
this definition as an illustration because these guidelines provide the basis for the first 
and second definitions. For this study, we regarded the time from first ECG to PCI 
as the reference standard for pragmatic reasons. We emphasise that this definition 
is not a gold standard as there is no common gold standard for measuring treatment 
delay due to national and international differences and differences in perceptions of 
stakeholders. Moreover, the definitions are used for comparison reasons and not to 
conclude what the best definition is.
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Figure 2  Delays from symptom onset to first intervention in patients with 
STEMI and five performance indicator definitions (A-E). GP general 
practitioner, EMS emergency medical services, ER emergency room. 
  
Figure 2 Delays from symptom onset to first intervention in patients with STEMI and 
five performance indicator definitions (A-E). GP general practitioner, EMS emergency 
medical services, ER emergency room.
OUTCOME MEASURES
DATA QUALITY
To investigate data quality (availability, accessibility and completeness), we assessed 
whether or not particular time points involved in the various definitions were recorded 
in each of the hospitals. If the data were recorded, the researcher noted how they were 
accessible. Accessibility was divided into three categories: (1) automatically accessible, 
(2) partly automatically accessible or (3) manually accessible.5 Automatically accessible 
meant that data elements stored within the hospital information system could be easily 
reviewed (‘only a few mouse clicks away’) and extracted by means of computerised 
search algorithms. Partly automatically accessible meant that data elements were 
available in the hospital information system and could be reviewed easily, but could 
not be extracted by means of a computerised search algorithm and that manual 
actions were required. Manually accessible meant that data elements were available 
but only through intense data handling such as paper-based medical record reviews. 
Additionally, two chart abstractors retrospectively noted per hospital where and 
in what form data were found, such as in medical records, nurse records, discharge 
letters, electrocardiograms, procedure letters, correspondence with other health care 
professionals and in paper form, scanned or in the hospital information system. Finally, 
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we assessed the completeness of the available information at the patient level. We 
measured the percentage of patients for whom all time points that should be recorded 
were indeed available.
INFLUENCE OF DEFINITIONS ON INDICATOR SCORES
To investigate the influence of the performance indicator definition on the scores, we 
calculated the percentage of patients for whom the treatment delay indicator was below 
the threshold for each hospital according to the different definitions.
RESULTS
PATIENT DATA
Secondary data were used from two university hospitals and five tertiary teaching 
hospitals performing PCI. The bed capacity in these hospitals ranged between 400 to 
over 1100. Initially, 4471 records were reviewed for inclusion. After excluding records of 
patients who were not diagnosed with STEMI or excluded based on exclusion criteria 
(n = 3454), 1017 records were available for analyses, ranging between 112 and 236 included 
records per hospital.
OUTCOME MEASURES
DATA QUALITY
The chart abstractors reported that some hospitals recorded all the required data 
elements for the calculation of the performance indicator scores. Moreover, automated 
access to these data was not possible in most cases. The most common ways to access 
the data were manual or partly automated access (four of the seven hospitals). Fully 
automated access was not available for any of the data elements, illustrating that data 
collection was time consuming and costly.
For all available and accessible data, we noted where this information was found 
(Table 2). For the extraction of data elements with partly automated or manual access, 
the chart abstractors had to review a combination of medical records, nurse records, 
discharge letters, electrocardiograms (ECG), procedure letters, correspondence with 
other health care professionals, and in paper form, scanned or in hospital information 
system. Table 2 illustrates that the accessibility of data did not only differ per hospital, 
but also per time point within hospitals.
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The completeness of the available information is illustrated in Fig. 3. In 24 % of patients 
the time of first contact was recorded, in 88 % of the patients the time of ECG, in 51 % 
of patients the time of arrival at the PCI centre, in 94 % of patients the time of sheath 
insertion and in 64 % of patients the time of first intervention was recorded. Thus, 
hospitals vary greatly in completeness of recording, particularly with respect to the 
time of first contact.
78 
 
 
Figure 3 - Completeness of time points per hospital.  
 
INFLUENCE OF DEFINITION ON INDICATOR SCORES 
Table 3 shows the percentage of patients satisfying the indicator threshold for each of 
the definitions and each of the hospitals. Indicator score B was reported best, with 15–
50 % missing data across hospitals. Missing data on indicator scores A, C and D were 
generally over 50 % ranging from 21 to 100 %. When calculable, indicator scores ranged 
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INFLUENCE OF DEFINITION ON INDICATOR SCORES
Table 3 shows the percentage of patients satisfying the indicator threshold for each 
of the definitions and each of the hospitals. Indicator score B was reported best, with 
15–50 % missing data across hospitals. Missing data on indicator scores A, C and D were 
generally over 50 % ranging from 21 to 100 %. When calculable, indicator scores ranged 
from 57 to 100 % within a given hospital, dependent on the indicator definition.
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DISCUSSION
This study illustrates that hospital performance indicator scores for the treatment delay 
performance indicator are largely incomparable, without laborious manual review.
Three reasons contribute to this incomparability. First, definitions vary for treatment 
delay performance indicators across the literature, which leads hospitals to vary in 
the extent to which different time points are recorded and/or used for calculating 
performance indicators. These differences are also due to the low number of patients 
and missing data. This is partly due to the choices hospitals make regarding which 
times to record, but also due to the format in which organisations compel hospitals 
to report indicators (as percentage or mean). To compare indicator definitions among 
patients with all data points would be a methodologically sound method. In practice, 
information is not available for all the data points in any of the patients, as hospitals 
use different definitions for treatment delay and vary greatly in the extent to which the 
necessary data are available, accessible and complete. So, this leads to substantially 
different indicator scores, especially between definitions A and B versus D. Second, 
the chart abstractors reported that some hospitals had all the required data elements 
for calculation of the performance indicators and data could not be retrieved easily in 
any of the hospitals. Moreover, data accessibility not only varied between hospitals, 
but also between data elements within hospitals. The same hospital could therefore 
have a relatively low indicator score following one definition and relatively a high score 
following another definition. Third, we found large variations between hospitals in 
completeness of time records.
Previous studies on the comparability of medical data in the Netherlands and across 
Europe similarly showed that required data elements for performance indicators were 
generally poorly available, accessible and incomplete.5, 10, 17, 18 This may partly be due to 
the enormous number of indicators hospitals have to report on for external quality 
control. In order to compare indicator scores among hospitals it is thus necessary to 
standardise definitions and record data uniformly, and possibly reduce the number of 
indicators that hospitals have to accurately measure.19, 20
To obtain structured data, predefined computer-based forms to record relevant 
procedures and findings in a structured, standardised format, have been shown to be 
advantageous.21 One way to convert the currently used open text into a more structured 
format is the use of Natural Language Processing tools. However, as most tools are 
developed in English, further research is required on how to handle the Dutch. 
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Moreover, to enhance the correctness of data items and thus efficiency of secondary 
use of data, the Netherlands Federation of University Medical Centres is detailing 
how to best apply the ‘collect once—use many times’ principle.22 A next step could 
be to automatically extract data quality items from the hospital information system, 
checked by a responsible party and submitted to quality registers or other authorised 
parties.20 Ideally, data that are in standard codes from comprehensive controlled clinical 
terminologies such as SNOMED CT can be reused automatically. In the Netherlands, 
an action plan was recently developed to create a standardised continuity of care 
record for Dutch hospitals and to create semantically sound subsets of terminologies 
using SNOMED CT and ICD 10.20 Moreover, the USA initiated a nationwide taskforce 
Meaningful Use of Complex Medical Data in order to overcome problems analysing 
large amounts of medical data in a timely fashion.23 Today, hospital performance 
data can be linked to national mortality databases to provide information on long-
term outcomes and survival, provided data can be tracked across providers, which 
is facilitated by unique person identifiers.24 Such a national registry is not available 
for acute coronary syndromes in the Netherlands, whereas this has been possible for 
many years in other countries, such as Sweden and the UK.25 Given these advances, 
performance indicators based on administrative data could be a very useful tool to flag 
possibilities for quality improvement in hospitals. The extent of these propositions, 
however, does not provide practitioners with a direct, simple solution. The proposed 
statements include steps which need to be taken in order to prevent incomparability 
in the future. Hospital associations in the Netherlands are now working on these steps. 
Despite the lack of solutions, we feel it is important to inform practice of the critical 
notion that hospital performance indicator scores for the treatment delay performance 
indicator are largely incomparable, without laborious manual review.
Our study has several limitations. The time points extracted to calculate indicator scores 
per hospital may be an overestimation of data completeness compared with indicator 
scores calculated and supplied by hospitals themselves, because data were extracted by 
chart abstractors who went to great lengths to obtain data. Moreover, the data obtained 
by our chart abstractors may deviate from hospital data as the chart abstractors made 
decisions to clarify which data were necessary to calculate performance indicator scores, 
such as manually checking all diagnoses in the discharge letter based on the diagnosis 
and procedure codes. Also, the presence of researchers collecting data on site and the 
provision of feedback of performance may have influenced documentation of times 
and performance indicator scores. However, as the patient safety program for which 
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the data were primarily collected was designed to improve guideline adherence and 
provide hospitals with feedback of their own performances, it would not be appropriate 
to withhold this information. Consequently, another limitation is the secondary use of 
data that were obtained for the goal of measuring guideline adherence. For example, 
the exclusion of uninformative charts means that data were preselected on their quality. 
In spite of these limitations, our results show that the comparability of indicator scores 
is influenced by data quality issues.
CONCLUSION
In sum, hospitals use different definitions of this one particular quality indicator and 
vary greatly in the extent to which the necessary data are actually available, accessible 
and complete, impeding comparability between hospitals. It is important to increase 
awareness among developers, users and producers of performance indicators regarding 
the impact of variations in indicator definitions and data quality on indicator scores.
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ABSTRACT 
Background: Rapid reperfusion with percutaneous coronary intervention (PCI) 
is vital for patients with ST-segment elevation myocardial infarction (STEMI). 
However, the guideline-recommended time targets are regularly exceeded. The 
goal of this study was to gain insight in how Dutch PCI centres try to achieve 
these time targets by comparing their care processes with one another and with 
the European guideline-recommended process. In addition, accelerating factors 
perceived by care providers were identified.
Methods: In this multiple case study, interviews with STEMI care providers were 
conducted, transcribed and used to create process descriptions per centre. Analyses 
consisted of within-case and between-case analyses of the processes. Accelerating 
factors were identified by means of open and axial coding. 
Results: In total, 28 interviews were conducted in 6 PCI centres. The 
centres differed from the guideline-recommended process on e.g. additional, 
unavoidable patient routings and monitoring delays, and from one another 
on the communication of diagnostic information (e.g. transmitting all, only 
ambiguous or no electrocardiograms) and catheterization room preparation. 
These differences indicated diverging choices to maintain a balance between speed 
and diagnostic accuracy. Factors perceived by care providers as accelerating the 
process included trust in the tentative diagnosis, and avoiding unnecessary inter-
caregiver consultations. The combination of processes and accelerating factors 
were summarized in a model.
Conclusions: Numerous differences in processes between PCI centres were 
identified. Several time saving strategies were applied by PCI centres, however 
in different configurations. To further improve the care for STEMI patients, best 
practices can be shared between centres and countries.
Multi-centre analysis of current ST-elevation myocardial infarction acute care pathways
85
5
INTRODUCTION
Rapid reperfusion treatment increases the chances of survival for patients with ST-
segment elevation myocardial infarction (STEMI).1, 2 Consequently, international 
STEMI care guidelines recommend to limit the time to treatment with percutaneous 
coronary intervention (PCI) to a maximum of 90 minutes from first (para)medical 
contact.3, 4 However, previous studies reported that attaining these time targets is 
difficult.5 
In the European Society of Cardiology guidelines, a model of care has been described to 
treat patients within 90 minutes after first (para)medical contact. In this description, 
patients contact the emergency medical services through a central telephone number. 
In case of a suspected myocardial infarction, the emergency medical services dispatch 
an ambulance. In the ambulance, an electrocardiogram is recorded and interpreted by 
trained paramedics, and/or the electrocardiogram is transferred for a teleconsultation 
with a cardiology centre. Triage, diagnosis and emergency treatment are all performed 
in the prehospital phase. The cardiology centres, with 24/7 PCI services, cooperate with 
other hospitals in the region and with the emergency medical services through clear 
geographic boundaries, shared protocols and bypassing of non-PCI hospitals. While 
the patient is en route to the hospital, the catheterization laboratory staff are called 
and the room is prepared. On arrival, the patient bypasses the emergency department 
and intensive coronary care unit and is immediately transferred to the catheterization 
laboratory. The treatment delays are measured and used to improve the process of care.
Despite the before mentioned guideline-recommended process, the recommended 
maximal treatment delay of 90 minutes is still exceeded for a considerable number of 
patients in the Netherlands.6 Although treating all patients within the recommended 
time targets is unlikely, there appears room for improvement. In addition to a well-
designed process, hospital, patient and physician related factors including annual PCI 
volume and time of presentation appear to influence the speed of the care process as 
well.7 Therefore, further optimizing the logistic processes and taking into account 
accelerating factors may reduce the treatment delay and subsequently lower the 
patients’ risk of adverse cardiac events.8 Therefore, the primary objective of this study 
was to explore how PCI centres in the Netherlands differed in their logistic processes 
from the European guideline-recommended process and from one another. The 
secondary objective was to identify factors potentially accelerating the process.
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METHODS
DESIGN
As quantitative information about the delays in the acute STEMI care process is lacking 
in many countries including the Netherlands, 9, 10 the study was performed in a multiple 
case study design, using PCI centres as cases. This type of design is well suited for 
exploring and comparing complex processes in a real life context.11 
SETTING
The study was conducted in the Netherlands, a country of approximately 34,000 km2 
where annually more than 11.000 patients are treated with primary PCI in 30 PCI 
centres.12 Due to an efficient geographical spread of PCI centres in the Netherlands, 
PCI is the preferred reperfusion therapy for all patients with STEMI who present within 
12 hours of symptom onset. Therefore, timely provision of fibrinolysis was not taken 
into account in this study.
To access a PCI centre, patients may take different routes. In the Dutch healthcare 
system, the general practitioner has a gatekeeping role, meaning that referral from a 
general practitioner is required to see a hospital physician. Exceptions are made for 
medical emergencies such as STEMI, but some patients with symptoms of STEMI 
contact their general practitioner or general practitioners’ after-hours office. In their 
guidelines for acute coronary syndrome, general practitioners are recommended to call 
the emergency medical services and perform an anamnesis and physical examination.13 
Alternatively, patients can contact the emergency medical services in the Netherlands 
directly by dialling the national emergency number (112). If indicated by the triage 
system, an operator of 1 out of 25 self-dispatching regional ambulance services sends an 
ambulance to the patient. Ambulances are staffed by a driver and by a nurse licensed to 
administer medical treatment at advanced life support level.14 All ambulance services 
work according to a national ambulance protocol which allows for regional adaptations 
in cooperation with the PCI centres.15 This protocol describes to transport patients with 
a (tentative) STEMI diagnosis directly to the nearest PCI centre.16 As a result of these 
national structures, the treatment delay in this study was defined as the period from 
first (para)medical contact in person to the PCI procedure. In addition, the care process 
was defined as all statements pertaining to individual tasks and responsibilities that 
contributed to getting the patient to a prepared catheterization room.
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SELECTION OF PCI CENTRES AND PARTICIPANTS
In total, 7 hospitals providing primary PCI 24/7 were invited to participate in the 
present study after participating in a previous study, for which they were selected using 
a multi-stage random selection procedure.17 These PCI centres differed among other 
things in ambulance region, annual PCI volume and type of hospital (University vs 
non-University teaching). At each centre, an interventional cardiologist specialized in 
acute coronary syndromes was invited by e-mail for an interview. In the interviews, 
cardiologists were asked to provide contact details of one person from each profession 
involved in acute STEMI care at the hospital or at the emergency medical services. 
These professionals were subsequently approached by email to participate in the study. 
Additionally, for verification of the information given about the additional prehospital 
care processes, cardiologists from referring hospitals and general practitioners were 
invited for participation through the interventional cardiologist. 
DATA COLLECTION
Data were collected by means of one-on-one semi-structured interviews at the 
workplace or home of the participant. The interviews were conducted with a topic list 
based on the European guideline-recommended process.3 The topic list was tested in two 
pilot interviews and adjusted accordingly, resulting in a final topic list (Supplemental 
Table 1). Each interview started with a grand tour question in which cardiologists were 
asked to describe the care process from symptom onset to reperfusion for patients with 
STEMI going for primary PCI. Subsequent questions were related to the steps in the 
care process described by the participant, the role of other care providers in the process, 
prior quality improvement efforts, and monitoring of the guideline-recommended 
time targets. 
The interviews were performed by one interviewer, trained in qualitative interviewing 
(JT), between May 2013 and February 2014, were audio-recorded and transcribed 
verbatim using the computer program F4 2012 (Version 5.2, Dr Dresing & Pehl GmbH 
- audiotranskription.de). 
DATA ANALYSES
In analysing the process of STEMI care, the data reduction strategy of Miles & Huberman 
for multiple case studies was used.18 Within-case and between-case analyses were 
performed with the care process for STEMI patients in the PCI centres as the unit of 
analysis. First, all interview transcripts were reviewed line-by-line and split into three 
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predetermined process steps: 1) first (para)medical contact in person to PCI decision; 
2a) activation of the catheterization room; and 2b) PCI decision to start of the PCI 
procedure. Process steps 2a and 2b occur simultaneously. Use of additional strategies 
to reduce the treatment delay are mentioned separately. Next, the care process per PCI 
centre, taking into account different patient routings, was described in detail (within-
case analysis). The textual and graphical descriptions (swim lane charts) were linked 
by using similar annotation. An example of a swim lane chart describing the general 
process of prehospital care is presented in Supplemental Figure 1. Differences of the 
logistic processes of PCI centres with the European guideline-recommended process 
and with one another were identified by comparing the textual and graphic process 
descriptions (between-case analysis).
Factors accelerating the care process but not pertaining to it were identified by reviewing 
all transcripts line-by-line. All issues related to accelerating factors as indicated by the 
participants were extracted from the transcripts and coded by means of open coding 
(content analysis). Subsequently, text fragments with similar open codes were bundled 
in an axial coding process and their contents were analysed inductively to reveal the 
core categories of factors accelerating the care processes.
After conducting and transcribing 12 interviews (covering all PCI centres), JT performed 
an interim analysis in which additional care providers in the process and potential 
gaps in the descriptions of the process per PCI centre were identified. To improve the 
reliability of the coding scheme, 3 interviews were coded independently by a second 
researcher [IvdW] and differences in the coding were discussed until consensus was 
reached. As a result, small modifications to the definitions in the coding scheme were 
made accordingly. 
All transcripts were coded using the computer program ATLAS.ti (Version 5.2, ATLAS.
ti Scientific Software Development GmbH).
VERIFICATION
The textual and graphical process descriptions of each PCI centre were sent back 
to the participating interventional cardiologists for verification. All interventional 
cardiologists responded, resulting in minor changes in the process descriptions.
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ETHICAL APPROVAL
This study was approved by the medical ethical committee of the VU University 
medical centre. All participants were informed about the study goals and data 
processing, and written consent for study participation and audio recording of the 
interview was obtained. Data were stored on a password protected network drive of the 
VU University medical centre, to which only the researchers had access. Codes were 
assigned to participants and centres for privacy purposes. Additionally, all transcripts 
were anonymised by removing all names of people, centres and geographical locations. 
RESULTS
From 6 PCI centres, 25 care providers were interviewed (Table 1). One centre did not 
respond to the invitation and could therefore not be included. Moreover, to verify 
the general prehospital care process, 2 general practitioners and 3 cardiologists from 
referring hospitals were invited for participation, of whom 1 general practitioner and 2 
cardiologists participated. This resulted in a total of 28 interviews with a mean duration 
of 45 minutes (range: 23 to 68 minutes).
Table 1. Characteristics of participating PCI centres and interview participants
Hospital a b c d e f
Type of hospital Teaching Teaching Academic Teaching Teaching Teaching
Provision of thoracic surgery No Yes Yes No Yes Yes
Number of catheterization rooms 
(primarily for PCI)
2 (1) 5 (3 or 4) 3 (2) 2 (1) 5 (2 or 3) 3 (2)
Number of primary PCI 
procedures per year
300-400 >500 400-500 <300 >500 >500
Interventional cardiologist x x x x x x
Cardiology resident x x x x
Catheterization room nurse x x x x x x
Cardiac care unit nurse x x x
Ambulance nurse/medical 
manager
x x x x x x
Referring cardiologist* x x
GP* x
*participants in Italic for verification; PCI: percutaneous coronary intervention
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DIFFERENCES FROM THE EUROPEAN GUIDELINE-RECOMMENDED 
PROCESS AND BETWEEN PCI CENTRES
Differences between the care processes of individual PCI centres, the European 
guideline-recommended process, and between PCI centres could be allocated to one of 
the process steps below. Differences between PCI centres are summarized in the lower 
part of Figure 1. Illustrative quotes are presented in Supplemental Table 2 and referred 
to in the text. The letters between brackets in the text correspond to the letters for the 
PCI centres presented in Table 1.
FIRST (PARA)MEDICAL CONTACT IN PERSON TO PCI DECISION 
The prehospital care processes of the PCI centres differed from the European guideline-
recommended process on one aspect. The European guideline-recommended process 
assume that patients arrive at the catheterization room from the emergency medical 
services. In this study, additional patient routings were identified in which patients were 
already admitted to a hospital department, e.g. the surgery department; or presented 
to emergency departments of PCI centres or non-PCI centres. The cooperation with 
the ambulance services was highly protocolled, while the cooperation with the general 
practitioners, emergency departments, other hospital departments or referring 
hospitals was much less protocolled. In case patients go to the general practitioner, 
no electrocardiogram is performed and the emergency medical services are contacted 
immediately. 
Between PCI centres, several differences were found. When patients are announced 
at the PCI centre by the emergency medical services, the emergency department 
or referring hospitals, there can be uncertainty or ambiguity about the working 
diagnosis. However, additional diagnostic tests might result in a prolonged treatment 
delay. The PCI centres differed in the way they dealt with the trade-off between 
diagnostic certainty and speed. Some PCI centres had dedicated facilities to receive 
prehospital electrocardiograms transmitted from the ambulance, followed by a 
telephone call (a,b,c,f). This provided the possibility for a coronary care unit nurse (a) 
or cardiology resident (b,c,f) to confirm the diagnosis. After hours, in one centre (c) 
all electrocardiograms were additionally forwarded to the interventional cardiologist 
on call for review. Other centres had no dedicated facilities for electrocardiogram 
reception, but occasionally electrocardiograms were received through (protected) 
mobile phone applications (d,e). One PCI centre was able to receive electrocardiograms, 
however, not all ambulance service providers in the region were equipped to transmit 
electrocardiograms (b), leading to variation within the region.
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In case there were facilities for transmitting and receiving electrocardiograms (a,b,c,f), 
different criteria were used for the decision to employ these facilities. Some PCI 
centres required all electrocardiograms to be transmitted (a,c), while others only 
required ambiguous electrocardiograms to be transmitted (b,f), thereby minimizing 
the number of consultations for unambiguous diagnoses (Quote 1). In the PCI centres 
where only the ambiguous electrocardiograms were transmitted or which had no 
dedicated facilities to receive electrocardiograms, the patient was always accepted for 
angiography and PCI without additional diagnostic testing or consultation when an 
ambulance nurse indicated with certainty the patient had a STEMI (b,d,e,f) (Quote 
2). As a result, no electrocardiograms were transmitted and the PCI centre was only 
contacted by telephone to convey additional information about the patient. In one 
centre (a), the decision to send a patient for PCI was made by a dedicated coronary care 
unit nurse, while in another centre (c) a cardiology resident made the decision. In case 
the diagnosis was uncertain, a cardiology resident or interventional cardiologist could 
be consulted, resulting in additional discussion before the patient was accepted. 
ACTIVATION OF THE CATHETERIZATION ROOM 
In all PCI centres included in this study, the catheterization room was activated by a 
dedicated care coordinator at the PCI centre. The profession of the care coordinator 
differed between PCI centres. In one centre (a), the coordinator was a dedicated nurse 
from the coronary care unit both during office hours and after hours. The nurse had 
the autonomy to read the electrocardiogram and activate the catheterization room 
without additional consult of a cardiologist or cardiology resident (Quote 3). In three 
centres, during office hours a cardiologist activated the catheterization room while 
after hours a cardiology resident (b,f) or coronary care unit nurse (d) was responsible. 
In two other centres, the cardiology resident was always responsible for catheterization 
room activation (c,e). However, in one of these centres (c) a coronary care unit nurse 
was contacted first through a landline, who subsequently transferred the call to the 
cardiology resident, resulting in an additional process step. The difference in profession 
of the care coordinator indicates different choices between speed (a readily available 
nurse) and reliability of the diagnosis (a more difficult to reach cardiologist).
During office hours, the catheterization room staff was already present as they 
performed elective PCI procedures and thus the catheterization room systems were 
already operational. When an incoming patient required primary PCI, ongoing or 
planned elective procedures in one of the catheterization rooms were cancelled and 
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rescheduled to free the room for the incoming patient. Up to the point where a sheath 
or guidewires were inserted, patients undergoing elective procedures were removed 
from the catheterization room to speed up its availability.
After hours, the catheterization room staff on call (interventional cardiologist and 
multiple catheterization room nurses) were generally not present at the centres. There 
were two exceptions. One centre required all staff on call that had to travel over 20 
minutes to the centre to stay overnight (f), while at another centre some cardiologists 
stayed overnight voluntarily (e). The catheterization room staff staying overnight at the 
centre initiated catheterization room preparations immediately after announcement of 
the patient, thereby optimally using the transport time of the patient. At two centres 
(a,b), preparation of the catheterization room was initiated by a coronary care nurse 
working evening- or nightshift while the catheterization room staff and patient were en 
route to the centre (Quote 4).
An addition to the European guideline-recommended process was found in the way the 
catheterization room staff was contacted after hours. The interventional cardiologist 
and catheterization room nurses were called by the care coordinator or doorman to 
present to the PCI centre within 20 to 30 minutes. None of the centres used a single-call 
page system but contacted the staff by (mobile) telephone instead, enabling immediate 
confirmation. To start the procedure as soon as possible, only the interventional 
cardiologist and at least one catheterization nurse had to be present.
PCI DECISION TO START OF THE PCI PROCEDURE
As recommended in the European guideline, the emergency department was 
bypassed upon arrival at the hospital and the patients were transported directly to the 
catheterization room on the ambulance stretcher. When the catheterization room was 
not available yet patients were accommodated to a holding area near the catheterization 
room or to the coronary care unit. In contrast to the European guideline-recommended 
process, in one centre the patients made an additional stop at the coronary care unit 
(d) (Quote 5), from where a coronary care unit nurse transported the patient to the 
catheterization room. The nurse stayed to assist in the procedure and transported the 
patient back to the coronary care unit to facilitate continuity of care.
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In case the catheterization room was not ready upon arrival of the patient at the PCI 
centre, several strategies for accommodating the patient were identified. Some PCI 
centres had a dedicated holding area for patients awaiting catheterization at the 
catheterization room complex on the ambulance stretcher (a,b), while others admitted 
patients at the coronary care unit (c,f,e). One centre sporadically set up these patients 
at another catheterization room, so that only the staff had to change rooms (b).
MONITORING OF DELAYS
An additional strategy in the European guideline-recommended process was to 
monitor the treatment delays and identify variation. However, only one PCI centre used 
this strategy (a), though, all centres recorded information about the treatment delay to 
report on national quality indicators.
ACCELERATING FACTORS
Several factors not pertaining to the process were identified by the healthcare providers 
as accelerating the care process. These factors were categorized as patient, healthcare 
provider, inter-provider and PCI centre characteristics and are summarized in the 
upper part of Figure 1.
PATIENT CHARACTERISTICS
Participants mentioned that the clarity of the signs and symptoms experienced by the 
patient determines the way patients interpret their complaints, and the care provider 
that they contact. The participants indicated that bypassing the general practitioner 
and calling the emergency medical services directly accelerated the care process. 
Furthermore, in contacting a care provider, the patient’s assertiveness can influence 
the priority that he/she is being given, e.g. by insisting that the complaints are severe. 
Additionally, when patients are hemodynamic stable fewer resources i.e. equipment, 
care providers (e.g. anaesthesiologist) and diagnostic procedures (e.g. an ultrasound) 
are required, which accelerates the process. 
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HEALTHCARE PROVIDER CHARACTERISTICS
A working diagnosis is the starting point for the PCI centre to initiate preparations 
for receiving a STEMI patient. Therefore, the working diagnosis needs to be made 
prehospital by an experienced and qualified diagnostician in order to make a reliable 
diagnosis to ensure activation of the catheterization room without further diagnostic 
testing (Quote 6). Also, participants indicated that in the communication with the 
PCI centre, it is vital that the diagnostician is assertive in case he/she is certain of the 
working diagnosis of STEMI in order to avoid additional transfer of information and 
unnecessary consultations. Consequently, in some centres a cardiology resident had 
to consult the interventional cardiologist, in which the same factors of experience, 
qualification and assertiveness are important for the cardiology resident, thereby 
limiting the potential delay caused by the additional consultations.
INTERPROVIDER CHARACTERISTICS
In case the working diagnosis is made, the communication between the ambulance 
crew and the PCI centre needs to be clear, quick, unambiguous and direct. Participants 
stressed that this will minimize discussion about the diagnosis, resulting in a shorter 
treatment delay. One important requirement is trust in the diagnosis made by the 
ambulance nurse or other diagnostician. When trust in the diagnosis is high, no further 
discussion is needed and preparations for the PCI procedure can be initiated (Quote 7). 
However, doubt about the working diagnosis can result in additional intercaregiver 
consults in which the diagnosis is discussed, potentially delaying catheterization 
room activation and patient transport. Therefore, multidisciplinary cooperation 
in minimizing doubt about the diagnosis and agreeing on an acceptable level of 
uncertainty in the region of a PCI centre is deemed as an important factor accelerating 
the process in the long run.
PCI CENTRE CHARACTERISTICS
The catheterization room location should ideally be near the ambulance entrance, the 
emergency department and the coronary care unit of the PCI centre to limit transfer 
times. In addition, having multiple catheterization rooms increases the chances that 
one is available. Having catheterization room equipment with a short start-up time as 
well as a having a simple protocol describing everyone’s responsibilities can reduce the 
time to prepare the catheterization room. 
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Anticipating on different patient routings and characteristics was identified by 
the participants as important for optimizing the process speed. For example, some 
PCI centres anticipate on transporting hemodynamically unstable patients to the 
catheterization room as soon as the patient is stable enough. The cardiologist goes to 
the emergency department immediately after prehospital notification to provide care 
and to remind other care providers that the patient needs to go to the catheterization 
room as soon as possible. At the catheterization room, specialized staff (e.g. 
anaesthesiologist) with advanced equipment are waiting to take care of the patient. 
PCI centres also anticipated on catheterization room occupancy by having a dedicated 
holding area near the catheterization room.
DISCUSSION
In this study, the care processes in multiple PCI centres for patients with STEMI 
going for primary PCI in the Netherlands were compared to the European guideline-
recommended process and to one another. In addition, factors accelerating the process 
were determined. The PCI centres differed from the European guideline-recommended 
process on additional, unavoidable patient routings and monitoring delays. Differences 
between PCI centres included the way diagnostic information was communicated and 
having personnel ready on-site to immediately prepare the catheterization room. 
Accelerating factors included the patients’ assertiveness, trust in the diagnosis of 
colleagues and avoiding inter-caregiver consultations and discussion.
In all PCI centres, the emergency medical services bypassed the emergency department 
upon arrival at the hospital. This is in accordance to previous study results, in which 
direct transport to the catheterization room was identified as a time-saving strategy.19 
However, the procedures for patients entering the PCI centres through alternative 
routings were less protocolized. Therefore, it is important that in optimizing the care 
process, PCI centres take into account all patient routings in shared protocols and 
infrastructure for all involved care providers in their region. Continuously updating 
and disseminating the guideline-recommended process enables individual PCI 
centres to compare their own process with the synthesis of best practices. Additional 
improvements in comparison to our model can be shared within and between STEMI 
care networks. 20
In the design of the acute care process for patients with STEMI, PCI centres appeared 
to seek a balance between accuracy of the diagnosis and speed of the process. While 
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some centres chose for a system in which the ambulance nurse decided to send the 
patient for PCI, other centres chose for a system in which the electrocardiogram 
first had to be evaluated by a coronary care unit nurse, cardiology resident or 
interventional cardiologist. This additional verification of the diagnosis may result 
in a prolonged treatment delay, while on the other hand it may prevent unnecessary 
catheterization room activations. Previous studies indicated proficient interpretation 
of electrocardiograms by emergency medical services staff,21, 22 indicating that 
transmittal of the electrocardiogram might not be required.23 However, transmitting 
the electrocardiogram allows for comparison to previous electrocardiograms, thereby 
potentially minimizing unnecessary catheterization room activation.24 An optimal 
configuration of the care process may be identified by means of computer simulation, 
in which the effect of an altered configuration on the treatment delay and the diagnostic 
certainty can be evaluated. Computer simulations have been applied in decreasing 
patient wait times at the emergency department, 25 and could also be of value in 
optimizing the treatment delay. 
Although driving times are prolonged in Denmark, a higher number of procedures per 
operator was linked with improved patient outcomes.26
The optimal level of centralization of primary PCI procedures within countries remains 
unclear. Although driving times can be shorter in a more decentralized approach, a 
more centralized approach can result in a higher number of PCI procedures per 
operator. Both aspects of care have been linked to improved patient outcomes, 2, 26 but 
they appear mutually exclusive. To gain insight in an optimal centralization strategy, a 
natural experiment can be used, e.g. by comparing patient outcomes in the Netherlands 
and Denmark. Denmark, with 5.6 million inhabitants on 43.000 km2 and approximately 
2700 primary PCI procedures each year 12, is comparable to the Netherlands on both 
the terrain, infrastructure and guideline recommendations. 27-30 The major difference 
appears the number of PCI centres providing primary PCI procedures: 30 PCI centres for 
16.8 million inhabitants (560.000 inhabitants per PCI centre) in the Netherlands versus 
4 PCI centres for 5.6 million inhabitants (1.4 million inhabitants per PCI centre) in 
Denmark. In addition, the organization of the emergency medical services (25 regions 
in the Netherlands versus 5 regions in Denmark) is also more centralized. It is unclear 
to what extent this further centralization of STEMI care influences patient outcomes. It 
would therefore be recommendable to compare patient outcomes between the Dutch 
and Danish systems in order to identify an optimal level of centralization.
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The accelerating factors could be organized in four categories: patient, provider, inter-
provider and PCI centre characteristics. In reducing the treatment delay, it appears 
crucial to redesign the process while taking into account factors that may influence 
the speed of the process. Although not all factors can be influenced directly by care 
providers, anticipating situations in which these factors play a role may help to minimize 
treatment delays e.g. having an adapted process for hemodynamically unstable 
patients. In addition, both provider and inter-provider characteristics are mentioned 
as accelerating the process. These categories justify multidisciplinary training within 
a region in order to align the views of all involved care providers, including general 
practitioners, referring hospitals and emergency department staff. Taking into account 
these accelerating factors may further decrease the treatment delay in the long run.
The differences in the care processes and the accelerating factors are presented as 
independent factors, while in real life they may be interrelated. For example, when 
an interventional cardiologist trusts the diagnosis made by an ambulance nurse or 
coronary care unit nurse, no further discussion is required. This trust can in turn be 
influenced by the experience and qualification of the diagnostician and by the clarity of 
the patients’ signs and symptoms. Low trust in the diagnosis might result in additional 
discussion or an additional stop at the emergency department for further diagnostic 
testing, prolonging the treatment delay. Consequently, in optimizing the process it is 
important to consider both process steps and accelerating factors.
STUDY LIMITATIONS
The study results should be interpreted taking potential limitations into consideration. 
Personal views and experiences of participants may have affected the reliability of 
data collected by means of interviews. The accelerating factors were perceived by 
the care providers and not tested quantitatively and should therefore be interpreted 
with caution. To increase the reliability of the data, a variety of PCI centres and care 
providers per PCI centre and its region were included.
The data were collected in a single country, which may have influenced the usability 
of the study findings for other countries. However, the care of patients with STEMI 
has been standardized in international cardiology guidelines and primary PCI is 
the reperfusion method of choice in many countries.10 Therefore the findings of this 
study can be useful internationally, though differences in the national protocols or 
accelerating factors may occur.
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In the present study, no professionals from the emergency department were interviewed. 
This was because cardiologists and cardiology residents were closely involved in the 
care for patients with a suspected cardiac disease at the emergency department. In 
addition, in the Netherlands only a very small number of patients arrive through the 
emergency department. Strategies to optimize care for STEMI patients that focus on 
the emergency department will therefore have limited effect in reducing the average 
treatment delay in a hospital. However, a part of the process was not directly explored 
in the present study which could have affected the reliability of the reported results. 
Finally, we were unable to link the processes identified per PCI centre in this study to 
time intervals or patient outcomes because of size differences between the regions in 
which centres were located which may affect the treatment delay. As a consequence, it 
cannot be determined to what degree the reported process differences and accelerating 
factors accounted for a shorter treatment delay. However, the overall treatment delay in 
the participating centres was relatively short 6 compared to other studies, and multiple 
time-saving strategies as identified in previous best practices were applied in all PCI 
centres, e.g. prehospital diagnosis and bypassing the emergency department 9.
CONCLUSIONS 
Several differences of the current acute care process for STEMI patients in comparison 
to the European guideline-recommended process and between PCI centres were found. 
These differences potentially affect the treatment delay, indicating room for further 
improvement. Hospitals can learn from each other’s process designs by identifying 
and sharing best practices. The results of this study therefore facilitate future quality 
improvement efforts and research that may eventually reduce the treatment delay of 
patients with STEMI.
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ABSTRACT 
Background: The prescription of guideline-recommended medication for 
secondary prevention after acute coronary syndrome has been suboptimal in the 
past. In the present study, guideline adherence and associated patient, care and 
hospital characteristics at hospital discharge after acute coronary syndrome were 
studied.
Methods: Charts of patients with acute coronary syndrome discharged from 13 
Dutch hospitals in 2012 were reviewed. Guideline adherence was defined as the 
prescription of acetylsalicylic acid, P2Y12 receptor inhibitor, statin, beta-blocker 
and angiotensin-converting enzyme (ACE) inhibitor at discharge, or a documented 
contraindication. Associated characteristics were identified by means of generalized 
linear mixed models for binary outcomes.
Results: In total, 2471 patients were included. Complete guideline adherence was 
achieved in 69.1 % of the patients, ranging from 42.1 to 87.0 % between hospitals. 
The ACE inhibitor was most often missing (21.2 %). Patients with non-ST-segment 
elevation myocardial infarction or unstable angina, patients with a history of 
coronary artery bypass grafting or elderly women were less likely to be discharged 
with the guideline-recommended medication.
Conclusions: Guideline adherence for secondary prevention medication 
following acute coronary syndrome was substantial; however, variation between 
hospitals and patient groups was found. Efforts to increase guideline adherence 
can focus on underperforming hospitals and undertreated patient groups.
Adherence to guidelines for theprescription of secondary preventionmedication at hospital
105
6
BACKGROUND
In recent years, the in-hospital survival rates of patients with an acute coronary 
syndrome (ACS) have increased1, yet patients with a history of ACS are at higher risk 
of adverse cardiac outcomes in the future2. As a result, discharge and post-discharge 
management, comprising referral to a cardiac rehabilitation program and the 
prescription of secondary prevention medication3, 4, have become more important in 
ACS care.
Prescribing medication for secondary prevention of adverse cardiac outcomes after 
discharge from the hospital is recommended by the European Society of Cardiology 
guidelines on the management of ACS. This medication comprises a combination of 
acetylsalicylic acid, P2Y12 receptor inhibitor, statin, beta-blocker and angiotensin-
converting enzyme (ACE) inhibitor3, 4 However, previous studies have identified non-
adherence to these guideline recommendations in several patient groups.5, 6 As a result, 
these patients have a higher but potentially preventable risk of adverse outcomes after 
discharge.7
Monitoring and improving guideline adherence for secondary prevention medication 
at hospital discharge has the potential to improve the quality of care and further 
reduce adverse outcomes in patients with ACS.8, 9 This was recognised by Dutch 
cardiology care providers, who included a focus on discharge medication in a national 
quality improvement program.10 In this study we investigated guideline adherence 
and associated patient, care and hospital characteristics for secondary prevention 
medication at discharge from the hospital for patients with ACS in the Netherlands 
during implementation of a nationwide quality improvement program.
METHODS
A detailed description of the study design, methods and the quality improvement 
program has previously been published.11
DESIGN
The study was conducted in a cross-sectional design.
SETTING AND INCLUSION
In 2012, 91 hospitals provided ACS care in the Netherlands. From this pool, 13 hospitals 
were selected by means of a multistage random sampling procedure to participate in 
the evaluation of the national quality improvement program.
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Potentially eligible study charts were selected from the hospitals’ financial system codes 
for ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation 
myocardial infarction (NSTEMI) and unstable angina (UA). All patients discharged in 
2012 with a diagnosis of ACS (as confirmed in the discharge letter) were considered for 
inclusion. Charts of patients transferred to another hospital or department for further 
evaluation or treatment, patients who died during hospital admission, who received 
palliative care, who left the hospital against medical advice or who had no information 
about the prescribed medication at discharge in their chart were excluded.
DATA COLLECTION AND PROCESSING
Data were collected by means of retrospective chart review. The chart reviewers visited 
the participating hospitals monthly. When the number of charts exceeded the screening 
capacity, charts were selected per month in chronological order of discharge until the 
screening capacity limit was reached.
In this study, guideline adherence was defined as the prescription of acetylsalicylic 
acid, P2Y12 receptor inhibitor, statin, beta-blocker and ACE inhibitor at discharge, 
or a documented contraindication or other motivation for not prescribing these 
medicines. From the charts, information related to the prescription of these five 
medicines was abstracted. In case one or more medicines were not prescribed, 
documented contraindications as reported in an annually updated Dutch database 
of pharmacotherapy12, or as motivated by the treating physician were retrieved (e.g. 
the prescription of anticoagulants instead of acetylsalicylic acid). The full list of 
contraindications was reported previously.11 Additionally, patient, care and hospital 
characteristics (n = 40), e.g. age, sex, cardiac medical history, risk factors, resuscitation 
and discharge diagnosis were recorded. Hospitals were characterised by type (academic, 
tertiary teaching or general) and presence of percutaneous coronary intervention (PCI) 
and/or coronary artery bypass grafting (CABG) facilities (yes/no).
A sample of the charts (n = 149 (6.0 %)) was screened by two chart reviewers 
independently and the percentage of agreement between the reviewers was calculated. 
The results were satisfactory, with all 40 variables above 85 % agreement indicating 
good to excellent data reliability.
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MISSING DATA
In total, 0.82 % of the data were missing, ranging per variable from 0.04 % (date of 
discharge) to 2.5 % (heart failure or arrival). Little’s test13 was non-significant (p = 0.57) 
and missing value analyses showed no relationship between the missing data and 
the complete data, indicating the missing data were missing completely at random.14 
Therefore missing data were imputed by means of full conditional specification using 
the imputation procedure in IBM SPSS (Version 20 for Windows). As a sensitivity 
analysis, the results of the final analysis were compared with the results of a full case 
analysis to determine the accuracy of the imputation procedure.
ANALYSIS
Characteristics of the study population, participating hospitals and guideline adherence 
were determined by means of descriptive statistics. Associations of predictor variables 
with guideline adherence (complete adherence vs incomplete adherence) were studied 
by means of generalized linear mixed models for binary outcomes. To correct for 
clustering of patients within hospitals, hospital was entered as random effect in the 
analyses.
The associations of the predictor variables with guideline adherence were tested 
in univariate models (Table 1). All predictor variables with a significant association 
(p ≤ 0.05) were added to a multivariable model. To account for collinearity, all predictor 
variables without a significant association in the univariate analyses were added to the 
multivariable model one by one. In case of a significant improvement of the model fit 
(p ≤ 0.05), they were added to the multivariable model. Additionally, several potential 
interactions between variables were tested in the multivariable model: age with 
treatment, discharge diagnosis and sex; and discharge diagnosis with treatment and 
sex. In case of a significant improvement of the model fit (p ≤ 0.05), the interactions were 
added to the multivariable model. From this model, the fixed effects were presented as 
odds ratios (OR) with 95 % confidence intervals (CI).
Associations of patient, arrival, discharge and hospital characteristics with prescription 
of discharge medication in univariable generalized linear mixed models (N = 2471).
The data were analysed in R (version 3.0.2 for Windows) using the lme4 package.
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ETHICAL APPROVAL
The study protocol was approved by the medical ethics review committee of the VU 
University medical centre.
RESULTS
SELECTION OF PATIENT CHARTS
In total, 3427 charts of patients with a confirmed discharge diagnosis of ACS in 2012 
were screened. Of these, 876 patients (26.6 %) were transferred to another hospital 
or department for further evaluation or treatment, 56 (1.6 %) died during admission, 
information concerning discharge medication was missing for 14 patients (0.4 %), 
6 (0.2 %) left the hospital against medical advice and 4 (0.1 %) received palliative care. 
After exclusion of these charts, 2471 patients were eligible for further analyses. Their 
mean age was 66.9 years and the majority were male (67.6 %) (Table 1).
GUIDELINE ADHERENCE
Overall, 49.1 % of the patients were prescribed all five guideline-recommended medicines 
at discharge from the hospital, while an additional 20.0 % had contraindications 
documented for the medicines that were not prescribed. Consequently, the complete 
guideline adherence for the combination of the five medicines was 69.1 %. Guideline 
adherence for the individual medicines ranged between 99.6 % for acetylsalicylic acid 
and 76.8 % for the ACE inhibitor. Complete guideline adherence for the combination of 
the five medicines ranged from 42.1 to 87.0 % between hospitals. Prescription rates and 
guideline adherence are presented in Table 2 and Fig. 1.
Table 2. Prescription patterns for the five medicines for secondary prevention (N=2471)
Drug type Prescriptions 
n(%)
Range (% in 
lowest – highest 
scoring hospital)
Guideline 
adherence 1
n(%)
Range (% in 
lowest – highest 
scoring hospital)
Acetylsalicylic acid 2271 (91.9%) 86.6%-97.2% 2460 (99.6%) 98.6%-100%
P2Y12 receptor inhibitor 2189 (88.6%) 70.3%-95.9% 2293 (92.8%) 75.7%-98.6%
Statin 2294 (92.8%) 81.1%-97.4% 2363 (95.6%) 83.8%-98.9%
Beta-blocker 2220 (89.8%) 83.5%-99.0% 2360 (95.5%) 90.5%-99.0%
ACE inhibitor 1603 (64.9%) 47.5%-74.5% 1898 (76.8%) 57.9%-93.1%
All 5 medicines 1214 (49.1%) 28.2%-59.0% 1708 (69.1%) 42.1%-87.0%
4 out of 5 medicines 2068 (83.7%) 67.8%-91.0% 2297 (93.0%) 78.4%-99.0%
ACE, angiotensin-converting enzyme; STEMI, ST-segment elevation myocardial infarction; 
NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina pectoris 
1 Guideline adherence refers to either prescription of the medicine or documentation of a 
contraindication
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Fig 1. Guideline adherence (%) per medicine per discharge diagnosis. ASA=acetylsalicylic 
acid; P2Y12=P2Y12 receptor inhibitor; ST=statin; BB=beta-blocker; ACE=angiotensin-
converting enzyme inhibitor; ACS=acute coronary syndrome; STEMI=ST-elevation 
myocardial infarction; NSTEMI=non-ST-elevation myocardial infarction; UA=unstable 
angina
FACTORS ASSOCIATED WITH (IN)COMPLETE GUIDELINE ADHERENCE
In univariate generalized linear mixed model analyses, discharge diagnosis, type of 
treatment, age, sex, resuscitation, transport from another hospital and length of stay 
were significantly associated with the probability of guideline adherence (Table 1). 
Additionally, the risk factors diabetes mellitus, kidney failure, a prior detected coronary 
stenosis, current smoking, and a medical history of angina pectoris, coronary artery 
disease, prior PCI or prior CABG were associated with the probability of guideline 
adherence. These were entered in a multivariable model. The variable ‘recent PCI, CABG 
or myocardial infarction (< 6 months before admission)’ significantly improved the 
multivariable model fit and was therefore subsequently added to the model secondarily. 
In addition, an interaction between age and sex was added to the multivariable model. 
No significant associations between hospital characteristics and guideline adherence 
were found.
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In the final model, patients with NSTEMI or UA compared with patients with STEMI, and 
patients who had a prior CABG were less likely to receive the guideline-recommended 
medication at discharge (Table 3). Further, adherence was higher for patients who 
were treated with PCI compared with patients who received pharmacological or CABG 
treatment, who had diabetes mellitus or kidney failure, who were resuscitated on 
admission, who had longer lengths of hospital stay, or who had a recent PCI, CABG 
or myocardial infarction (< 6 months before admission). Additionally, the effect of 
age differed between men and women, i.e. the medication was less likely completely 
according to the guidelines for older women compared with older men.
Table 3. Associations of patient, arrival, discharge and hospital characteristics with 
prescription of secondary prevention medication in the multivariable generalized 
linear mixed model
Variable OR (95% CI) P-value
Discharge diagnosis
STEMI (intercept) N/A 0.37
NSTEMI 0.64 (0.49 - 0.82) ***<0.001
UA 0.29 (0.21 - 0.39) ***<0.001
Female patient 4.09 (1.32 - 12.7) **<0.01
Coronary artery disease 1.13 (0.79 - 1.61) 0.51
Angina pectoris 1.04 (0.79 - 1.38) 0.76
Prior PCI 0.98 (0.76 - 1.26) 0.87
Prior CABG 0.70 (0.51 - 0.95) *0.02
Diabetes mellitus 2.67 (2.06 - 3.45) ***<0.001
Kidney failure 2.10 (1.23 - 3.57) *0.007
Smoker 1.19 (0.94 - 1.50) 0.16
Coronary stenosis 0.82 (0.56 - 1.20) 0.30
Resuscitation 2.65 (1.29 - 5.44) **0.008
Transportation from another hospital 0.81 (0.60 - 1.10) 0.18
Age 0.97 (0.96 - 0.99) ***<0.001
Length of stay 1 1.43 (1.19 - 1.72) ***<0.001
PCI 2.05 (1.63 - 2.59) ***<0.001
CABG 0.98 (0.63 - 1.55) 0.94
Recent PCI, CABG or MI (<6 months before admission) 1.91 (1.23 - 2.95) **0.004
Interaction between Age and Sex 1.02 (1.00 - 1.04) **0.003
STEMI, ST-segment elevation myocardial infarction; N/A, not applicable; NSTEMI, non-ST-
segment elevation myocardial infarction; UA, unstable angina pectoris; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting; MI, myocardial infarction
1 Length of stay was log-transformed after careful consideration of the residuals of  a model 
without random intercept
* significant at ≤0.05 level; ** significant at ≤0.01 level; *** significant at ≤0.001 level
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SENSITIVITY ANALYSIS
As a sensitivity analysis the current model was compared with a full case analysis model 
(n = 2253). No differences were found in variable selection or significant associations, 
indicating a reliable imputation procedure.
DISCUSSION
In this multicentre study, guideline adherence for secondary prevention medication 
prescription at hospital discharge for patients with ACS was investigated. Complete 
guideline adherence was 69.1 %, with the highest adherence for acetylsalicylic acid 
and the lowest for the ACE inhibitor. Several patient and care characteristics were 
significantly associated with guideline adherence, while hospital characteristics were 
not.
The level of complete guideline adherence found in this study was comparable with 
another Dutch study in which 65.2 % of the patients with ACS were discharged with the 
recommended secondary prevention discharge medication.15 Also, in accordance with 
other studies, guideline adherence for the recommended discharge medication was 
lowest for the ACE inhibitor.16 This finding may be explained by the recommendation 
to prescribe the ACE inhibitor to all patients with ACS, but an exception may be made 
for normotensive patients without heart failure, left ventricular (LV) dysfunction 
or diabetes mellitus.4 Furthermore, an angiotensin-II-receptor inhibitor can be 
prescribed as an alternative for the ACE inhibitor, although the ACE inhibitor is the 
primary choice, as previous studies showed superiority in reducing adverse outcomes.17 
Therefore, prescription of an angiotensin-II-receptor inhibitor was not abstracted from 
the charts in this study.
Although there was substantial variation in guideline adherence between hospitals, 
this could not be explained by the hospitals’ characteristics (presence of intervention 
facilities and type of hospital). A recent study found that hospitals with interventional 
facilities treated more patients according to the guidelines.15 The different findings in 
this study might be explained by the use of a statistical correction for clustering of 
patients in hospitals, thereby reducing the effective sample size.18 When no statistical 
correction for clustering is used, the hospital characteristics are attributed to individual 
patients (n = 2471) instead of hospitals (n = 13), resulting in spurious significant results.
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The odds of complete guideline adherence were lowest for patients with UA, 
intermediate for NSTEMI patients and highest for patients with STEMI. This finding 
confirms the results of previous studies.19, 20 The difference in guideline adherence 
between STEMI and NSTEMI/UA might be explained by small differences in the 
European Society of Cardiology guidelines for the management of ACS patients with 
and without ST-segment elevation. One difference is the recommendation to prescribe 
a beta-blocker to all patients with STEMI, while only to patients with NSTEMI/UA who 
have LV dysfunction. However, this difference in the guidelines does not explain the 
differences found in the present study, as the differences between STEMI and NSTEMI/
UA were mostly caused by lower guideline adherence for the ACE inhibitor and the 
P2Y12 receptor inhibitor. Moreover, the high prescription rates of beta-blockers in 
NSTEMI and UA patients might indicate overmedication or adherence, potentially 
caused by adherence to previous guidelines21 as guideline adoption takes time.
Interestingly, the negative association of age with guideline adherence was stronger in 
women than in men. This finding is worrisome, as the most recent European guidelines 
recommend managing both genders in a similar fashion.22 To our knowledge, there 
is limited information on the impact of sex and age on the decision of physicians to 
prescribe secondary prevention medication after acute coronary syndrome. Therefore, 
additional research is required to identify potential (reasons for) treatment biases of 
physicians towards treatment of elderly women.
Since the estimated guideline adherence for secondary prevention medication after 
ACS was substantial, it would be recommended to focus future quality improvement 
efforts on reducing variation between patient groups and between hospitals. Several 
interventions exist for improving guideline adherence, e.g. feedback of performance23, 
continuing education24 or integrated care25. These interventions can focus on 
undertreated patient groups, e.g. facilitating educational meetings for cardiology care 
providers about the treatment of elderly women with ACS.
LIMITATIONS
Several limitations of this study might influence interpretation of its results.
Having no information on one of the medicines prescribed at discharge in the patient 
chart can be the result of no prescription, or no documentation of the prescription, 
contraindication or another reason for not prescribing the medicine (e.g. preserved 
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LV function for the ACE inhibitor). As the charts were not screened by physicians, 
implicit decisions could not be included in the chart review. Instead, a standard list of 
contraindications was used, thus minimising inter-reviewer variation. Consequently, 
the rates of guideline adherence in this study might differ slightly from real-life 
guideline adherence and are therefore only an estimate. An additional limitation 
relating to documentation is the selection of patients by means of the hospital billing 
systems with manual review of the discharge diagnosis in the chart. Potentially some 
ACS patients were missed who received a billing code not related to ACS or with a 
different discharge diagnosis documented in their chart, which could limit the external 
validity of the findings in this study.
Another limitation of this study was that the potential prescription of suboptimal doses 
of medicines was counted as adhering to the guidelines.26 As optimal doses tend to 
differ between patients, and the optimal dose can often not be prescribed at discharge, 
it was not possible to incorporate doses in this study. Counting suboptimal doses as 
guideline adherence may have led to an overestimation of the quality of care in this 
study. In addition, prescribing medicines that are not indicated can also be considered 
to be incomplete guideline adherence. However, as the charts were not screened by 
physicians, this could not be taken into account in this study.
Prescription behaviour of individual physicians can be an additional source of variation 
in guideline adherence27; however, in this study it was not feasible to identify the 
physician responsible for medication prescription at discharge from the charts.
As a result of the large number of patients in PCI centres, the screening capacity limited 
the number of included patient charts per month. However, this should not have 
affected the results in our study since patients were selected in chronological order of 
discharge and there was no difference in guideline adherence between hospitals with 
and without PCI and/or CABG facilities.
Finally, participation in a national quality improvement program and the monthly 
measurements might have overestimated guideline adherence. However, the effect 
of this program on guideline adherence is expected to be limited as no significant 
association between month of discharge and guideline adherence was found.
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CONCLUSION
Guideline adherence concerning the prescription of discharge medication in the 
Netherlands is substantial though differs between hospitals and patient groups. Efforts 
to further improve guideline adherence can be targeted on those patient groups who 
receive suboptimal treatment at discharge from the hospital, e.g. elderly women and 
patients with NSTEMI or UA.
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ABSTRACT 
Background: Improving guideline adherence in the process of care for patients 
with acute coronary syndromes has a strong link with improved patient outcomes. 
However, improving guideline adherence is difficult, as many interventions can be 
used, either stand-alone or combined into more complex interventions. The aim of 
this review is to identify intervention components used to improve the guideline 
adherence in the process of ACS care; to identify their effectiveness; and to identify 
whether combining multiple components is more effective than single or two 
components. 
Methods: In this review, the Cochrane Effective Practice and Organisation of 
Care methodology was followed where appropriate. A systematic search was 
performed in PubMed, EMBASE, CINAHL, PsycINFO, the Cochrane Library and 
ABI/INFORM. All studies aiming to improve guideline adherence in the process of 
ACS care were included. After providing an overview of study characteristics, the 
studies with the strongest research designs ((cluster) randomized trials, controlled 
before-after studies and interrupted time series) were included. The studies were 
summarized and effects of interventions were estimated. 
Results: The systematic search resulted in 4560 unique papers. In total, 265 
studies aimed to improve guideline adherence in the process of ACS care. Most 
studies attempted to improve pharmaceutical prescription or timely invasive or 
thrombolytic intervention. After selecting the strongest study designs, 24 studies 
were included and summarized and assessed for risk of bias. In these studies, the 
most common intervention components were audit and feedback, educational 
interventions, educational materials and local opinion leaders. Combining three 
or more components appeared more effective in improving the ACS care process.  
Conclusions: In most studies, similar components were used. Combining multiple 
component interventions appeared more effective in improving the care process 
of patients with ACS. The most effective intervention appeared a combination of 
audit and feedback, educational materials and meetings, and continuous quality 
improvement.
Interventions to improve guideline adherence of care providers in hospitals in the management
121
7
INTRODUCTION
Adhering to (inter)national guideline recommendations in the hospital management 
of patients with acute coronary syndromes (ACS) is important as it prevents cardiac 
damage and improves chances of survival.1, 2 Lower guideline adherence can result in a 
higher risk of dying, especially in elderly patients.3 Because of the positive association 
between guideline adherence and patient outcomes, measuring guideline adherence 
is an important tool for identifying room for improvement in the quality of care in 
clinical practice.
Several studies showed that guideline adherence has been suboptimal in ACS care, 
indicating large differences between individual patients 4, hospitals 2 and countries 5. 
For example, the prescription of medication at discharge and treating patients within 
the recommended treatment delays were suboptimal.6, 7 Although there should always 
be room to deviate from guideline recommendations in order to adapt a treatment to 
individual patient characteristics and needs, interventions with the goal to increase 
guideline adherence have led to improved patient outcomes in the past.8 This finding 
indicates that deviating from the guidelines is not always beneficial. Therefore, quality 
improvement programs aiming to stimulate guideline adherence are implemented on 
local, regional, national and international levels.
Improving guideline adherence is difficult however, and various interventions have been 
applied in the past. In the field of research on guideline implementation, multiple types 
of interventions or intervention components have been proposed, e.g. education in 
continuous quality improvement and feedback of the performance in treatment delay.9, 
10 However, it is unclear what interventions are used in practice and what interventions 
were effective in improving guideline adherence in the management of patients with 
ACS. In addition, combining multiple intervention components into more complex 
interventions might be more effective than using one or two intervention components. 
The aims of this study were therefore to 1) provide an overview of studies aiming 
to improve guideline adherence in ACS hospital care; 2) identify the intervention 
components in the studies with the strongest research design and evaluate their 
effectiveness; and 3) assess whether combining multiple intervention components is 
more effective than single or double component interventions. This study will provide 
policy makers with a comprehensive overview of interventions aiming to improve 
guideline adherence in ACS care, and hence facilitate effective quality improvement 
efforts.
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METHODS
DESIGN
In this systematic review of the literature, interventions applied to improve guideline 
adherence in the treatment of patients with ACS were identified. The Cochrane Effective 
Practice and Organisation of Care (EPOC) methods for systematic reviews were used 
where appropriate. 
SEARCH STRATEGY
The search strategy was set up by JT in cooperation with a library information specialist 
of the VU University medical centre, and contained terms for acute coronary syndromes, 
guideline adherence and hospital care (Additional file 1, not included in this thesis). 
The following electronic medical research databases were searched: PubMed, EMBASE 
through Embase.com, CINAHL through EBSCO, PsycINFO through EBSCO and 
the Cochrane Library through Wiley (up to April 2014). For studies from the field of 
operations management the electronic business research database ABI/INFORM was 
searched through ProQuest. Additionally, experts in the fields of cardiology, guideline 
adherence and quality improvement for patients with ACS (n=17) were approached 
by email to identify relevant studies. References of potentially relevant articles and 
narrative reviews, and potential result publications of published study designs were 
screened for additional citations.
INCLUSION AND EXCLUSION CRITERIA
Studies were included when one or more of their research questions or research 
objectives were to improve the process of ACS care by increasing guideline adherence 
(e.g. improving performance on process quality indicators) among health care 
professionals in hospitals. All guidelines by professional cardiology organizations 
worldwide (e.g. American College of Cardiology/American Heart Association, 
European Society of Cardiology or the Japanese Circulation Society) and process 
quality indicators were considered. Consequently, the primary or secondary outcome 
variable(s) of the included studies were measures of guideline adherence or process 
quality indicator scores. 
Articles were excluded when the study did not evaluate the effectiveness of an 
intervention to increase guideline adherence, or no results of quantitative data analyses 
were presented (e.g. editorials, research protocols or qualitative studies). When multiple 
articles were published about the same study, only the main article about the effect of 
the intervention on guideline adherence was included. From systematic reviews, the 
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relevant primary studies were included. No articles were excluded based on their year 
of publication.
The titles and abstracts of all citations found in the electronic databases or referred to 
by the experts were screened by two raters independently (JT and IvdW). The citations 
were categorized as inclusion, exclusion or unclear. In case the citation was marked as 
unclear by either rater, it was discussed until consensus on in- or exclusion was reached. 
When no consensus was reached, a third rater (MdB) was consulted. 
OVERVIEW OF STUDIES
After the first screening on title and abstract, the papers were reviewed in-depth by 
retrieving the full-text where possible and screened for inclusion or exclusion. To 
provide an overview of the preliminary included studies, basic elements of these studies 
were extracted: study design, the processes which the intervention aimed to improve, 
the number of hospitals that participated and the number of ACS patients included. 
For the citations where no full-text could be obtained (n=22), the information was 
extracted from the abstract. Data extraction was initially performed by two reviewers 
independently (JT and SvS) until the definitions in the data extraction tool were 
adequate and the agreement between the two reviewers was satisfactory; afterwards 
the data extraction was performed by a single reviewer (JT). 
DATA EXTRACTION
From the studies included in the overview, only studies with the study designs 
recommended by EPOC were included in the final study selection: (cluster) randomized 
controlled trials; controlled before-after studies with at least more than 1 intervention 
site; and interrupted time series with at least three measurements before and after the 
intervention (as recommended by the EPOC group). From these studies, the design, 
methods (including a description of the intervention and its components according to 
the EPOC framework11, Table 1) and results were recorded. The risk of bias of individual 
studies was estimated using the EPOC suggested risk of bias criteria12, as appropriate 
for (cluster) randomized trails/controlled before-after studies or interrupted time 
series. All information was recorded in evidence tables (Additional file 2, not included 
in this thesis). The description of the intervention components and study outcomes are 
additionally described in the results section of this paper.
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Table 1. Summary of the main categories of the Effective Practice and Organisation 
of Care (EPOC) framework
Delivery arrangements Financial
How and when care is delivered Collection of funds
Where care is delivered Insurance schemes
Who provides care Mechanism of payment
Coordination and management Targeted financial incentives
Information and communication technology Governance arrangements
Implementation Authority and accountability for policies
Interventions targeted at organizations Authority and accountability for organizations
Interventions targeted at professionals Authority and accountability for commercial 
products
Interventions targeted at specific types of 
practices
Authority and accountability for professionals
In this table, only the main categories are described. Each main category has multiple 
subcategories, for example implementation interventions aimed at professionals includes 
audit & feedback, local consensus processes, etc.
DATA SYNTHESIS
During our systematic review, it was found that either the number of patients was 
not reported per process measure, or only the number of hospitals was reported. 
Consequently, no confidence intervals or pooled effect sizes could be calculated. 
Therefore, synthesis was performed by averaging the overall effectiveness of the 
interventions in the studies. The overall effectiveness was calculated by averaging 
the difference in performance (%) between the intervention and control groups post-
intervention for all included process measures reported as percentages in the study. 
Overlapping outcome measures (e.g. overall performance scores) were excluded to 
avoid double counting. To assess the effectiveness of relatively simple versus more 
complex interventions, studies with ≤2 component interventions were compared with 
≥3 component interventions. To reduce potential effects of sampling variation, smaller 
studies (an arbitrary 1000 patients included in the study) were excluded from average 
effectiveness calculations. 
RESULTS
Searches in the electronic databases yielded 5815 citations. These results were 
supplemented with 576 citations recommended by the experts in the fields of quality 
improvement research in cardiology. After deduplication, 4560 unique citations were 
screened, of which 582 citations were about improving guideline adherence in ACS care. 
After excluding studies in which no quantitative data were reported, 265 papers met our 
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inclusion criteria and basic study characteristics from these papers were extracted. Most 
of these studies aimed to improve pharmaceutical prescription, time to percutaneous 
coronary intervention or time to thrombolysis. Few studies aimed to improve use of 
risk scoring instruments, risk assessment or referral to cardiac rehabilitation (Table 2). 
Table 2 Care process measure and number of studies
Study subject # of times studied*
Pharmaceutical prescription 133
Time to percutaneous coronary intervention 104
Time until thrombolysis 78
Other 51
Referral to smoking cessation 43
Time until diagnosis 36
Use of diagnostic instruments / use of interventional therapy 31
Referral to cardiac rehabilitation 23
Risk assessment 17
Use of risk scoring instruments 5
* multiple process measures per study could be reported.
The majority of the studies were performed with a non-controlled before-after design 
(Table 3). In ten papers, the study design not mentioned or described in a way that did 
not allow for identification of the study design and were therefore excluded. Figure 1 
shows the flow chart of the study selection.
Table 3 The study design of the included studies for in-depth review
Study design # of times used
Non-controlled before-after study 181
Case series 32
Cohort study 14
Cluster randomized controlled trial 11
Controlled before-after study 12
Randomized controlled trial 4
Interrupted time series 1
Unclear 10
From the studies included in the overview, 241 studies were excluded on research 
design or because there were multiple publications about the same study. In total, 24 
studies met our criteria, from which in-depth information was abstracted and the risk 
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of bias was assessed. The studies were performed in different designs: 4 randomized 
controlled trials; 11 cluster randomized controlled trials; 8 controlled before-after 
studies and 1 interrupted time series study. 
131 
 
Figure 2 Flow chart of the study selection process. 
 
RISK OF BIAS ASSESSMENT 
Most studies had a high risk of bias because of not reporting baseline characteristics 
(n=12), inadequate allocation concealment (n=9) or no random sequence generation 
(n=8); the majority of these studies were performed with a controlled before-after 
design. Only 2 studies reported the number of missing values and how they were 
handled, while the other 22 studies did not. In addition, baseline characteristics were 
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(n=8); the majority of these studies were performed with a controlled before-after 
design. Only 2 studies reported the number of missing values and how they were 
handled, while the other 22 studies did not. In addition, baseline characteristics were 
most often only described of the hospitals and/or patients, but characteristics of the 
care providers on which the interventions were focused (e.g. physicians) were rarely 
reported. All but one study (Karagounis et al, interpretation of electrocardiograms 
13) used objective outcome measures. The results of the risk of bias assessments are 
presented in Figure 2.
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Figure 3 Results of the risk of bias assessment of all included studies (n=24) 
according to the suggested EPOC risk of bias criteria. 
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In total, 23 different intervention components were identified in the studies. The 
component audit & feedback was most often used (12 studies)14-25, followed by 
educational interventions (11 studies)16-20, 23, 26-30, educational materials (7 studies)16, 26, 
28-32 and local opinion leaders (6 studies)15, 19, 20, 27, 30, 32. The other 19 intervention 
components were applied in fewer than 4 studies. Five studies had an intervention of 
1 component, 3 studies had 2 components and the other 16 studies had an intervention 
with ≥3 components. The median number of components per study was 3, ranging 
from 1 to 6. The intervention components are summarized in Table 4. 
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PROCESS MEASURES
In the studies, the following measures were subjected to improvement interventions: 
the number of pharmaceutical prescriptions, time to diagnosis, time to medication, 
time to PCI, referral to a smoking cessation program, risk assessment, risk stratification, 
use of diagnostics, referral to cardiac rehabilitation, referral to dietary counselling, 
length of hospital stay, number of blood transfusions, cholesterol measurement, and 
use of quality improvement tools. Of the 24 studies, only two studies included patient 
outcomes in addition to process outcomes.14, 18 Negative indicators, i.e. a process that 
should not be initiated when it is not required (e.g. because a superior alternative is 
available, it has no value or its effectiveness has been disproved), were reported in two 
studies (use of lidocaine30 and use of thrombolysis in patients without a confirmed 
myocardial infarction22). Few studies reported the actual number of patients who were 
eligible for a process measure and what the performance was (e.g. the total number of 
patients without contraindications that received a beta blocker on admission). 
SYNTHESIS
Most studies only reported the performance in percentages without reporting measures 
of variance/spread such as standard deviations or confidence intervals, rendering it 
impossible to calculate pooled effect sizes and confidence intervals. Consequently, the 
overall effects of the interventions were estimated by only calculating the performance 
in percentages and ranges between studies. Four studies could not be included in 
the synthesis since their outcomes were continuous instead of dichotomous.13, 19, 28, 
31 In addition, six studies were considered small and were therefore not included in 
calculating the average effects. 20, 22, 23, 29, 33, 34
The average performance improved 3.8%, ranging from a deterioration of 3% to an 
improvement of 14%. In Figure 3, the comparison between studies with simple (≤2 
components) or more complex (≥3 components) is presented. For the larger studies, 
the average percentage improvement in performance was 0.6% (range: -3% to +3%) 
for the simple interventions and 5.6% (range: +2% to +14%) for the more complex 
interventions. 
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Figure 4 Comparison of the total change in performance between simple (top 
part of the figure) and more complex (bottom part of the figure) interventions. 
The studies are arranged on the number of patients included from least to 
most; studies in the grey areas included fewer than 1000 patients. In studies 
with an * the total number of patients was not reported, but the number of 
included hospitals was high enough to assume inclusion of more than 1000 
patients. 
 
In the Figures 3-6, the results of the most common intervention components are 
displayed. For audit and feedback, the interventions with audit and feedback as a 
component resulted in an average improvement of 3.6% (range: -3% to 14%). For 
educational meetings, the total intervention resulted in an average improvement of 
6.5% (range: +3 to +14%). Interventions with educational materials as a component 
resulted in an average improvement of 5% (range: +3 to +6%). For local opinion 
leaders, the average improvement was 4.5% (range: +2 to +6%).  
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In the Figures 3-6, the results of the most common intervention components are 
displayed. For audit and feedback, the interventions with audit and feedback as 
a component resulted in an average improvement of 3.6% (range: -3% to 14%). For 
educational meetings, the total intervention resulted in an average improvement of 
6.5% (range: +3 to +14%). Interventions with educational materials as a component 
res lted i  an av rage improvement of 5% (ra g : +3 to +6%). For local opini n leaders, 
the ave ge improvement was 4.5% (range: +2 to +6%). 
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Figure 5 Overview of interventions with audit and feedback as a component. 
Studies in the grey areas included fewer than 1000 patients. After the study ID, 
the performance in the intervention group, performance in the control group 
and the difference are presented. 
 
 
Figure 6 Overview of interventions with educational meetings as a component. 
Studies in the grey areas included fewer than 1000 patients. After the study ID, 
the performance in the intervention group, performance in the control group 
and the difference are presented. 
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Figure 7 Overview of interventions with educational materials as a component. 
Studies in the grey areas included fewer than 1000 patients. After the study ID, 
the performance in the intervention group, performance in the control group 
and the difference are presented. 
 
 
Figure 8 Overview of studies with interventions with local opinion leaders as a 
component. Studies in the grey areas included fewer than 1000 patients. After 
the study ID, the performance in the intervention group, performance in the 
control group and the difference are presented. 
 
DISCUSSION 
In this systematic review, an overview of interventions to improve the process of care 
for patients with acute coronary syndrome was provided. The majority of the studies 
focused on improving pharmacological prescriptions and were single centre, non-
controlled before-after studies. After including only the studies with the strongest 
designs, most studies showed that interventions were overall modestly effective in 
improving guideline adherence. More complex interventions appeared more effective 
in improving performance than simpler interventions. 
Although most interventions resulted in improvement, the differences between the 
interventions were large. The majority of interventions consisted of multiple 
components, however only four EPOC intervention components were identified more 
than four times. There is a nearly infinite number of combinations of these elements 
Figure 7 Overview of interventions with educational materials as a component. Studies 
in the grey areas included fewer than 1000 patients. After the study ID, the performance 
in the intervention group, performanc  in the control group and the difference are 
presented.
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DISCUSSION
In this systematic review, an overview of interventions to improve the process of care 
for patients with acute coronary syndrome was provided. The majority of the studies 
focused on improving pharmacological prescriptions and were single centre, non-
controlled before-after studies. After including only the studies with the strongest 
designs, most studies showed that interventions were overall modestly effective in 
improving guideline adherence. More complex interventions appeared more effective 
in improving performance than simpler interventions.
Although most interventions resulted in improvement, the differences between 
the interventions were large. The majority of interventions consisted of multiple 
components, however only four EPOC nte ventio  components were id ntified
more than four times. There is a nea ly infinite number of mbinations of thes
ele ents to design an intervention. After excluding smaller studies, he largest 
improvement was achieved in a setting where a national ACS care register was used 
to measure performance and facilitate targeted quality improvement. In the study, 
multidisciplinary teams of cardiologists and nurses were trained in continuous quality 
improvement in accordance with the breakthrough method.35 Additional papers have 
been published on the study, describing the intervention and follow-up results in more 
detail.8, 36, 37 One precondition for such an intervention is a fully operational national 
cardiology registry, which emphasizes the value of such a registry as the foundation for 
quality management. 
In this systematic review, the overall effectiveness of interventions containing similar 
components was calculated. Interventions with audit and feedback appears to have 
a small positive effect on the process measures, thereby confirming findings of other 
Interventions to improve guideline adherence of care providers in hospitals in the management
133
7
studies.38 Several aspects facilitate the effectiveness of audit and feedback: a low 
pre-intervention performance; interdisciplinary provision; a higher frequency, both 
verbal and written feedback; and inclusion of clear targets and action plans.38 Other 
intervention components also resulted in small improvements, which confirms the 
findings of other reviews on reminders 39, 40, local opinion leaders 41, printed educational 
materials 42 and educational meetings 43. 
The study designs identified in the overview of studies (n=265) generally resulted in 
a low level of evidence. The majority of the studies were single centre, non-controlled 
before-after studies. After selecting only the studies with the strongest research designs, 
high risks of bias were regularly identified. The baseline characteristics of neither 
care providers nor patients were reported in many studies, thereby limiting external 
validity. In addition, authors often did not report how missing data were handled or did 
not make (report the) use of a random sequence generation. In several studies, the data 
analyses were not corrected for clustering of patients within centres, which can lead to 
spurious significant results.44 It appeared that smaller studies reported more extreme 
results (either positive or negative) than larger studies.
All studies included in this review reported the performance on process measures for 
eligible patients, i.e. implementation. However, only two studies also reported negative 
measures, i.e. measuring the number of patients not eligible for a process measure 
who do receive it.22, 30 Although implementation research is important to distribute 
effective interventions, there appears little attention for de-implementation of obsolete 
interventions, or for appropriate use. In studies on e.g. the prescription of beta blockers, 
usually only the number of eligible patients (without contraindications) receiving them 
is reported. In contrast, the number of patients with contraindications that do receive 
them can be informative from a patient safety perspective.
IMPLICATIONS FOR PRACTICE
Many different interventions can be used for improving process measures. In this study, 
multifaceted interventions appeared more effective in improving practice than single 
interventions. It can be recommended to combine several intervention components in 
order to achieve a larger improvement in performance. It is not known what the most 
effective combination of components is and whether there is an optimal combination of 
intervention components. However, combining intervention components with specific 
purposes (e.g. providing an overview of current performance, organizing educational 
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meetings and materials to initiate change, and continuing efforts to ensure change) is 
highly recommended. It is paramount that the performance is not only measured, but 
feedback is provided and there is a system to use targeted quality improvement efforts, 
sufficiently supported by the care providers. In addition, to limit the administrative 
burden, only the most essential variables should be recorded. 
Implementation research has taught us that the attitude of care providers affects their 
likelihood to adopt an intervention. Lack of knowledge of, and a negative attitude 
towards guideline recommendations have been identified as the most important 
barriers in guideline adherence.45 Despite this large impact on implementation, the 
attitude of care providers towards the process measures was only reported in one 
study.29 Interventions such as educational meetings, educational materials and local 
opinion leaders are predominantly aimed at affecting the attitude and can therefore be 
important when improving guideline adherence.
IMPLICATIONS FOR RESEARCH
In this study, the quality of reporting of studies was frequently inadequate. This has 
been identified as an issue in a previous systematic review of interventions to improve 
care for patients with diabetes mellitus type II.46 Reporting of complex interventions is 
frequently inadequate for policy makers to translate into practice. As a result, reporting 
criteria for complex interventions (StaRI 47) and quality improvement efforts (SQUIRE 
48) can be of great benefit to the quality of reporting quality improvement efforts. In 
addition, the EPOC framework can be used to report the different components of the 
intervention.11
Adequate reporting is not only important for composition of the intervention and the 
setting in which it is applied, but also for its delivery. In this review, we found that 
only few studies reported information on compliance of interventions. In one of the 
studies included in this systematic review, it is reported that only 13 of the 19 hospitals 
held the planned educational sessions for hospital staff, while 6 did not.19 Reporting 
the delivery of the intervention is advocated in all studies on complex interventions 
49 and can be a valuable addition in health services research. For policy makers and 
quality officers, it is vital to assess whether an intervention could work in their setting. 
Through collecting data on the process of implementation by means of document 
analyses, stakeholder interviews, observations and/or monitoring of routine data, the 
process of implementation can be evaluated (process evaluation).50 In the report, the 
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authors should describe what the intervention entailed, how it was implemented, and 
what the mechanisms of impact were. 
LIMITATIONS
The results of this study should be considered in the light of some limitations. First, 
although full meta-analyses (with a pooled effect sizes and corresponding confidence 
intervals) are the preferred form of knowledge synthesis, this could not be performed 
in this study. Most studies did not report the number of eligible patients per process 
measure, thereby rendering the calculation of confidence intervals impossible. The 
calculation of the average effects and corresponding ranges of the comparisons in this 
review (simple vs complex and the four intervention components) are crude measures 
and should therefore be interpreted with caution. Second, there were large differences 
in the settings, interventions, outcomes and number of outcomes per study, making 
comparison between interventions difficult. In this review, the aim of our study was to 
provide an overview of the interventions used in cardiology, and therefore we decided 
to include all interventions aimed at improving guideline adherence in ACS care. It is 
not known whether these studies can be repeated with similar results in other settings. 
Fourth, although a taxonomy was used for characterizing the interventions, within the 
categories there is ample room for variation. For example, feedback of performance can 
vary in the person or institution providing the feedback, the delivery method (digitally, 
on paper, in person) and the frequency of feedback. Also, different interventions 
components can be combined, making it unclear what the contribution of a single 
component is. The average effects should therefore be interpreted with caution. Finally, 
in the calculation of the improvement per study, the performance on multiple process 
measures was compared between the intervention and control groups of the studies. 
These results do not take potential baseline differences in the measures or variation 
into account. 
CONCLUSION
Many studies have attempted to improve the process of ACS care, especially the 
prescription of medication and to reduce the time to PCI. However, the study designs 
generally resulted in a low level of evidence. In studies with stronger research designs, 
audit & feedback, educational materials and meetings, and local opinion leaders 
were the most common interventions. Improvement of performance was reported in 
the majority of studies, no matter what intervention(s) was/were used. Combining 
multiple intervention components appeared more effective than one or two 
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components. Quality in reporting was poor however, and recent reporting guidelines 
on complex interventions and quality improvement can be of great value to the field of 
implementation research and ACS care.
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Although the quality of care for patients with ACS has improved tremendously over 
the years, the burden of this disease is still high.1 To further improve the quality of care 
and consequently patient outcomes, European clinical guidelines have been released. 
However, the implementation of these guidelines appears to be suboptimal in Dutch 
hospitals,2 potentially resulting in unwarranted practice variation and suboptimal 
patient outcomes. To improve guideline adherence in ACS care, a quality improvement 
program was developed. This program consisted of, among other things, multiple 
quality indicators and a national online tool where the hospitals could upload their 
results on the quality indicators.3 However, the proposed online tool was terminated 
prematurely. Consequently, the information about the quality of ACS care in Dutch 
hospitals is scarce.
To fill this gap, the quality of ACS hospital management was evaluated by measuring 
multiple process quality indicators, as presented in the previous chapters of this thesis. 
The research questions of the research presented in this thesis were: 
1) to what degree are the guideline recommendations for minimizing treatment 
delay in STEMI and the prescription of secondary prevention medication in 
ACS adhered to in Dutch hospitals?
2) to what extent is there unwarranted process variation in the performance of 
hospitals on these quality indicators? 
3) what interventions are effective for improving the ACS care process?
In this chapter, the main findings of the studies are synthesized per research question; 
the VMS ACS quality indicators are reflected upon; (methodological) considerations 
about the research are presented and recommendations for clinical practice and future 
research are made.
1) To what degree are the guideline recommendations for minimizing treatment 
delay in STEMI and the prescription of secondary prevention medication in 
ACS adhered to in Dutch hospitals?
Because no reliable national data on ACS management were available, these were 
collected in a cross-sectional study (chapter 2). This study was designed to measure 
guideline adherence for treatment delay in STEMI; use of risk scoring tools in NSTEMI 
and UA (results presented in the thesis of Engel4); and prescription of secondary 
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prevention medication in all ACS patients. In total, 13 hospitals participated in this 
study. The results are discussed per indicator.
GUIDELINE ADHERENCE: TREATMENT DELAY
Seven of the 13 hospitals provided primary PCI. Of the 1017 STEMI patients going for 
primary PCI, 800 (78.7%) were treated within the recommended maximal treatment 
delay of 90 minutes. The median treatment delay was 64 minutes (interquartile range: 
47-82 minutes) (chapter 3). 
The median treatment delay in our study appeared shorter than as reported in a 
recent Dutch publication: 64 minutes versus 75 minutes (interquartile range: 51-108 
minutes).5 The data for this publication was collected by a Dutch data registry during 
four ‘snapshot weeks’. In these weeks, several hospitals reported multiple performance 
indicators to the data registry. Potential explanations for the difference between the 
results are differences in the patient population (e.g. more patients with acute heart 
failure / cardiogenic shock) and the method of data collection. 
Although room for improvement was identified in our study, the overall performance 
in Dutch hospitals was high in comparison to studies performed abroad. The median 
delay in studies performed abroad was 86-90 minutes.6-8 However, several factors 
impede direct comparison of these results to results of studies performed abroad: the 
small land area of the Netherlands and the relatively high number of PCI centres; the 
distinctive health care system (with an important role for general practitioners); the 
developed emergency medical services system with prehospital ECGs; and the use of 
different definitions of treatment delay. In countries similar to the Netherlands in some 
factors (e.g. other countries with a small total land area and highly developed emergency 
medical services such as Denmark), similar short treatment delays were reported.9 
In the Danish study, the treatment delay was defined as ranging from the call to the 
emergency medical services to PCI. Despite this broader definition, the median delay 
was 75 minutes (for patients living within 10 km of a PCI centre). However, Denmark 
has more centralized PCI services, with only four centres performing primary PCI10 
instead of the 30 centres in the Netherlands. Their median delay was higher for patients 
living further from a PCI centre: a median delay of 134 minutes for patients living >100 
km from a PCI centre.9 In contrast, in the Netherlands no, or very few, patients live >100 
km from a primary PCI centre, with consequently shorter driving times and treatment 
delays. Nevertheless, the research presented in this thesis shows areas for improvement 
in acute STEMI management in the Netherlands.
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GUIDELINE ADHERENCE: SECONDARY PREVENTION MEDICATION
The guideline adherence for prescribing secondary prevention medication at discharge 
from the hospital was substantial. Of the 2471 patients with ACS, 1708 (69.1%) were 
treated according to the guidelines. This performance was comparable to the results 
of a regional study performed in the Netherlands, in which 65.2% of the patients were 
discharged with the recommended secondary prevention medication.11 The percentage 
of guideline adherence in our study varied between medications, from 76.8% for the 
ACE inhibitor to 99.6% for acetylsalicylic acid. 
Although the performance in studies performed abroad showed a similar picture, some 
differences occur. For example, in a large European study (the Euro Heart Survey), the 
average percentages of discharge medication ranged from 66% for thienopyridines to 
99.6% for the acetylsalicylic acid in STEMI patients, and from 59% for thienopyridines (a 
subgroup of p2Y12 inhibitors) to 88% for aspirin in NSTE-ACS patients.12 Consequently, 
the performance as measured in our study was relatively high. This might be caused by 
the fact that individual patient records were screened and potential contra-indications 
were retrieved from all records. Not including contra-indications, the performance on 
guideline adherence in our study was 49.1% for all five medications, ranging from 64.9% 
for the ACE inhibitor to 92.8% for the statin. In contrast, a recent publication about 
a study performed in the United Kingdom reported guideline adherence as high as 
ranging from 89.3% for P2Y12 inhibitor to 98.7% for aspirin.13 Therefore, the guideline 
adherence appears to have improved over the years and further improvement in the 
Netherlands appears feasible.
2) To what extent is there unwarranted process variation in the performance of 
hospitals on these quality indicators?
PROCESS VARIATION: TREATMENT DELAY
Despite a short median treatment delay, we identified several non-medical factors 
associated with a longer treatment delay, indicating unwarranted process variation. 
These factors were similar to the ones identified in previous international studies7, 14: 
requiring inter-hospital transfer and presentation with acute heart failure (chapter 3). 
However, these studies also identified presentation during off-hours and co-morbidity 
such as diabetes and chronic heart failure as predictors of time delays, while this 
was not the case in our study. The difference in presentation during off-hours can be 
explained by potential differences in the after-hours care between the study settings. 
For example, due to the small country size of the Netherlands in comparison to the 
United States, the majority of interventional cardiologists and catheterization room 
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nurses live near the hospital and can arrive at the hospital within 20 minutes of being 
called. In contrast, in the United States, only 10.7% hospitals expected their staff to 
arrive within 20 minutes.15 
In a qualitative study, numerous differences in the processes from first electrocardiogram 
to PCI were identified between PCI centres. In addition, accelerating factors were 
identified and the results were synthesized in a model (chapter 5). The most important 
differences between the centres were: the profession of the care coordinator; 
communication of diagnostic information (transmittal of ECGs); making the decision 
to initiate catheterization; catheterization room preparation; and accommodation 
of the patient in case the catheterization room is occupied. Different choices in 
maintaining the balance between speed and accuracy of the diagnosis, as well as 
situational differences (e.g. the presence of residents), resulted in differences in the 
processes. Furthermore, several factors were identified by care providers as influencing 
the speed of the process. These factors could be categorized as patient characteristics 
(e.g. clear signs and symptoms); healthcare providers characteristics (e.g. experience), 
inter-provider characteristics (e.g. clear communication); and hospital characteristics 
(e.g. anticipating variations in patient routing). Both the variation in the process as well 
as the factors influencing the speed of the process were summarized in a model, which 
can be used by PCI centres to reflect upon their acute care process and to identify the 
factors that can be improved.
PROCESS VARIATION: SECONDARY PREVENTION MEDICATION
Considerable variation between hospitals and patient groups was identified in the 
prescription of secondary prevention medication after ACS (chapter 6). While in the 
most compliant hospital the guidelines were adhered to in 87% of the patients, this was 
only 42.1% in the least compliant hospital. These differences could not be explained 
by differences in the patient populations. Furthermore, several patient groups were 
identified that received secondary prevention medication less often according to 
the guidelines. These were patients with NSTEMI or UA (compared to patients with 
STEMI); patients with a history of CABG; and elderly women. A potential explanation 
for the suboptimal prescription of secondary prevention medication could be the 
limited hospital length of stay. With a median length of stay of five days, there is little 
room for establishing the optimal dosage, in particular for the blood pressure lowering 
medication in elderly women. 
Internationally, differences between hospitals in the prescription of secondary 
prevention medication for ACS patients have also been identified. For example, in a 
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study performed in Sweden and the UK, the prescription of statin at discharge from 
the hospitals was 87.2% (interquartile range for hospitals: 81.4-91.3%) and 94.3% 
(interquartile range for hospitals: 90.7-96.9%) respectively.13 For the ACE inhibitor/
angiotensin II receptor inhibitor (AIIRB) this was 63.6% (interquartile range for 
hospitals: 57.1-69.8%) and 84.9% (interquartile range for hospitals: 79.7-90.5%) 
respectively. In addition to differences between hospitals, these results also show large 
differences between countries. In a European study, the guideline adherence for the ACE 
inhibitor ranged from 61% in Spain to 90% in the Czech Republic. In the Netherlands 
and Belgium, the guideline adherence ranged between 68% for the ACE inhibitor to 
92% for the dual anti-platelet (acetylsalicylic acid and clopidogrel, a P2Y12 inhibitor).16 
Direct comparison between the results of this study and our study is difficult, however. 
Many differences in definitions were identified. For example, there were differences 
in the patient groups (e.g. ACS, STEMI, NSTEMI, NSTE-ACS), the medications (e.g. 
clopidogrel, thienopyridine, P2Y12 inhibitor, dual antiplatelet therapy), timing (at 
discharge, after 30 days) or how contra-indications were handled (not taking contra-
indications into account, only including patients without contra-indications, defining 
contra-indications per medication). Consequently, comparisons between studies 
should be interpreted with caution.
These variations in both treatment delay and the prescription of secondary prevention 
medication indicate that, despite an overall fair performance, differences in processes 
and performance occur between countries, between hospitals and between patient 
groups. These differences indicate room for improvement in the quality of the process 
of care for patients with ACS in Dutch hospitals. 
3) What interventions are effective for improving the ACS care process?
One of the reasons to choose ACS as a subject for the VMS quality improvement 
program was that several interventions to improve the care process were previously 
described in scientific literature. However, these interventions had never been 
systematically assessed on their effectiveness in ACS management. In our systematic 
review, we showed that studies evaluating these interventions often had an inadequate 
research design. From the studies with the strongest research designs, we learned that 
audit & feedback, educational interventions, educational materials and local opinion 
leaders were the most often used intervention components. The interventions were 
aimed at improving e.g. pharmaceutical prescriptions; time to diagnosis; time to PCI; 
referral to a smoking cessation program; and use of risk stratification. The majority 
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of the interventions were modestly effective in improving guideline adherence. The 
findings in our systematic review confirm the findings of several Cochrane reviews. 
In these reviews, single components of interventions were evaluated, e.g. audit and 
feedback17, reminders18, 19, local opinion leaders20 printed educational materials21 and 
educational meetings22. In all these systematic reviews, the authors concluded that 
the intervention had small to modest effects on improving professional practice. In 
addition, the results of our systematic review showed that interventions consisting of 
multiple components were more effective in improving the process of ACS care than 
interventions with one or two components. To further improve the process of care for 
patients with ACS, multicomponent interventions (e.g. a combination of feedback of 
performance, training of care providers in continuous quality improvement and use of 
local opinion leaders) are therefore recommended (chapter 7).
REFLECTION
REFLECTION ON THE VMS QUALITY INDICATORS
Development and measurement of quality indicators is a time- and resource-intensive 
process.23 Although many quality indicators are measured by all Dutch hospitals24, not 
all quality indicators provide relevant information for the stakeholders. Several criteria 
can be used to separate useful quality indicators from indicators that predominantly 
contribute to an administrative burden. According to the study of Campbell et al25, a 
useful indicator should be: 
- acceptable to stakeholders;
- feasible (e.g. data availability);
- reliable (e.g. minimal measurement error);
- sensitive to change;
- predict patient outcomes (predictive validity).
It is of vital importance to keep these criteria in mind when developing quality 
indicators. Additionally, these criteria can be used to evaluate and improve current 
quality indicators, such as the VMS ACS quality indicators. 
Although the evaluation research on the VMS program concluded that a broad 
movement in patient safety had been initiated and the program should be continued,26 
several opportunities for improving the VMS ACS indicators can be identified in 
retrospect by applying the criteria of Campbell et al.. 
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Acceptable to stakeholders: 
Both the VMS ACS indicators and their evaluation received considerable criticism 
from cardiologists.27, 28 This criticism potentially points out a lack of support for, and/
or priority of the subject. This might have contributed to the lack of data entry in the 
online VMS tool. A potential reason for the lack of support and/or priority is that 
although the VMS ACS care guide states that the quality indicators were based on the 
ESC guidelines, they deviate from these guidelines on multiple aspects (for examples, 
see chapters 3, 4 and 6). The Netherlands Society of Cardiology (NVVC) decided to 
endorse the ESC guidelines as the foundation for Dutch ACS care. An exception is the 
2015 guideline on the management of ACS patients without persistent ST-segment 
elevation29, which was not endorsed for, among other reasons, the bleeding risk of 
triple antithrombotic therapy (i.e. aspirin, P2Y12 inhibitor and (non-vitamin K) oral 
anticoagulation). Separate recommendations for the care of this patient group were 
published in an NVVC working group statement.30 The current VMS quality indicator 
for secondary prevention medication deviates from the ESC guidelines and working 
group statement (published after the development of the quality indicators) on several 
aspects. For example, the strong recommendations (level of evidence 1A) for prescribing 
an ACE-inhibitor and a beta-blocker in the ESC guideline only apply to patients with 
heart failure or left ventricular dysfunction. In contrast, the VMS quality indicator makes 
no distinction. In addition, the quality indicators as described in the ESC guidelines 
only apply to the care for patients with STEMI and NSTEMI, while the VMS indicators 
also include patients with UA.31 Recently, a working group of the Acute Cardiovascular 
Care Association (ACCA) published a position paper on the use of quality indicators 
in evaluating STEMI and NSTEMI management.32 In re-evaluating the definitions and 
in- and exclusion criteria of the Dutch quality indicators, it is recommendable to stay as 
close to the endorsed European guidelines and working group statements as possible.
Feasible: 
In most hospitals, the data required for reporting the quality indicators was only 
available in the patient records. This meant that a tremendous effort would be required 
of hospital personnel to retrieve the available data. In addition, not all relevant time 
points were available in the hospital information systems, forcing hospitals to initiate 
labour- and time-intensive manual data extraction. This might have been another 
factor in the lack of data delivery to the prematurely terminated online VMS tool. 
In future quality indicator development, either data availability should play a more 
influential role in the selection of the indicators, or hospitals should be assisted in data 
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retrieval. Pilot testing of the indicators can lead to tremendous improvements before 
implementation on a national level. For example, many hospitals had no straightforward 
procedure to retrospectively select patients with ACS. During these pilot tests, a uniform 
procedure for selecting the patients with ACS eligible for the quality indicators could 
have been described. Pilot testing can also be used for finetuning the definitions and 
in- and exclusion criteria of the indicators, and thereby contribute to the selection of 
comparable patient groups in all hospitals.
Reliable: 
The reliability of both the treatment delay and secondary prevention medication 
indicators can be further improved by re-evaluating their definitions and in- and 
exclusion criteria. For example, the starting point of the treatment delay indicator 
was defined as the time of first (para)medical contact. However, it was not defined 
whether this concerns physical contact or e.g. calling the national emergency number. 
This led to the use of different definitions between hospitals, thereby hampering 
the reproducibility as well as the comparability of the results between hospitals. For 
secondary prevention medication, developing clear in- and exclusion criteria (taking 
into account contra-indications) is strongly recommended. These in- and exclusion 
criteria can be based on the codebooks developed for our studies (chapter 2).
Quality indicator developers in the Netherlands can learn from the AHA/ACC 
quality indicators33, which are developed using a template with clear definitions for 
e.g. a numerator, denominator, period of assessment, data source, rationale and 
corresponding guideline recommendations. The recent ESC Acute Cardiovascular Care 
Association (ACCA) working group position paper can also be used as an example for 
improving the definitions.32 
Sensitive to change: 
In our systematic review (chapter 7), several studies were included with similar quality 
indicators, i.e. treatment delay and prescription of medication. Many of these studies 
showed improvements in indictor scores after quality improvement programs were 
initiated. Therefore, the quality indicators appear sensitive to change.
Predictive validity: 
Both treatment delay and secondary prevention medication are correlated with 
mortality in studies with ACS patients and therefore these quality indicators fulfil this 
criterium.34, 35 
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(METHODOLOGICAL) CONSIDERATIONS
The results presented in this thesis need to be interpreted in the light of several 
considerations. 
CROSS-SECTIONAL DESIGN
The studies presented in this thesis were performed in a cross-sectional design. Two 
important assumptions were made: 1) that the performance of hospitals is (to some 
extent) consistent over time, and 2) that the random selection of hospitals was 
representative for all Dutch hospitals. When these assumptions are met, random 
samples from the time period can be extrapolated to the entire time period, i.e. the 
year 2012, and from the selected hospitals to all hospitals in the country. However, the 
measurements were performed during the VMS quality improvement program, which 
might have led to improved performance over the year. By adding the measurement 
times to the statistical models as a covariate, potential influences of the measurement 
times on the results can be identified. No significant influences were identified in 
these models, which indicate no or limited influence of the measurement times on 
the performance. Since not all hospitals agreed to participate in the study, there is a 
risk of selection bias, in that only the hospitals motivated for quality measurement 
participated. However, the number of hospitals that declined participation was small. 
Also, different types of hospitals did participate (academic, PCI hospital and non-
PCI hospital, teaching and non-teaching), which enhances the generalizability of the 
results of our studies. We therefore assume that potential effects on the outcomes of 
our studies are limited.
In our cross-sectional study, data were only collected on the hospital management 
and a minor part of prehospital management of ACS. However, multiple health care 
providers play a role in ACS management, i.e. from control of risk factors at the general 
practitioner to the acute care at the hospital, rehabilitation and eventually the long-term 
check-ups with the cardiologist and general practitioner for secondary prevention. In 
addition, several other elements such as patient outcomes and successfully performed 
PCI or CABG are (at least) equally important in the quality of hospital care for patients 
with ACS. Consequently, no conclusions can be drawn about the overall quality of ACS 
management in the Netherlands.
STRUCTURE, PROCESS AND OUTCOME
The final goal of all quality improvement efforts should be to improve the patient 
outcomes. Measuring processes is not a substitute for measuring outcomes, but it does 
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provide us with the insights to improve the process, in order to improve outcomes.36 
The works of Donabedian were based on the idea that process improvements should 
eventually lead to improvements in patient outcomes. However, establishing the link 
between process and outcome is challenging. In the management of ACS, several 
studies have been able to establish this link. For example, the study of Peterson et al. 
showed that improvements in the process of ACS management in Sweden correlated 
with improvements in outcomes.35 The results of other studies agree that there appears a 
correlation between the quality as measured by processes and outcomes13, 37, 38, although 
there is no definitive answer yet.39 In contrast, the study of Menees et al. showed that an 
average reduction of 16 minutes in the door-to-balloon times did not result in reduced 
mortality for patients with STEMI in a large data registry.40 This study highlights the 
importance of critically evaluating the association of process measures and patient 
outcomes. Although measuring process measures can contribute to an effective quality 
improvement system, it should always be the means to an end.
MISSING DATA
The retrospective nature of the data collection in the patient record review studies 
(chapters 2, 3 and 6) has several important implications. The results of this type of 
study are dependent on the quality of the data documented at the hospitals. It is 
challenging to assess the quality of this data retrospectively. For example, missing 
information can have multiple causes: the information was not obtained (e.g. no past 
medical history of the patient was obtained prior to an emergency PCI procedure); the 
information was not documented (e.g. a past medical history was obtained but not 
documented in the patient record); or there was nothing to report (e.g. the patient had 
no relevant past medical history). Identifying the cause of the missing data is difficult, 
thereby impeding the choice between for example ‘not documented/missing’ or ‘no 
medical history’ on the case report form. This might have affected the results of the 
patient record review studies. However, no major differences between the multiple 
chart reviewers were identified in the inter-reviewer measurements, indicating that the 
information was interpreted similarly by different chart reviewers. The most common 
situations with missing data were documented in a codebook for the chart reviewers. 
This codebook was updated regularly, as is considered good practice in patient record 
review.41 In addition, when the information was considered not to be obtained or not 
documented, appropriate data imputation techniques were used, depending on the 
pattern of missingness.42 Exclusion of patients with incomplete data would result in 
discarding valuable information that was collected for these patients. In addition, it has 
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the potential to introduce bias when the patients with incomplete data differ from the 
patients with complete data. Multiple imputation was required for treatment delay, as 
there were associations between the chance of missingness in one variable and the value 
of another variable.42 As these associations were absent in the secondary prevention 
medication data, single imputation was sufficient. The results of all analyses on these 
imputed data sets incorporate an uncertainty about the imputed data, resulting in 
larger confidence intervals. We therefore expect limited influence on the direction or 
size of the results.
APPROPRIATE USE CRITERIA
The focus on guideline adherence in this thesis is limited to identifying adherence 
with positive recommendations of the guidelines: evaluating whether patients who are 
eligible for a certain intervention also receive it, i.e. appropriate use. Another side of 
guideline adherence is evaluating whether patients who are not eligible for a certain 
clinical intervention do receive that intervention, i.e. inappropriate use. For example, 
one of the recommendations in the European Society of Cardiology guidelines is that 
a PCI of a totally occluded artery >24h after symptom onset in stable patients without 
signs of ischaemia is not recommended. For these patients, the PCI procedure offers no 
or very little benefit, while it does have the potential to harm. It is possible to identify 
patients with a totally occluded artery >24h after symptom onset and measure how 
many of these patients underwent PCI. In the systematic review on interventions to 
improve guideline adherence, only two studies reported such measures (chapter 7). A 
tool for dealing with such issues is to identify appropriate use criteria, for example for 
revascularization.43 The method of appropriate use criteria involves the presentation of 
clinical scenarios which were developed to mimic patient presentations encountered 
in everyday practice. These scenarios are scored by a panel of experts on whether 
revascularization is appropriate, uncertain or inappropriate. This approach facilitates 
monitoring of processes, both for appropriate use and inappropriate use. 
Internationally, there has been much attention for these ‘negative’ recommendations. 
In the United Kingdom, the National Institute for Clinical Excellence (NICE) has 
developed a ‘do-not-do’ list, in which clinical practice that should be discontinued 
or not used routinely is described.44 This has been translated to the Dutch setting in 
the ‘beter niet doen’ list.45 In future practice, these ‘negative’ recommendations can be 
considered for the development of quality indicators. 
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RECOMMENDATIONS FOR CLINICAL PRACTICE AND FUTURE 
RESEARCH
From the results of the research presented in this thesis, several recommendations can 
be made for clinical practice and future research. 
MAINTAIN THE BALANCE BETWEEN SPEED AND DIAGNOSTIC ACCURACY
An optimal balance between speed of the process and diagnostic accuracy should be 
identified for patients with STEMI referred for emergency PCI. This balance should 
minimize both the treatment delay and the number of false catheterization room 
activations. The balance is also influenced by the strength of the association between 
treatment delay and the risk of dying. When the association is strong,46 then the 
balance will swing more to prioritizing speed. When the association is weaker,40 the 
balance will swing more to prioritizing the accuracy of the diagnosis, resulting in fewer 
inappropriate catheterizations. Use of computer simulation allows for manipulation of 
multiple variables at once and can therefore be used to determine an optimal balance.
Although many patients arrive through the emergency medical services, the longest 
delays were identified in patients arriving through alternative routes. In countries such 
as the United States, where the majority of treatment delay research was performed, 
more patients arrive through the emergency department.37 Therefore, multiple 
interventions to decrease treatment delay at the emergency department have been 
developed, which might be applicable to the Dutch emergency departments. For 
patients arriving through the emergency department of both PCI centres and non-PCI 
centres, rapid rule out protocols can play an important role in keeping the treatment 
delay short. Also, activation of the catheterization laboratory by emergency physicians 
can be useful in reducing the treatment delay.47 
In addition, improving cooperation between all stakeholders in the region of a PCI centre 
has the potential to reduce the treatment delay. In both our study and international 
studies7, arriving through a non-PCI hospital was the strongest predictor of a longer 
treatment delay. Therefore, efforts to improve cooperation should focus on health 
care providers working in the alternative patient routes, i.e. emergency physicians, 
cardiologists at non-PCI hospitals, general practitioners and care providers working 
at non-cardiac hospital departments. This should result in shared protocols with 
not only the emergency medical services, but also general practitioners, emergency 
departments, other hospital departments and referring hospitals.48
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REDUCE VARIATION IN THE PRESCRIPTION OF SECONDARY PREVENTION 
MEDICATION
To improve the quality of secondary prevention, cardiologists should be aware of their 
leading role in the prescription of secondary prevention medication and referral to 
cardiac rehabilitation. From a study in Denmark, we learned that patients who are not 
prescribed the recommended medication at discharge from the hospital are unlikely to 
ever receive it in their entire post-hospital care trajectory.49 Prescribing this medication 
at discharge from the hospital or during a follow-up visit is therefore essential in 
maintaining the continuum of care.50 In case the short length of hospital stay after an 
ACS leaves too little time to initiate the medication adequately, clear instructions for 
the patient’s primary care provider on prescribing secondary prevention medication 
are vital.
Although large differences between hospitals in prescribing the secondary prevention 
medication at discharge were identified in our study, the data offers no insight in the 
causes of these differences. For example, the data were inadequate to identify differences 
between cardiologists. Therefore, in-depth research is needed, both quantitative 
(e.g. differences between individual cardiologists/residents/nurse specialists) and 
qualitative (e.g. the differences in culture between departments).
To improve the prescription of secondary prevention medication, there are tools that use 
potential differences between individuals as the foundation for quality improvement. 
One commonly used tool in the Netherlands is the medical audit: a systematic 
evaluation of guideline adherence, most often performed in the preparation for a peer 
quality review. In a medical audit, cardiologists working within a department evaluate 
each other’s records of patients with ACS on guideline adherence and collectively 
identify targets for improvement. This offers cardiologists the possibility to learn from 
one another and improve the overall quality of care provided at their department. 
Consequently, a medical audit should be developed for ACS care in the Netherlands 
including secondary prevention, based on the ESC guidelines and the NVVC and ACCA 
position papers.
IMPROVE INFORMATION SYSTEMS
Before the quality of care can be measured uniformly between hospitals, much 
improvement is required in the information systems of hospitals. In the process of acute 
care for patients with STEMI, much of the required information was lacking, resulting 
in difficulties in measuring performance on quality indicators. Hospitals varied greatly 
in the extent to which they documented the different time variables, resulting in large 
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differences in quality indicator performances (chapter 4). While some hospitals had 
almost complete data about the entire care pathway of patients in one database, others 
relied on multiple freestanding databases that were difficult to link on a patient level. 
One of the most important improvements that can enable uniform measurements 
between hospitals and facilitate future quality improvement is the formation of a 
national cardiology data registry in which all hospitals participate.27 Examples of these 
databases can be found all over Europe, including the UK (MINAP)51 and Sweden 
(SWEDEHEART)52. These registries can facilitate improvement in guideline adherence, 
sharing of best practices and monitoring of patient outcomes over time. Setting up 
a widely used registry has proven to be difficult, deeming by Dutch initiatives such 
as the Dutch National Cardiology Data Registry (NCDR), Begeleidingscommissie 
Hartinterventies Nederland (BHN) and Meetbaar Beter. Each of these registries 
focusses on a specific part of cardiology services: NCDR on devices and interventions, 
BHN on interventions, and Meetbaar Beter on patient outcomes (but not processes). 
These multiple initiatives have led to an incomplete and fragmented view of the 
quality of cardiology services in Dutch hospitals. Each approach has its advantages and 
disadvantages. For example, an outcome based approach incorporates what eventually 
matters (improved patient outcomes), but many outcomes are relatively rare, making it 
difficult to identify differences between hospitals.53 In case clinically relevant differences 
are found and processes were not measured, it is unclear how these improved patient 
outcomes were achieved. Consequently, structure and process indicators can contribute 
to further quality improvement in an outcome-based approach. 
Recently, the chairmen of the boards of the three Dutch data registries have signed 
a letter of intent for integrating their registries into one: the Netherlands Heart 
Registry. Combining the registries should result in a more integrated insight in both 
cardiology structures, processes and patient outcomes. An additional benefit is that 
combining three registries into one results in uniform definitions and a reduction of 
the administrative burden. In integrating multiple registries into a national registry, 
experiences from other countries (e.g. Sweden)54, 55, or other medical conditions (e.g. 
stroke)56 can be used to facilitate optimal use of the registry as the foundation for 
quality improvement at hospitals. 
One hiatus in the current registries is cardiac rehabilitation. In a previous report, it is 
demonstrated that the cardiac rehabilitation programmes offered in hospitals can be 
improved.26 For example, not all cardiology departments had written agreements with 
cardiac rehabilitation providers. Therefore, cardiac rehabilitation should be included 
in the Netherlands Heart Registry.
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The data in the Netherlands Heart Registry should be validated at least periodically 
and/or by other means of sampling. In the cross-sectional studies presented in this 
thesis, a sample of the patient records was screened by two raters independently and 
differences were identified. Although the overall agreement was good, the double 
screening of records resulted in some improvements in the data, but even more so 
in the definitions in the codebooks. In addition, the data were entered in a data entry 
program with fixed entry fields using different data types (e.g. date, time, binary, 
category) and were compared to the original case report form by a second researcher. 
Finally, the data were checked for impossible combinations, e.g. a negative treatment 
delay, and outliers, e.g. ages >100 years. All these steps improved the quality of the data 
used for the analyses performed as part our research, and should also be considered for 
the Netherlands Heart Registry, as is already the case in the Meetbaar Beter program.
LIMIT THE ADMINISTRATIVE BURDEN
In Dutch health care, the role of quality indicators has been growing in the last 
decades. In addition to multiple health care quality indicators (e.g. Dutch Healthcare 
Inspectorate indicators, Zichtbare Zorg, VMS), indicators about e.g. the quality 
management system, continued education, fire safety and finances are also obligatory. 
Although digitalization of hospitals’ information systems facilitated data management 
and retrieval, retrieving the right information to calculate these indicators still puts an 
incredible burden on health care organizations. This requires a significant investment 
of hospitals in software and personnel for administrative support, data management 
and quality management.57 The number of measures and the number of data items 
per measure will always be a balance between informational needs on the one hand 
and administrative burden on the other. By spending more time on administration, 
resources are used that could have been employed for patient care. However, when 
the information is used in a correct way, it might lead to a return on investment, i.e. 
the improvement that can be made based on the quality information is larger than the 
care that could have been provided by e.g. hiring an additional nurse. Therefore, it is 
recommended to only measure aspects of quality which are likely to be used for quality 
improvement and/or accountability. Primarily, the focus should be on performance 
measures with a proven relationship with quality (e.g. the number of PCI procedures per 
operator58). Consequently, current quality indicators with a questionable or no relation 
to quality should be considered for abandonment. Since the ultimate goal of quality 
indicators is to improve care, indicators with a lack of support from care providers, or 
with little or no variation in performance or room for improvement have little added 
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value.25 From the field of general practice, we have learned that quality indicators can 
be withdrawn without negative consequences for the quality of care.59
Another way to limit the administrative burden is uniformization of data and data 
requirements. Ideally, the information in patient records recorded by care providers is 
recorded once and can subsequently be used for multiple purposes, e.g. patient care, 
quality improvement, communication with other care providers and accountability. 
However, the documentation and especially the possibilities for data extraction have 
been suboptimal so far, hampering the use of this information for other purposes 
than patient care. Consequently, the Netherlands Federation of University Medical 
Centres in cooperation with Nictiz (centre of expertise for standardisation and 
eHealth) initiated the program ‘Registratie aan de bron’.60 The goals of this program 
are to improve the quality, re-use and interoperability of the documented information 
in hospitals; to optimize the care processes; and to demonstrate improved patient 
outcomes. By streamlining the information requirements of multiple stakeholders, 
the program should alleviate the administrative burden of health care providers while 
improving the quality of the documentation of medical information.24 Only when 
relevant high quality data can be generated without intensive manual labour is (real-
time) comparison of performance on quality indicators between hospitals feasible. 
FACILITATE CONTINUOUS QUALITY IMPROVEMENT
While the information presented in this thesis can be used to target quality improvement 
efforts in the Dutch cardiology care, current use of quality information by health care 
providers for quality improvement is limited.57 In our systematic review, the most 
effective intervention for improving ACS care from a reliable study was based on the 
use of quality information in national registry combined with training of care providers 
in continuous quality improvement, i.e. targeted quality improvement.61 It should be 
clear that providing feedback of performance alone is not enough to stimulate quality 
improvement. National organizations of cardiologists and nurses working in cardiology 
should offer training to care providers in targeted quality improvement. This training 
should focus on how can you use the results of quality indicators, national registries 
and/or local databases to further improve the quality of care. However, this is only 
possible when the administrative burden is diminished and the time saved is attributed 
to targeted quality improvement. 
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RESEARCH DEPARTMENT COMPETENCIES AND SUSTAINABILITY OF 
QUALITY IMPROVEMENT
The differences in prescription of secondary prevention medication between hospitals 
could not be explained by hospital characteristics. However, they might be related 
to characteristics of departments or teams. For the education of future physicians, a 
framework was developed for competencies of individual physicians: the CanMEDS 
framework. However, a department of competent individuals does not automatically 
make it a competent department. It is unclear what characteristics of departments 
or teams are related to guideline adherence and a high quality of care. In chapter 7, 
interventions were identified that promote guideline adherence. However, it is unknown 
whether these interventions are equally effective in all departments and teams, or 
that characteristics of these departments or teams determine the effectiveness of 
these interventions to some extent. It would therefore be recommendable to research 
characteristics of departments or teams that are associated with guideline adherence 
and effective use of quality improvement interventions. These characteristics could be 
used to create a framework of for department competencies.
In addition, if departments are able to improve the quality of care, it is essential to 
sustain that improvement. Several context factors that contribute to sustainability have 
been identified in past research,62 however long-term effects have not been researched. 
Recommendations for research would therefore be: 1) to identify characteristics of high 
quality departments in order to create a framework of department competencies; and 
2) identify effective interventions for sustaining quality improvement. 
IMPROVE GUIDELINE DEVELOPMENT AND ADAPTATION IN CARDIOLOGY
In the management of ACS in hospitals, the NVVC is responsible for the development 
and distribution of clinical guidelines. The NVVC has opted for endorsing several 
ESC guidelines, thereby agreeing that these guidelines are the foundation for the 
treatment of patients with ACS in the Netherlands. However, the development of 
the ESC guidelines does not appear to adhere to the current quality standards for the 
development of evidence-based guidelines.63 For example, there is no description 
of the clinical questions that the guidelines should answer; the literature searches 
and seeking patients’ views and preferences are not described in the methods; and 
the criteria for selecting the evidence are missing. Without adhering to these quality 
criteria, the guideline development process is insufficiently transparent. This lack of 
transparency can result in a diminished support for the guideline recommendations and 
less successful implementation.64-66 A European effort is required in order to improve 
the cardiology guideline development, of which the NVVC can be the instigator.
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In addition, the translation of international guidelines to a national setting is 
difficult. Therefore, the Guidelines International Network (GIN) developed a toolkit 
to adapt guidelines from other settings (ADAPTE).3 Use of this toolkit should result 
in improved translation of the international guideline recommendations (including 
the performance indicators) to the Dutch setting and thereby improving guideline 
adherence and eventually patient outcomes.
CONCLUSION
In conclusion, although the performance of hospitals on the VMS quality indicators 
for treatment delay and secondary prevention medication is fair, there is still room 
for improvement. PCI centres can learn from one another about how to design and 
execute an efficient care process for patients with STEMI, in consultation with other 
involved care providers (e.g. ambulance services, non-PCI hospitals and emergency 
departments). Also, there is unwarranted variation between hospitals in the 
prescription of secondary prevention medication at discharge. The VMS ACS quality 
indicators may have contributed to improving ACS care to some extent, however there 
are several possibilities for improving them. Further quality improvement in ACS care 
can be facilitated by synthesizing the information in current ACS quality registries 
into the Netherlands Heart Registry, facilitating continuous quality improvement, 
and initiating multicomponent quality improvement interventions based on the 
results of the Netherlands Heart Registry. Further research is required on the balance 
between speed and diagnostic accuracy; the cause of variation in the prescription of 
secondary prevention medication; a framework of department competencies and the 
sustainability of quality improvement. Finally, a European effort is required to improve 
the development of the ESC guidelines and their translation to the Dutch setting. 
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SUMMARY
INTRODUCTION
Acute coronary syndrome (ACS) is the most common ischaemic heart disease and one 
of the leading causes of death in the world. Although improvements in the quality of 
care have led to tremendous improvements in patient outcomes, the burden of the 
disease is still high. Three clinical manifestations can be distinguished: ST-segment 
elevation myocardial infarction (STEMI); non-ST-segment elevation myocardial 
infarction (NSTEMI) and unstable angina (UA). The management of these three 
clinical manifestations differs on some aspects. In the acute management of STEMI, it 
is vital that patients are treated with percutaneous coronary intervention (PCI) as soon 
as possible, as the likelihood of dying after STEMI increases with time. All patients 
with an ACS have an increased risk of a recurring ACS. Therefore, they receive several 
medications for secondary prevention: acetylsalicylic acid, P2Y12 inhibitor, statin, beta 
blocker and an Angiotensin converting enzyme (ACE)-inhibitor. 
In the Netherlands, the Dutch Society of Cardiology (NVVC) has adopted the 
European Society of Cardiology guidelines as the foundation for the management of 
ACS patients. In general, adhering to these guidelines can be considered good quality 
of care, although the physicians can always deviate from the guidelines with sound 
medical rationale. However, the guideline adherence is often suboptimal. To measure 
the guideline adherence, the most important recommendations of guidelines can be 
translated into quality indicators. 
Following a critical report on the quality of Dutch care, a national quality improvement 
program (VMS) was initiated in 2008, in which ACS management was one theme. 
Within this VMS program, five quality indicators were developed for the management 
of patients with ACS. In this thesis, two of these indicators with an established 
association with patient outcomes were evaluated: use of PCI within 90 minutes of first 
medical contact for patients with STEMI; and the prescription of secondary prevention 
medication at discharge from the hospital for all patients with ACS. For these two 
indicators: 1) the performance in Dutch hospitals was measured; 2) (unwarranted) 
process variation was investigated in-depth; and 3) effective interventions to further 
improve the care processes were identified. 
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METHODS AND RESULTS
Because no reliable national data on ACS management was available, a cross-sectional 
study was designed to measure guideline adherence in hospitals using the VMS ACS 
quality indicators (Chapter 2). In total, 13 hospitals selected by means of a multistage 
random selection procedure participated in the study, of which seven provided PCI. 
The data were extracted from the patient records. In addition to data on guideline 
adherence, data on several patient and hospital characteristics were collected in order 
to identify (unwarranted) practice variation. Missing data were handled with the 
appropriate (multiple) imputation procedures. The data were analysed with generalized 
linear (mixed) models.
TREATMENT DELAY
In total, 1017 records of patients with STEMI going for immediate PCI were included 
in the study. The majority (78.7%) were treated within the recommended 90 minutes. 
The median treatment delay was 64 minutes (interquartile range: 47 – 82 minutes). 
Significantly prolonged treatment delays were found in patients of whom their first 
electrocardiogram was performed at the general practitioner’s practice or at the hospital; 
who required interhospital transfer; or who presented with acute heart failure (Chapter 
3). Large differences in the quality of the data impeded comparison of the treatment 
delay between the PCI centres. In addition, different definitions of treatment delay 
are used internationally, hampering comparison of our results to the results of studies 
performed abroad (Chapter 4). To investigate the acute STEMI care process in-depth, 
a qualitative study was performed in six of the seven PCI centres. At each hospital, 
involved care providers were interviewed, resulting in 28 interviews. For each centre, 
the acute care process was mapped and compared to the guideline recommended 
care process and to the processes of other PCI centres. The processes in the centres 
differed from the guideline recommended process on e.g. additional (unavoidable) 
patient routings such as patients coming through the general practitioner, and no 
continuous monitoring of the treatment delay. The processes in the centres differed 
from one another in the communication of diagnostic information (e.g. transmitting 
all, only ambiguous or no electrocardiograms) and catheterization room preparation. 
These differences indicate that in hospitals different choices are made to maintain a 
balance between speed and diagnostic accuracy. Factors perceived by care providers 
as accelerating the process included trust in the tentative (prehospital) diagnosis, and 
avoiding unnecessary inter-caregiver consultations. The differences in the processes 
and the accelerating factors were summarized in a model, which can be used in other 
PCI centres to critically reflect on their own STEMI care process (Chapter 5).
Summary
171
SECONDARY PREVENTION MEDICATION
In total, 2471 records of patients discharged with an ACS were included in the study. 
Guideline adherence was defined as prescription of all five recommended medications 
at discharge from the hospital or documentation of a contra-indication or other reason 
for not prescribing them. Complete guideline adherence was achieved in 69.1% of 
the patients. However, this ranged from 42.1% to 87.0% between hospitals. The ACE 
inhibitor was most often missing (21.2%). Guideline adherence was less often achieved 
patients with NSTEMI or UA; patients with a history of coronary artery bypass 
grafting or elderly women. Because the overall performance was substantial, quality 
improvement efforts can be targeted at underperforming hospitals and undertreated 
patient groups. (Chapter 6)
QUALITY IMPROVEMENT
In order improve the guideline adherence in the hospital care of patients with 
ACS, a systematic review was performed to identify effective quality improvement 
interventions for optimizing the ACS care processes. In this systematic review, 
an overview was provided of 265 papers on initiatives aimed at improving the ACS 
care process. The most often reported subjects for improvement were medication 
prescription; treatment delay, and referral to smoking cessation. However, the findings 
of the majority of these studies were insufficiently reliable. Consequently, the 24 studies 
with the strongest research designs were selected for further investigation. Using the 
Cochrane Effective Practice and Organisation of Care (EPOC) taxonomy of health 
systems interventions, 23 different intervention components were identified. The 
most commonly used intervention components were audit & feedback; educational 
interventions; educational materials; and local opinion leaders. In the majority of 
the studies, the interventions were (to some extent) effective in improving guideline 
adherence. Interventions consisting of multiple components (e.g. a combination of 
feedback of performance, training of care providers in continuous quality improvement 
and use of local opinion leaders) appeared more effective than single or dual component 
interventions. (Chapter 7)
REFLECTION, (METHODOLOGICAL) CONSIDERATIONS AND 
RECOMMENDATIONS
Although the performance of hospitals on the VMS quality indicators for treatment 
delay and secondary prevention medication was fair, there was unwarranted practice 
variation. Although the VMS program has initiated a broad movement in patient safety, 
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several opportunities for improving the VMS ACS indicators could be identified in 
retrospect (Chapter 8). Especially the acceptability to the stakeholders, feasibility (e.g. 
required data) and reliability (e.g. definitions and in- and exclusion criteria) require 
further attention in case the use of these indicators is continued. 
 
The results of the research presented this thesis should be interpreted in the light 
of several considerations. First, the guideline adherence was measured using cross-
sectional studies performed in hospitals and not in the entire ACS care pathway. Second, 
only processes were measured in the research presented in this thesis, not structures 
or outcomes. However, measuring processes offers the most practical information 
for quality improvement and therefore were the focus of this thesis. Third, due to 
the retrospective nature of these studies, the percentage of missing data was high. 
Therefore, we had to use appropriate statistical techniques to correct for this. Fourth, 
by measuring the VMS ACS quality indicators, we only evaluated whether patients 
who were eligible for an intervention also received it. In contrast, we did not evaluate 
whether patients who were not eligible for an intervention did receive it (appropriate 
use). The recent initiative of the ‘beter niet doen’ list shows that some of these ‘negative’ 
recommendations can be considered for the development of quality indicators. 
From the research presented in this thesis, several recommendations can be made for 
clinical practice and future research:
•	 Maintain the balance between speed and diagnostic accuracy
Although the median treatment delay was relatively short in comparison to studies 
abroad, the recommended maximal treatment delay of 90 minutes was exceeded 
occasionally. To further improve care processes, hospitals can learn from one another 
about how to design the acute care process for patients with STEMI. They can focus 
on patients presenting through other routings than the emergency medical services. 
The model presented in Chapter 5 can be helpful in this. Although further speeding 
up the process can be important, it is vital to maintain the balance between speed 
of the process and diagnostic accuracy. Consequently, both the treatment delay and 
the number of unnecessary catheterization room activations should be monitored in 
hospitals.
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•	 Reduce variation in the prescription of secondary prevention 
medication
Although the prescription of secondary prevention medication was largely in 
accordance with the guidelines, there was much unwarranted variation among 
hospitals and among different patient groups. Cardiologists should be aware of their 
leading role in initiating secondary prevention medication in the entire care pathway. 
Further research is needed on the causes of the large differences between hospitals and 
potentially between cardiologists. By making use of the interventions recommended in 
Chapter 7 of this thesis, unwarranted practice variation can be reduced and the quality 
of care further improved. Besides these interventions, ACS management including 
secondary prevention medication can be a subject for the medical audits as used in the 
Dutch system of peer quality review.
•	 Improve information systems
Currently, there are several national data registries of the management of ACS that have 
different visions in monitoring and improving the quality of care. By combining these 
efforts, comparable to the Swedish SWEDEHEART model, the current fragmented 
view of the quality of ACS management in the Netherlands can be improved and 
the administrative burden reduced to some extent. It is essential to follow-up on the 
letter-of-intent to integrate the current data registries into the Netherlands Heart 
Registry. In a national registry, data validation is essential for the quality of the data 
and consequently the reliability of the results. 
•	 Limit the administrative burden
An opportunity for alleviating the administrative burden is to abandon quality indicators 
which show no or limited room for improvement. To efficiently use the available data, 
care providing institutions should employ the time gained by abandoning quality 
indicators for using results of relevant quality indicators and registries for targeted 
quality improvement efforts. Another way to limit the administrative burden is 
standardization of data and data requirements, e.g. through the ‘Registratie aan de 
bron’ initiative.
•	 Facilitate continuous quality improvement
The results of our systematic review showed that only providing feedback of performance 
is not enough to stimulate quality improvement. The largest improvements were 
achieved by a combination of feedback of performance and training in continuous 
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quality improvement, i.e. targeted quality improvement. Therefore, national 
organizations of cardiologists and nurses working in cardiology could offer training to 
care providers in targeted quality improvement.
•	 Research department competencies and sustainability of quality 
improvement
A department of good individuals does not make a good department. Therefore, 
identifying a framework for high performance departments can be of added value. In 
addition, if quality improvement is achieved, it needs to be sustained. Consequently, 
the sustainability of quality improvement should be further researched. 
•	 Improve guideline development and adaptation in cardiology
Finally, the VMS ACS quality indicators were based on the European Society of 
Cardiology guidelines for STEMI and for NSTEMI & UA management. However, the 
development of these guidelines does not adhere completely to the current quality 
standards for guideline development. In addition, because the Dutch Society of 
Cardiology adopts these guidelines, there is room for improvement in the adoption 
and adaptation process. 
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SAMENVATTING
INTRODUCTIE
Acuut coronair syndroom (ACS) is de meest voorkomende ischemische hartziekte en 
één van de belangrijkste oorzaken van vroegtijdige sterfte in de wereld. Ondanks dat 
veranderingen in de zorg hebben geleid tot grote verbeteringen in uitkomsten voor 
patiënten en een betere kwaliteit van zorg, is de ziektelast nog steeds hoog. ACS is 
te onderscheiden in drie klinische manifestaties: ST-segment elevatie hartinfarct 
(STEMI); niet-ST-segment elevatie hartinfarct (NSTEMI) en instabiele angina pectoris 
(IAP). De behandeling van deze drie klinische manifestaties verschilt op enkele 
onderdelen. In de acute behandeling van STEMI is het essentieel dat ze zo snel mogelijk 
gedotterd worden, omdat de kans op overlijden toeneemt naarmate de tijd verstrijkt. 
Alle patiënten die een ACS hebben doorgemaakt hebben een verhoogd risico op nog 
een ACS. Daarvoor krijgen ze secundaire preventie medicatie: acetylsalicylzuur, P2Y12-
remmer, statine, bètablokker en een angiotensine converterend enzym (ACE) remmer. 
In Nederland heeft de Nederlandse Vereniging voor Cardiologie (NVVC) de Europese 
richtlijnen geadopteerd als basis van de behandeling van patiënten met een ACS. 
Het handelen conform deze richtlijnen wordt in het algemeen gezien als goede zorg, 
hoewel afwijken van de richtlijnen om medische redenen altijd mogelijk is. Echter, 
de implementatie van de richtlijnen is vaak suboptimaal. Om de implementatie 
te meten worden de belangrijkste aanbevelingen uit de richtlijnen vertaald in 
kwaliteitsindicatoren. 
In navolging van een kritisch rapport over de kwaliteit van de Nederlandse zorg werd 
een nationaal kwaliteitsverbeterprogramma opgezet (VMS), waarvan ACS één van de 
thema’s was. Binnen dit thema werden vijf kwaliteitsindicatoren ontwikkeld. In dit 
proefschrift zijn de twee kwaliteitsindicatoren geëvalueerd die een bewezen associatie 
met patiëntuitkomsten hebben: het dotteren binnen 90 minuten na eerste (para)
medisch contact voor patiënten met STEMI, en het voorschrijven van secundaire 
preventie medicatie bij ontslag uit het ziekenhuis voor alle patiënten met ACS. Voor 
deze twee indicatoren: 1) zijn de prestaties van Nederlandse ziekenhuizen gemeten; 2) 
is de variatie in de processen onderzocht; en 3) zijn interventies voor het verbeteren van 
de zorgprocessen geïdentificeerd.
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METHODEN EN RESULTATEN
Omdat betrouwbare landelijke data niet beschikbaar waren, is een dwarsdoorsnedestudie 
opgezet om het volgen van de richtlijnen te meten middels de VMS ACS indicatoren. 
(Hoofdstuk 2) In totaal werden met een procedure voor gestratificeerde willekeurige 
selectie 13 ziekenhuizen geselecteerd voor deelname, waarvan zeven ziekenhuizen 
dotterbehandelingen uitvoerden. De data werden verzameld uit patiëntendossiers. 
In aanvulling op informatie over het volgen van de richtlijnen werd tevens informatie 
over patiënt- en ziekenhuiskarakteristieken verzameld om (onnodige) praktijkvariatie 
te kunnen onderzoeken. Voor ontbrekende data werden gepaste (meervoudige) 
imputatieprocedures gebruikt. De data werden vervolgens geanalyseerd door middel 
van generaliseerde lineaire (mixed) modellen. 
TIJD TOT DOTTERBEHANDELING
In totaal werden 1017 dossiers van patiënten met STEMI die een acute dotterbehandeling 
kregen geïncludeerd in de studie. Het overgrote deel (78,7%) werd binnen de aanbevolen 
90 minuten gedotterd. De mediane tijd tot dotterbehandeling was 64 minuten 
(interkwartielafstand: 47 – 82 minuten). Een significant langere tijd tot behandeling 
werd gevonden bij patiënten van wie het eerste elektrocardiogram gemaakt werd bij 
de huisarts of in het ziekenhuis, patiënten die van het ene ziekenhuis naar het andere 
vervoerd moesten worden, en patiënten die zich presenteerden met acuut hartfalen 
(Hoofdstuk 3). Door grote verschillen in de kwaliteit van de data was de tijd tot 
behandeling moeilijk te vergelijken tussen de dottercentra. Tevens werden internationaal 
andere definities gehanteerd voor tijd tot dotterbehandeling, waardoor onze resultaten 
moeilijk te vergelijken zijn met resultaten uit buitenlandse studies (Hoofdstuk 4). 
Om het acute STEMI zorgproces nader te onderzoeken, werd een kwalitatieve studie 
uitgevoerd in zes van de zeven dottercentra. In totaal werden 28 interviews afgenomen 
met de belangrijkste betrokkenen in het zorgproces van ieder ziekenhuis. Van ieder 
dottercentrum werd het acute zorgproces in kaart gebracht en vergeleken met het 
proces zoals aanbevolen in de richtlijnen en met elkaar. De processen in de dottercentra 
verschilden van het proces zoals aanbevolen in de richtlijnen op, onder andere, het 
hebben van aanvullende (onvermijdelijke) patiëntstromen zoals patiënten die via de 
huisarts komen, en het niet continu monitoren van de tijd tot dotterbehandeling. De 
processen in de centra verschilden van elkaar in de communicatie van diagnostische 
informatie (bijvoorbeeld het doorsturen van alle, alleen onduidelijke/dubieuze, of 
geen elektrocardiogrammen), en het voorbereiden van de hartcatheterisatiekamer. 
Deze verschillen tonen aan dat in ziekenhuizen verschillende keuzes worden gemaakt 
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in het waarborgen van een balans tussen snelheid en accuratesse van de diagnose. 
Zorgverleners ervoeren vertrouwen in de voorlopige (prehospitale) diagnose en het 
vermijden van onnodige consultaties tussen zorgverleners als versnellende factoren. De 
resultaten van de variatie in de processen en de versnellende factoren zijn samengevoegd 
in een model wat gebruikt kan worden in andere dottercentra om op hun eigen acute 
zorgproces te reflecteren (Hoofdstuk 5).
SECUNDAIRE PREVENTIE MEDICATIE
In totaal werden 2471 patiëntendossiers van patiënten ontslagen met een ACS 
geïncludeerd in de studie. Het handelen conform de richtlijnen was gedefinieerd als 
het voorschrijven van alle vijf de aanbevolen medicijnen of het documenteren van een 
contra-indicatie of andere reden voor het niet voorschrijven van de medicijnen. De 
richtlijnen werden volledig gevolgd bij 69,1% van de patiënten. Echter, dit varieerde van 
42,1% tot 87,0% tussen ziekenhuizen. De ACE-remmer ontbrak het vaakst (21,2%). De 
richtlijnen werden minder vaak gevolgd bij patiënten met NSTEMI of IAP; patiënten 
met een openhartoperatie in de voorgeschiedenis; en oudere vrouwen. Omdat de 
resultaten in het algemeen ruim voldoende waren, kunnen kwaliteitsverbeteringen 
gericht worden ingezet bij minder goed presterende ziekenhuizen en onderbehandelde 
patiëntgroepen. (Hoofdstuk 6)
KWALITEITSVERBETERING
Om het volgen van de richtlijnen in de ziekenhuiszorg voor patiënten met ACS 
te verbeteren, is een systematisch literatuuronderzoek uitgevoerd om effectieve 
interventies te identificeren. In dit systematische literatuuronderzoek werd een 
overzicht gegeven van 265 artikelen over kwaliteitsverbeterinitiatieven rondom het ACS 
zorgproces uit de wetenschappelijke literatuur. De meest voorkomende onderwerpen 
voor verbetering waren het voorschrijven van medicatie; de tijd tot dotterbehandeling 
of trombolyse en verwijzen naar stoppen met roken programma’s. Echter, de resultaten 
van het merendeel van deze studies waren onvoldoende betrouwbaar. Daarom zijn 
de 24 studies met de sterkste onderzoeksdesigns geselecteerd voor nader onderzoek. 
Met het Cochrane Effective Practice and Organisation of Care (EPOC) classificatie van 
interventies binnen zorgsystemen werden 23 verschillende interventie componenten 
onderscheiden. De meest voorkomende componenten waren audit & feedback, 
onderwijsinterventies, onderwijsmaterialen en lokale opinieleiders. Het merendeel 
van de onderzochte interventies zorgden er (tot op zekere hoogte) voor dat richtlijnen 
beter gevolgd werden. Interventies die bestonden uit meerdere componenten 
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(bijvoorbeeld een combinatie van het meten en terugkoppelen van prestaties, trainen 
van zorgverleners in continue kwaliteitsverbetering en het inzetten van lokale 
opinieleiders) leken een groter effect te hebben dan interventies bestaande uit één of 
twee componenten. (Hoofdstuk 7) 
REFLECTIE, (METHODOLOGISCHE) OVERWEGINGEN EN AANBEVELINGEN
Hoewel de VMS programma heeft gezorgd voor een brede beweging in patiëntveiligheid, 
zijn er verschillende mogelijkheden om de ACS indicatoren van het programma te 
verbeteren (Hoofdstuk 8). Met name de onderwerpen acceptatie door betrokkenen, 
haalbaarheid (bv. de benodigde data) en betrouwbaarheid (bv. de definities en in- en 
exclusiecriteria) vereisen aandacht wanneer de indicatoren gebruikt blijven worden. 
De resultaten van het onderzoek uit dit proefschrift moeten worden geïnterpreteerd 
in het licht van enkele (methodologische) overwegingen. Ten eerste, het volgen van de 
richtlijnen is gemeten door middel van een dwarsdoorsnede onderzoek in ziekenhuizen 
en daarmee niet in het volledige ACS zorgproces. Ten tweede zijn in het onderzoek 
zoals gepresenteerd in dit proefschrift alleen processen gemeten, geen structuren of 
uitkomsten. Echter, het meten van processen biedt de meeste aangrijpingspunten voor 
kwaliteitsverbetering en was daarom het onderwerp van dit proefschrift. Ten derde, 
vanwege de retrospectieve aard van het onderzoek was het percentage ontbrekende 
data hoog. Daarom hebben we passende statistische technieken moeten gebruiken om 
hiervoor te corrigeren. Ten vierde, door het meten van de VMS ACS kwaliteitsindicatoren 
hebben we alleen onderzocht of patiënten die in aanmerking kwamen voor een 
interventie deze ook kregen. Daarentegen hebben we niet onderzocht of patiënten die 
niet in aanmerking kwamen deze interventie toch ontvingen (gepast gebruik).
Uit het onderzoek gepresenteerd in dit proefschrift, kunnen verschillende conclusies 
en aanbevelingen voor de praktijk en onderzoek worden gehaald. 
•	 Waarborg de balans tussen snelheid en diagnostische accuratesse
Ondanks dat de mediane tijd tot dotterbehandeling relatief kort was in vergelijking 
met studies uit andere landen, werd de maximale tijd tot dotterbehandeling nog af 
en toe overschreden. Om de zorgprocessen verder te verbeteren kunnen ziekenhuizen 
veel van elkaar leren over hoe het acute zorgproces voor patiënten met STEMI ingericht 
kan worden. Het model zoals gepresenteerd in Hoofdstuk 5 kan ziekenhuizen 
helpen hierbij. Hoewel het verder versnellen van het proces belangrijk kan zijn in het 
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terugdringen van de sterfte aan STEMI, is het essentieel om de balans tussen snelheid van 
het proces en de zorgvuldigheid omtrent het stellen van de diagnose goed te bewaken. 
Daarom dient men in ziekenhuizen zowel de tijd tot dotterbehandeling als het aantal 
keren dat de hartcatheterisatiekamer onnodig geactiveerd wordt te monitoren.
•	 Reduceer de variatie in het voorschrijven van secundaire preventie 
medicatie
Hoewel secundaire preventie medicatie grotendeels conform de richtlijnen werd 
voorgeschreven, was er veel onnodige variatie in de prestaties tussen ziekenhuizen en 
tussen patiëntgroepen. Cardiologen dienen zich bewust te zijn van hun leidende rol in 
het initiëren van secundaire preventie medicatie in het hele zorgproces. Meer onderzoek 
is nodig naar de redenen van de grote variatie tussen ziekenhuizen en mogelijk tussen 
cardiologen. Door de interventies te gebruiken zoals beschreven in Hoofdstuk 7 van 
dit proefschrift, kan onnodige praktijkvariatie worden verminderd. Aanvullend hierop 
kan secundaire preventie medicatie onderwerp worden van de ‘medical audits’, zoals 
worden uitgevoerd in het Nederlandse systeem van de kwaliteitsvisitaties. 
•	 Verbeter de informatiesystemen
In de huidige situatie bestaan er verschillende landelijke kwaliteitsregistraties die 
verschillende visies hebben op het monitoren en verbeteren van de kwaliteit van ACS 
zorg. Door de verschillende registraties te combineren, vergelijkbaar met het Zweedse 
SWEDEHEART model, kan de huidige, gefragmenteerde monitoring verbeteren en 
de administratieve last enigszins worden beperkt. Het is essentieel dat er een vervolg 
wordt gegeven aan de recent getekende intentieverklaring om de drie bestaande 
dataregistraties samen te voegen in de Nederlandse Hart Registratie. In een landelijke 
registratie is het essentieel dat de data gevalideerd worden. Dit komt de kwaliteit van 
de data en de betrouwbaarheid van de resultaten ten goede. 
•	 Verminder de administratieve last
Een mogelijkheid voor het verlichten van de administratieve last is om 
kwaliteitsindicatoren die geen, of een beperkte, ruimte voor verbetering laten zien te 
schrappen. Om de beschikbare gegevens beter te benutten, dienen zorgverlenende 
instellingen de gewonnen tijd door het schrappen van indicatoren in te zetten om de 
resultaten van relevante kwaliteitsindicatoren en kwaliteitsregistraties te gebruiken 
voor gerichte kwaliteitsverbetering. Een andere mogelijkheid om de administratieve 
last te reduceren is standaardisatie van data en data vereisten, bijvoorbeeld in het 
‘Registratie aan de bron’ programma.
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•	 Faciliteer continue kwaliteitsverbetering
De resultaten van ons systematische literatuuronderzoek tonen aan dat alleen het 
terugkoppelen van prestaties onvoldoende is om kwaliteitsverbetering te stimuleren. 
De grootste verbeteringen werden behaald door een combinatie van het terugkoppelen 
van prestaties en het trainen in continue kwaliteitsverbetering, de zogenaamde 
gerichte kwaliteitsverbetering. Daarom zouden nationale organisaties van cardiologen 
en cardiologieverpleegkundigen trainingen aan kunnen bieden aan zorgverleners in 
gerichte kwaliteitsverbetering.
•	 Onderzoek vakgroepcompetenties en duurzaamheid van 
kwaliteitsverbetering
Een vakgroep van goede individuen maakt nog geen goede vakgroep. Daarom kan 
het van meerwaarde zijn om een raamwerk te ontwikkelen voor goede vakgroepen. 
Daarnaast dient kwaliteitsverbetering geborgd te worden. Dit vraagt om verder 
onderzoek naar duurzame kwaliteitsverbetering.
•	 Verbeter de richtlijnontwikkeling en adaptatie binnen de cardiologie
Tot slot zijn de VMS ACS kwaliteitsindicatoren gebaseerd op de Europese cardiologie 
richtlijnen voor STEMI en NSTEMI & IAP. Echter, de ontwikkeling van deze richtlijnen 
voldoet niet volledig aan de huidige kwaliteitsstandaarden voor richtlijnontwikkeling. 
In aanvulling daarop adopteert de NVVC deze richtlijnen, waarbij ruimte voor 
verbetering is in het proces van adopteren en tevens adapteren. 
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DANKWOORD
Voor alle mensen die altijd geïnteresseerd hebben gevraagd hoe ver het stond met mijn 
promotie: ik ben blij nu te kunnen zeggen: klaar! Ondanks dat alleen mijn naam voor 
dit boekje staat, was dit nooit mogelijk geweest zonder de bijdragen van velen. 
Als eerste wil ik mijn promotor, Cordula, bedanken voor het mogelijk maken van dit 
onderzoek. Je was altijd in de weer, hoewel niet iedereen altijd goed wist waar je mee 
bezig was. Wanneer ik echter mensen uit het veld sprak, dan bleek je bij vrijwel ieder 
onderzoek naar patiëntveiligheid of kwaliteit van zorg betrokken te zijn. Je concrete 
feedback en het bewaken van de rode lijn en de planning hebben er mede voor gezorgd 
dat ik alles goed heb kunnen afronden. 
Daarnaast natuurlijk mijn copromotoren, Martine en Ineke. Martine, je hebt me erg 
veel geleerd over dat onderzoek een balans is tussen strenge methodologie en praktische 
mogelijkheden. Je enthousiasme wist je altijd goed over te brengen op anderen, wat bij 
werving van ziekenhuizen erg handig was. Je dacht altijd in mogelijkheden en zelden 
in barrières, waardoor je soms een ware ideeënfontein was. 
Ineke, door de dagelijkse begeleiding halverwege het traject over te nemen heb je 
gezorgd voor veel structuur. Daarnaast wist je mensen iedere keer weer te verrassen 
met je originele manier van presenteren. Je probeerde overal leven in de brouwerij te 
brengen, zelfs wanneer het over oersaaie materie als missende data ging. Ik heb je leren 
kennen als een ware onderzoekspunker; iemand die het niet eens is met misstanden in 
de wetenschap en de barricades op wil om het te verbeteren. Ik hoop dat je je voorliefde 
voor onderzoeksmethodologie en apps ooit nog kunt combineren. 
Daarnaast wil ik uiteraard de promotiecommissie danken voor de aandacht en tijd die 
ze aan het kritisch beoordelen van mijn proefschrift hebben besteed: Prof. dr. N.S. 
Klazinga, Prof. dr. A.C. van Rossum, Prof. dr. M.W. van Tulder, Prof. dr. A.W.J. van ’t 
Hof, Prof. dr. J.D. de Jong. 
Josien, we zijn in 2012 samen aan een promotietraject begonnen met allebei onze 
eigen focus. Het eerste punt was om als een bezetene de dataverzameling voor 
het dossieronderzoek op te zetten. Je gestructureerde manier van werken en 
doorzettingsvermogen waren een inspiratie. Ik heb zelden twee bureaus gezien 
die meer van elkaar verschilden dan de onze; de jouwe keurig opgeruimd, de mijne 
Dankwoord
182
bezaaid met onderzoekspapers. Ik ben er van overtuigd dat je een grote toekomst in het 
(verpleegkundig) onderzoek tegemoet gaat!
Suzanne, meer dan een half jaar lang ben je voor de dataverzameling meegesleept naar 
ziekenhuizen in alle uithoeken van het land. Het was prettig om tijdens deze lange 
dagen van ploeteren door dossiers een lotgenoot te hebben. Daarna heb je je vooral 
bezig gehouden met het invoeren van vragenlijsten, welke je veruit de meeste van ons 
allemaal hebt ingevoerd. Ik wens je alle succes met het aandachtsgebied waar je hart 
ligt: de voeding!
Felix, Julie en Rixt, ook jullie aandeel in de dataverzameling mag niet onderschat 
worden. Jullie hebben ons allemaal op jullie eigen manier geholpen: Felix aan het 
begin, toen we met zijn allen in hetzelfde schuitje zagen; Julie als ‘lotgenoot’ van Josien, 
en Rixt voor de verste uithoeken van het land. Dank voor jullie harde werk!
Lisanne, je hebt je dapper gestort op een totaal nieuw onderwerp. Ik heb je een 
spoedcursus mogen geven in de cardiologie, zodat je op basis van onze data een mooi 
artikel kon schrijven. De overtuiging waarmee je schreef heeft me erg geïnspireerd. Dit 
heeft bij mijzelf ook tot veel nieuwe inzichten geleid.
De cardiologen, arts-assistenten, verpleegkundigen en kwaliteitsmedewerkers van de 
deelnemende ziekenhuizen, voor de tijd die ze hebben gestoken in het faciliteren van 
onze dataverzameling, de gezelligheid en interessante discussies die ze boden bij het 
doorspitten van de dossiers. 
De collega’s van de onderzoeksgroep patiëntveiligheid van de VU en het NIVEL wil 
ik bedanken voor alle gezelligheid tijdens de befaamde kerstdiners, barbecues en 
bijvoorbeeld het zeiluitje.
Ondanks dat de H0 gang een nieuwe functie heeft gekregen, zal ik altijd met veel 
plezier terugdenken aan mijn tijd daar. 
Daarnaast alle andere mensen die waren betrokken vanuit het EMGO+ Instituut 
/ VU medisch centrum / afdeling SG en het NIVEL, zoals Caroline en Maaike voor 
het organiseren van het SG uitje, Brahim die altijd alles wist te regelen, Trees en 
Inge die altijd in waren voor een praatje, en alle mensen die in waren voor een potje 
beachvolleybal na het werk.
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En niet te vergeten alle mensen bij het Kennisinstituut van de Federatie Medisch 
Specialisten en de Federatie zelf, voor het inspireren van de praktische adviezen van 
dit proefschrift en het bieden van de ruimte om het op een goede manier af te ronden.
Mijn vrienden wil ik ook bedanken voor alle weekendjes, avonden, Budels & tafelvoetbal, 
klaverjassen, noem maar op: de BOB groep, DHK en BMW Nimma. 
Staf, Anne, Sander en Milan, jullie leven is een stuk hectischer geworden tijdens mijn 
promotie! Volgens mij is het hebben van twee kinderen minstens net zoveel werk 
als een promotieonderzoek. Dank voor jullie steun en de leuke discussies over de 
cardiologische zorg. 
Ons pa en ma, de ontspannen weekendjes in Oirschot waren altijd een oase van rust in 
de hectische weken. Volgens mij wisten jullie vaak niet waar ik nou precies mee bezig 
was, maar ik kon merken dat jullie trots op me waren. Dit heeft erg geholpen om deze 
promotie tot een goed einde te brengen.   
Jette, jarenlang hebben we ons door de lange dagen en vreemde werktijden 
heengeslagen. Als ik aan het eind van de dag naar huis kon was ik altijd erg blij. Door 
onze voorliefde voor lekker eten was het altijd een genot om thuis te komen, of het nou 
voor de zelfgemaakte pasta, phở of ovenfrietjes was. Ik wil je bedanken voor de mooie 
jaren die we samen hebben gehad! 
En voor iedereen die ik hierboven niet heb genoemd maar die wel direct of indirect 
waren betrokken: er is een prachtig Brabantse zin die de lading prima dekt: 
Da ge bedankt zijt, da witte!
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